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Abstract
Seizure first aid training for people with epilepsy attending
emergency departments and their significant others: the SAFE
intervention and feasibility RCT
Adam Noble ,1* Sarah Nevitt ,2 Emily Holmes ,3 Leone Ridsdale ,4
Myfanwy Morgan ,5 Catrin Tudur-Smith ,2 Dyfrig Hughes ,3
Steve Goodacre ,6 Tony Marson 7 and Darlene Snape 1
1Department of Health Services Research, University of Liverpool, Liverpool, UK
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5Institute of Pharmaceutical Science, King’s College London, London, UK
6School of Health and Related Research, University of Sheffield, Sheffield, UK
7Department of Molecular and Clinical Pharmacology, University of Liverpool, Liverpool, UK
*Corresponding author adam.noble@liv.ac.uk
Background: No seizure first aid training intervention exists for people with epilepsy who regularly
attend emergency departments and their significant others, despite such an intervention’s potential to
reduce clinically unnecessary and costly visits.
Objectives: The objectives were to (1) develop Seizure first Aid training For Epilepsy (SAFE) by
adapting a broader intervention and (2) determine the feasibility and optimal design of a definitive
randomised controlled trial to test SAFE’s efficacy.
Design: The study involved (1) the development of an intervention informed by a co-design approach with
qualitative feedback and (2) a pilot randomised controlled trial with follow-ups at 3, 6 and 12 months and
assessments of treatment fidelity and the cost of SAFE’s delivery.
Setting: The setting was (1) third-sector patient support groups and professional health-care
organisations and (2) three NHS emergency departments in England.
Participants: Participants were (1) people with epilepsy who had visited emergency departments in the
prior 2 years, their significant others and emergency department, paramedic, general practice, commissioning,
neurology and nursing representatives and (2) people with epilepsy aged ≥ 16 years who had been
diagnosed for ≥ 1 year and who had made two or more emergency department visits in the prior 12 months,
and one of their significant others. Emergency departments identified ostensibly eligible people with
epilepsy from attendance records and patients confirmed their eligibility.
Interventions: Participants in the pilot randomised controlled trial were randomly allocated 1 : 1 to
SAFE plus treatment as usual or to treatment as usual only.
Main outcome measures: Consent rate and availability of routine data on emergency department use at
12 months were the main outcome measures. Other measures of interest included eligibility rate, ease
with which people with epilepsy could be identified and routine data secured, availability of self-reported
emergency department data, self-reported emergency department data’s comparability with routine data,
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SAFE’s effect on emergency department use, and emergency department use in the treatment as usual
arm, which could be used in sample size calculations.
Results: (1) Nine health-care professionals and 23 service users provided feedback that generated an
intervention considered to be NHS feasible and well positioned to achieve its purpose. (2) The consent
rate was 12.5%, with 53 people with epilepsy and 38 significant others recruited. The eligibility rate was
10.6%. Identifying people with epilepsy from attendance records was resource intensive for emergency
department staff. Those recruited felt more stigmatised because of epilepsy than the wider epilepsy
population. Routine data on emergency department use at 12 months were secured for 94.1% of people
with epilepsy, but the application process took 8.5 months. Self-reported emergency department data
were available for 66.7% of people with epilepsy, and people with epilepsy self-reported more emergency
department visits than were captured in routine data. Most participants (76.9%) randomised to SAFE
received the intervention. The intervention was delivered with high fidelity. No related serious adverse
events occurred. Emergency department use at 12 months was lower in the SAFE plus treatment as usual
arm than in the treatment as usual only arm, but not significantly so. Calculations indicated that a
definitive trial would need ≈ 674 people with epilepsy and ≈ 39 emergency department sites.
Limitations: Contrary to patient statements on recruitment, routine data secured at the pilot trial’s
end indicated that ≈ 40% may not have satisfied the inclusion criterion of two or more emergency
department visits.
Conclusions: An intervention was successfully developed, a pilot randomised controlled trial conducted
and outcome data secured for most participants. The consent rate did not satisfy a predetermined
‘stop/go’ level of ≥ 20%. The time that emergency department staff needed to identify eligible people
with epilepsy is unlikely to be replicable. A definitive trial is currently not feasible.
Future work: Research to more easily identify and recruit people from the target population is required.
Trial registration: Current Controlled Trials ISRCTN13871327.
Funding: This project was funded by the National Institute for Health Research (NIHR) Health Services
and Delivery Research programme and will be published in full in Health Services and Delivery Research;
Vol. 8, No. 39. See the NIHR Journals Library website for further project information.
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Plain English summary
L imited knowledge of how to manage seizures leads some individuals with epilepsy to visitemergency departments following seizures despite not needing medical attention. Such visits are
expensive for the NHS and can be inconvenient for patients.
Part A of this project aimed to develop a self-management course for patients frequently visiting
emergency departments for epilepsy, as well as for their significant others, such as family and friends.
Having developed the course, a large trial was needed to find out if it would be beneficial. Before
doing that we needed to answer the following question: ‘can such a trial be done?’. Part B of this
project aimed to answer this by conducting a ‘pilot randomised controlled trial’. A pilot is like a
practice run.
In part A, nine health-care professionals and 23 service users helped us to develop the course, which we
called Seizure first Aid training For Epilepsy (SAFE). They considered it acceptable and NHS feasible.
In part B, 53 patients diagnosed with epilepsy (and 38 significant others) were recruited from three
emergency departments. Patients were randomly assigned to either an invitation to attend SAFE
(with or without their significant other) or usual treatment only. All participants took their medication
as usual. Participants were asked to complete questionnaires on their use of emergency departments
and confidence managing seizures 3, 6 and 12 months later.
The pilot trial found that emergency departments could not easily identify people to invite, and fewer
people agreed to take part than expected (12.5% rather than at least 20%). Those who did take part
tended to participate for the full length of the trial, and information on their use of emergency
departments 12 months later was obtained in over 90% of cases. Nearly all participants said that they
would take part in such a trial again.
Even though parts A and B were carried out successfully, it was difficult to identify potential
participants and fewer people agreed to participate than we expected, so a large trial, as currently
designed, is not feasible.
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xix
Scientific summary
Background
Epilepsy is one of the UK’s most common serious brain disorders. Up to 20% of people with epilepsy
visit hospital emergency departments each year, approximately 60% of whom do so multiple times.
These visits are expensive for the NHS; half result in hospital admission.
People with epilepsy visiting emergency departments report more seizures, anxiety and stigma and are
more likely to live in a socially deprived area than those in the wider epilepsy population. Identifying
people with epilepsy who visit emergency departments can be challenging; most are unknown to
specialist epilepsy services and are not referred on to them following emergency department visits.
General practitioners are also not always informed of the contact that people with epilepsy have with
emergency services.
National Audit of Seizure Management in Hospitals data and similar data indicate that many emergency
department visits by people with epilepsy are clinically unnecessary. This is because most of these
emergency department attendees have known, rather than new, epilepsy and have experienced
uncomplicated seizures. Although frightening, such seizures can be managed by people with epilepsy
and their family and friends without medical attention, as guidelines state.
Emerging evidence suggests that people with epilepsy and their significant others, to whom care
decisions can be delegated, have low confidence in their own seizure management, which may explain
why some people with epilepsy make clinically unnecessary visits. Offering people with epilepsy who
frequently attend emergency departments, and their significant others, a self-management intervention
that improves their confidence and ability to manage seizures may lead to fewer visits.
We report a project seeking to develop the first such intervention: Seizure first Aid training For
Epilepsy (SAFE). To develop the intervention, an existing group-based seizure management course,
which is offered by the Epilepsy Society (www.epilepsysociety.org.uk; Chalfont St Peter, UK) in the
voluntary sector to a broader audience, was adapted. A pilot randomised controlled trial of SAFE was
then conducted. A pilot was appropriate because the feasibility and optimal design of a definitive trial
was unclear.
Aim and objectives
Part A: intervention development
l Optimise the content, delivery and behaviour change potential of the Epilepsy Society’s course for
people with epilepsy attending an emergency department and their significant others.
Part B: pilot randomised controlled trial
l Conduct an external pilot randomised controlled trial of SAFE plus treatment as usual versus
treatment as usual only to estimate recruitment, consent and follow-up rates in a definitive trial.
l Estimate the annual rate of emergency department visits in the treatment as usual arm and
the dispersion parameter to inform the sample size calculation of a definitive randomised
controlled trial.
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l Test the acceptability of the randomisation to participants.
l Evaluate SAFE’s implementation fidelity in the pilot randomised controlled trial.
l Analyse the cost of implementing the SAFE programme.
Methods and analysis
Part A: intervention development
Design
An experience-based co-design approach comprising three iterative stages identified the changes
required to the Epilepsy Society’s intervention: stage 1 – leading representatives from professional
groups supporting people with epilepsy reviewed the course materials and were interviewed about the
changes needed; stage 2 – the Epilepsy Society’s original intervention was not underpinned by a clear
behaviour change mode and, therefore, the intervention’s behaviour change potential was optimised;
stage 3 – focus group discussions took place with service user representatives who received an initial
adaption of the intervention. Data from the different stages were captured using audio-recordings,
thematically analysed and considered by a multidisciplinary intervention panel.
Recruitment
A purposive sample of representatives from neurology, emergency medicine, the ambulance service,
specialist nursing, general practice, user groups and health-care commissioning was recruited with the help
of professional organisations. Epilepsy user groups helped to recruit service user representatives. To be
eligible, user representatives (be they a person with epilepsy or one of their significant others) needed to
be aged ≥ 16 years and able to provide informed consent. User representatives who were people with
epilepsy needed to have visited an emergency department in the previous 2 years for epilepsy.
Part B: pilot randomised controlled trial
Design
The design was an external pilot randomised controlled trial. Recruited people with epilepsy (and their
significant other if they took part with one) were randomised to receive SAFE plus treatment as usual
or treatment as usual only. The SAFE programme was delivered by an epilepsy nurse in a hospital’s
educational centre. Participants allocated to treatment as usual received SAFE only after the trial finished.
The proposed primary outcome measure for a definitive trial of SAFE is emergency department use in
the 12 months following randomisation measured using routine hospital data. In the pilot trial this was
captured by Hospital Episode Statistics. Participants provided consent for the release of these data.
Proposed secondary outcomes included self-reported emergency department use, fear of seizures,
knowledge and confidence managing seizures, quality of life, distress, seizures, stigma, carer burden,
service use and adverse events. These were measured by a researcher, blind to treatment allocation,
who completed questionnaires with participants at 3, 6 and 12 months post randomisation. At the
assessment at 12 months, participants also provided feedback on trial participation.
Rates of recruitment and retention were calculated, as was the emergency department event rate in
the control arm. Emergency department visits measured using routine hospital data for the 12 months
prior to and 12 months following randomisation were also compared with self-reported emergency
department visits for these periods. The estimates from the pilot trial were evaluated against two
predetermined ‘stop/go’ progression criteria for a full trial: ≥ 20% of eligible people with epilepsy
needed to agree to take part and primary outcome data at 12 months needed to be secured for ≥ 75%
of people with epilepsy. Although the trial was not designed to detect a clinically important difference
in emergency department use, an estimate of SAFE’s effect on this measure was also calculated to help
to inform the possible design of a future trial.
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It was anticipated that 12 months of attendances at three NHS type 1 emergency departments would be
sufficient to secure a sample of 80 people with epilepsy for the pilot trial, with 40 people with epilepsy in
each treatment arm, permitting the study to estimate a drop-out rate of 25% (with a 95% confidence
interval of 10%) and a consent rate of 20% (with a 95% confidence interval of 4%). Assuming data on
emergency department use at 12 months were not available for 25% of people with epilepsy, outcome
data from 60 people with epilepsy would still allow for robust estimation of the emergency department
rate and dispersion parameter.
Measures of implementation fidelity (adherence and competence) for SAFE were developed and their inter-
rater reliability assessed. Adherence was assessed by a checklist of the items constituting the intervention.
Competence was measured by calculating facilitator speech during the intervention (didacticism). The
measures were then used by independent raters, who listened to audio-recordings of all trial SAFE sessions.
A microcosting exercise calculated the fixed and variable costs of delivering SAFE. The process
involved a health economics researcher meeting with intervention staff and mapping out the work
and resources required for each of the courses run. The cost of developing SAFE was also determined.
Recruitment
Using electronic attendance records and triage cards, local principal investigators at three NHS type 1
emergency departments in north-west England retrospectively identified people with epilepsy who
had visited emergency departments in the previous 12 months for epilepsy and posted an invitation
letter. Inclusion criteria were an age of ≥ 16 years, an established diagnosis of epilepsy (≥ 1 year), an
antiepileptic medication prescription, reported visits to an emergency department on two or more
occasions in the previous 12 months, and the ability to provide informed consent, participate in SAFE
and complete questionnaires in English. Those receiving an invitation letter were instructed that if they
were not interested in taking part in the trial or not eligible that they should opt out of further contact
within 3 weeks. A research worker telephoned those not opting out to explain the study further and
verify patient eligibility and willingness to participate. The research worker met with those who wanted
to take part and their significant others, and secured informed consent and completed baseline
questionnaire assessments.
Results
Part A: intervention development
Over a period of 8 months, feedback from nine representatives from different professional groups,
13 people with epilepsy and 10 significant others was secured and the finalised SAFE intervention
developed.
During stage 1, health-care professionals considered the Epilepsy Society’s course to provide a good
foundation but requested changes to its language and presentation style to make it less didactic and to
emphasise the benefits to service users. They recommended the inclusion of new content to elicit and
address service users’ fears relating to seizures. To promote consistency and make the intervention
suitable for delivery in the NHS, a trainer’s manual was also developed. During stage 2, the behaviour
change potential of the intervention was optimised. Specifically, the intervention development panel
considered self-affirmation theory to be pertinent because the course would highlight to some participants
that their past behaviour conflicted with medical guidance. To mitigate against the defensive processing of
information that, according to the theory, can result, a brief kindness questionnaire was inserted at the
intervention’s start. During stage 3, service users reported having a positive view of the intervention, its
videos and the associated educational materials. Their feedback resulted in changes to the order of the
content, the addition of information relating to post-ictal states and the generation of a website that held
the content of the course to mitigate the effect of memory difficulties and to allow the information to be
shared with other significant others.
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The finalised SAFE intervention was intended for delivery to groups of up to 10 patient–carer dyads by
a single facilitator with knowledge of epilepsy and to last ≈ 4 hours, including breaks. It contained six
modules centred around basic epilepsy and first aid knowledge, the recovery position, informing others
about epilepsy and how to help if seizures occur, medical identifications, seizure triggers and home
safety. Materials included presentation slides and professionally produced videos. The total cost of
developing SAFE was £9947.
Part B: pilot randomised controlled trial
Fifty-three people with epilepsy and 38 of their significant others were recruited over ≈ 7.5 months. The
consent rate (12.5%, 95% confidence interval 9.3% to 15.6%) and eligibility rate (10.6%, 95% confidence
interval 9.6% to 11.5%) were low. Despite an amendment to extend the period within which people with
epilepsy could be identified from emergency departments (i.e. the previous 18 months rather than the
previous 12 months of attendances), the intended sample size could not be recruited.
A lack of granularity by which attendances were coded in the emergency departments’ record systems
meant that identifying people with epilepsy was resource intensive, requiring ≈ 3 days of a local
principal investigator’s time at each site. Contacting patients by telephone was also challenging.
The researcher made successful contact with only 47.8% of eligible patients.
The mean age of the people with epilepsy recruited was 39.9 years, 29 (56.9%) were female and most
lived in areas of high levels of social deprivation. The median time since diagnosis was 21 years. Those
recruited were similar in age and social deprivation to those declining participation. The recruited
sample might not have been representative of the target population in sex. Moreover, 74.5% reported
seeing an epilepsy specialist in the previous 12 months, which is higher than expected.
Of those recruited, 51 people with epilepsy (and 37 significant others) were randomised: 26 people
with epilepsy (and 18 significant others) to SAFE plus treatment as usual and 25 people with epilepsy
(and 19 significant others) to treatment as usual only. The demographics, disease characteristics and
scores on the assessment tools at baseline were similar in each treatment arm, but there was some
imbalance in prior emergency department use. Most people with epilepsy (76.9%) randomised to SAFE
received the intervention and it was found to have been delivered with high fidelity. No participants
allocated to treatment as usual attended a SAFE course by mistake. Delivering SAFE was estimated to
cost £333 per patient (with or without a significant other) and it is plausible that it could be delivered
for as little as £261 per patient.
Routine data on emergency department use at 12 months were secured for 94.1% of people with
epilepsy, but obtaining it took 8.5 months and was resource intensive, and the application for these
data was initially rejected by NHS Digital on the basis of what proved to be incorrect reasoning.
Self-reported emergency department data at 12 months were secured for only 66.7% of people
with epilepsy. It was found that participants reported more emergency department visits than
were recorded in routine data. For the 12 months prior to randomisation, participants reported
3.8 more emergency department visits on average than were recorded in routine data.
Negative binomial regression estimated emergency department use at 12 months to be, according to
routine data, ≈ 47% lower in the SAFE plus treatment as usual arm than in the treatment as usual only
arm, but not significantly so. In the SAFE plus treatment as usual arm, emergency department use
reduced from 2.1 visits over a 12-month period to 1.8 visits; in contrast, the mean number of visits in
the treatment as usual arm increased from 3 to 3.4.
No serious adverse events related to participation occurred, and all but one of the 32 (68.1%) people
with epilepsy and the 20 (62.5%) significant others providing feedback on trial participation said that
they would participate again, with SAFE participants valuing the intervention.
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The estimated effect of SAFE on emergency department use and the dispersion parameter in the
control arm (k = 0.69, range 0.17 to 1.21) indicated that a definitive trial of SAFE’s efficacy would
require a sample of ≈ 674 people with epilepsy. The consent rate in the pilot indicates that it would
need ≈ 39 emergency department recruitment sites.
Conclusions
The co-design approach allowed for a brief, manualised intervention that was supported by
stakeholders and based on an NHS-feasible delivery method to be rapidly developed.
A pilot randomised controlled trial was conducted successfully. Persons from the target population
could be identified, recruited, randomised and treated as intended. Outcome data for the proposed
primary outcome measure could be secured for most participants and meant that the trial satisfied the
predetermined ‘stop/go’ criterion of ≥ 75%.
However, the consent rate for the pilot trial was low and meant that the second ‘stop/go’ criterion of
≥ 20% was not met. The low consent rate raises concerns about the representativeness of the sample
that would be recruited into a definitive trial and its external validity. The low consent rate also means
that a definitive trial would require a larger number of recruitment sites than most definitive trials and
be expensive. It may even not be possible to secure the required emergency departments to act as
recruitment sites because the resources required from them to identify participants may be prohibitive.
Implications for NHS service commissioning, policy and practice
l The trial was not designed to determine SAFE’s efficacy. There remains limited evidence to justify
the commissioning of such a service.
l Some people with epilepsy are unknown to ambulatory care services and cannot be readily
identified. Increasing the granularity with which attendances at emergency departments are coded
could enable them to be readily identified, supported and involved in research.
l Using routine data on emergency department use in trials could make trials less vulnerable to losses
to follow-up and mean that trials are not exposed to apparent recall bias. However, stakeholders
need to be given more assurances from those holding the data that the data are likely to be
provided, and provided in a timely manner.
l A case can be made for converting SAFE into a free online resource to which people could be
directed in the short term, going some way to address the otherwise unmet seizure first aid training
needs of people with epilepsy who visit emergency department and their significant others.
Recommendations for further research
l A full definitive trial of SAFE, with the current design, is not feasible.
l Research to determine how people from the target population can be better recruited is required.
l Converting SAFE into a free online resource could provide an opportunity for an alternative method
of evaluating its effect. Via a pre–post design, persons accessing the online resource could complete
brief measures to assess change in seizure first aid confidence and skills and give their consent for
researchers to access routine data on their use of emergency departments before and after viewing
the resource.
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Chapter 1 Introduction
This project sought to develop and pilot seizure first aid training for adults with established epilepsywho frequently visit hospital emergency departments (EDs) and their significant others (SOs). It had
two parts and used mixed methods. In part A, we developed the intervention: Seizure first Aid training
For Epilepsy (SAFE). This was done by adapting a broader course that was being offered by the Epilepsy
Society (ES) (www.epilepsysociety.org.uk; Chalfont St Peter, UK). Part B was a pilot randomised
controlled trial (RCT) of the SAFE intervention with people with epilepsy (PWE) from the target
population and their SOs, with the aim of assessing the feasibility and optimum design of a definitive
RCT to test SAFE’s efficacy.
The primary and secondary objectives for the project are described here.
Primary objectives
Part A: intervention development –
l optimise content, delivery and behaviour change potential of the ES’s course for PWE attending an
ED, and their SOs.
Part B: pilot RCT –
l conduct a pilot RCT of SAFE plus treatment as usual (TAU) versus TAU only to estimate probable
recruitment, consent and follow-up rates in a definitive trial.
Secondary objectives
Part B: pilot RCT –
l calculate estimates of the annual rate of ED visits in the TAU arm and dispersion parameter to
inform the sample size calculation of a definitive RCT
l test the acceptability of randomisation to participants
l evaluate SAFE’s implementation fidelity in the pilot RCT
l analyse the cost of implementing the SAFE programme.
In this chapter, the rationale for providing seizure first aid training is provided, we describe how the
existing intervention was adapted and we outline why a pilot RCT, rather than proceeding straight to a
definitive trial, was appropriate.
Background
Epilepsy and its epidemiology
With a prevalence of ≥ 1% in the UK,1–3 epilepsy is the UK’s second most common serious neurological
condition.4
The International League Against Epilepsy (Flower Mound, TX, USA) defines a person as having
epilepsy if they experience two or more unprovoked (or reflex) seizures more than 24 hours apart or if
they have experienced one such seizure and the probability of them experiencing another over the
next 10 years is akin to that of a person who has experienced two (i.e. ≥ 60%).5
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Epilepsy’s aetiology is variable. It can, for example, arise as a consequence of cerebrovascular disease,
head trauma, congenital abnormalities and neurodegenerative disease, or be idiopathic.6 Mortality risk
varies for PWE but, with a standardised mortality ratio of ≈ 2.2, it is higher than that in the general
population.7,8
Trial data indicate that most PWE (≈ 70%) can theoretically become ‘seizure free’ via treatment, typically
using antiepileptic drugs. However, up to 48% of PWE in the UK continue to experience seizures.9
However, epilepsy is more than ‘just’ seizures. This is reflected in the International League Against
Epilepsy’s definition of epilepsy as ‘a disorder of the brain characterized by an enduring predisposition to
generate epileptic seizures, and by the neurobiological, cognitive, psychological, and social consequences
of this condition’.10 The diagnosis itself can be associated with significant psychological and social costs
for the individual. Being labelled negatively as ‘epileptic’ can be accompanied by discrimination,11,12 with
potential detrimental effects on education, unemployment and driving. Around 30% of PWE also meet
diagnostic criteria for an anxiety and/or depressive disorder. All undermine well-being.9,13,14
Use of emergency hospital services for epilepsy and societal implications
Epilepsy has societal impacts. One of these is the cost of providing health care. In the European Union,
the total cost of epilepsy in 2004 was €15.5B,15 with a cost per case of €2000–11,500. One costly
element is the provision of emergency care, which international evidence shows PWE frequently utilise.
In the UK, ≤ 20% of PWE visit a hospital ED for epilepsy each year.16–18 Most (≈ 90%) are transported
there by an emergency ambulance.19–21 The 2015/16 cost of providing emergency care to PWE in
England was estimated to be at least £70M (excluding indirect costs).22
Costs are high in part because half of ED attendances by PWE result in hospital admission.16,19,23
Indeed, 85% of all admissions for epilepsy occur on such an unplanned basis.24 Among chronic
ambulatory care sensitive conditions, epilepsy is the second most common cause of unplanned
admissions (17%).25–27
Reattendance also drives up costs. The exact distribution of ED use for epilepsy is unclear, but it is apparent
that reattendance rates are high. The 2014 UK-wide National Audit of Seizure management in Hospitals
(NASH)28 examined data from ≈ 4000 seizure-related ED attendances from 85% of acute hospitals. Among
those with established epilepsy, 60% had attended the same ED as a result of a seizure in the previous
12 months.20 Whitson et al.29 found epilepsy to be the most frequent neurological reason for emergency
readmission into UK hospitals. Dickson et al.’s30 findings are also instructive: they examined data on
unplanned admissions in hospitals in England for suspected seizures of any cause (not just epilepsy) in
adults between 2007 and 2013. They found that 22.4% of patients had more than one admission per year
and that there was a 34% chance of readmission within 6 years.
The most detailed evidence on ED use among PWE comes from a previous National Institute for
Health Research (NIHR)-funded study (reference identifier 08/1808/247) by Ridsdale et al.27,31,32
This study prospectively recruited 85 PWE from three London EDs and asked them to self-report on
ED use in the prior 12 months; 60% reported multiple ED attendances,27 25% reported two attendances
and 36% reported at least three attendances. The median number of visits for those who had made
multiple visits was two [interquartile range (IQR) 2–5]. This pattern contrasts with that seen in the
general ED population. Moore et al.33 reported that only 24% of people from the general ED population
reattend London EDs within 12 months.
Emergency department use for epilepsy is often clinically unnecessary but attendees often
require more support
Seeking emergency care for epilepsy can be important, even life-saving. Reasons include a first seizure
and status epilepticus. Some ED visits by PWE are for these reasons; most are not. The NASH,20,21,28 for
example, found that most people attending an ED for a suspected seizure had diagnosed, rather than new,
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epilepsy. Moreover, most appear to have experienced an uncomplicated seizure. Dickson et al.34 reviewed
records for 178 seizure incidents presenting to one regional ambulance service over 1 month in 2012.
Medical emergencies were uncommon and seizures had self-terminated before the emergency vehicle
arrived in > 90% of cases. In only 8% of incidents were emergency drugs required to terminate the seizure.
Uncomplicated seizures in someone with established epilepsy, although potentially frightening and
distressing to experience and observe, do not typically require the full facilities of an ED and can be
managed within the community by the person with epilepsy and their SOs. Indeed, going to an ED in these
circumstances may result in iatrogenic harms caused by unnecessary investigations and interventions
(e.g. unused intravenous cannulations, unnecessary head computerised tomography scans).35–37
Although a high proportion of epilepsy-related ED visits do result in hospital admission, most appear
unnecessary,38 with factors beyond the patient’s clinical need appearing to play a role in why the
admission occurred (e.g. lack of access to senior medical review, need to avoid breaches of ED
waiting-time targets).39
Although the acute episodes leading PWE to visit an ED do not typically require the facilities of an ED,
PWE attending an ED do often have poorer health than those in the wider epilepsy population. They
report more seizures, poorer quality of life, less epilepsy knowledge, more anxiety and feeling more
stigmatised because of epilepsy.27,40–45 Despite this, most (≈ 65%) have not seen an epilepsy specialist in
the prior 12 months.28
There is also inequality in the use of EDs, with attendees being more likely to reside in areas where
social deprivation is high and seizure control worse.41,46,47 Indeed, ED admissions for seizures vary by
more than fivefold between geographical regions in England42,44 and are most frequent in more socially
deprived areas.47,48
The National Institute for Health and Care Excellence (NICE)49 recommends that when seizures are not
controlled a patient should be referred to specialist services. However, going to an ED because of an
epileptic seizure does not typically lead to an increase in support. The NASH20,28 found that most (80%)
PWE are not seen by a specialist during their attendance, usual care providers are often not informed
of the attendance and most (60%) PWE are not referred to a specialist for follow-up. Among PWE
attending an ED, those living in the most deprived areas are among those least likely to be referred to
a specialist for follow-up.50
Epilepsy as one area where opportunities exist to reduce demands
The NHS has been operating in a context of rising demand, slow funding growth and increasing
operating costs. In 2015–16, this culminated in an aggregate funding deficit of £1.85B.51,52 The NHS
Plan,53 Five Year Forward View54,55 and related publications challenge the NHS to make substantial
savings while working with patients and SOs to improve care experience and outcomes and reduce
health inequalities. Epilepsy has been identified as one condition for which opportunities exist to
improve patient outcome and experience, reduce demands and generate savings.56
Although there is a drive to reduce ED visits for epilepsy and enhance patient outcomes, it has been
challenging to identify how to achieve this,25,57 not least because the reason(s) for ED visits for epilepsy
in publicly funded health-care systems has been unclear. The association between seizure frequency and
ED use is, for example, only modest in size, and seizure type has not proved a robust predictor.17,27,31,40
Emerging evidence highlights the potential importance of a person’s self-management skills in their use
of EDs, specifically the confidence and skills that they and those around them have to manage seizures,
with this potentially moderating the relationship between an uncomplicated seizure and the help
sought at the time.
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The importance of seizure management skills and confidence in emergency health-care
service use
‘Self-management’ is a broad term. It refers to an ‘individual’s ability to manage their symptoms,
treatment, physical and psychosocial consequences and lifestyle changes inherent in living with a
chronic condition’.58 In the context of epilepsy, self-management of adult epilepsy has been defined as
‘activities that an individual can perform alone that are known to either control frequency of seizures
or promote well-being of the person with seizures’.59
Much of the evidence regarding the potential importance of self-management skills in ED use comes
from Ridsdale et al.’s aforementioned NIHR study.27,31,32 This study followed up its sample of 85 PWE
for 12 months. A subgroup was interviewed about the reasons for their visits. Analyses indicated that
participants fell into two groups. In the first were participants who reported high levels of confidence
in managing their epilepsy. Their views closely aligned with seizure first aid guidelines. Explanations
offered by these participants for their visits included having experienced an unusually long seizure
or having sustained a significant injury. These persons had typically visited an ED only once in the
previous 12 months.
By way of contrast, participants in the second group reported not feeling confident in managing
seizures. They expressed a need for immediate access to urgent care when they had a seizure and had
typically made two or more ED visits in the previous year. They explained that they and their family
(to whom care decisions were often delegated when the patient was unconscious or lacked capacity)
were fearful of seizures, including the possibility of death and brain damage, and were unsure about
how to manage seizures and could not tell others about how to help should they have a seizure.31,32
This, they reported, could lead them to call for an ambulance when they were about to have, or had
had, a seizure. Despite having been diagnosed with epilepsy for an average of ≈ 10 years, these
participants reported that they had not received sufficient information about epilepsy. Telling
quotations from those interviewed included the following:31,32
[With] cancer, you’re awake. I know you can die, but you’re awake. I’d prefer something like that [. . .]
Having epilepsy, you’re going into a fit. You don’t know if you’re going to wake up or die. That’s why I call
[UK emergency services telephone number]!
Patient 23
[I was] just worried because I don’t know anything about epilepsy [. . .] I only know the bad things [. . .] I
know you can die [. . .] I am so worried I decided just to ring an ambulance [. . .] Better safe than sorry.
SO 60
Quantitative results from the study reinforced what participants said at interview. There was, for
example, evidence of less first aid knowledge in the ED sample than in the wider epilepsy population.
One-third of the ED sample incorrectly stated that it was always necessary to call a doctor or
ambulance if a person with epilepsy has a seizure, even if it occurs without complications.27 Only 11%
of the wider epilepsy population believe this.60
Also important were the results of regression analyses to determine which baseline data could predict
the number of ED visits participants reported 12 months later. A range of variables were examined for
their association, including seizure frequency, seizure severity and medication management skills. It
was participants’ level of confidence about managing epilepsy (as measured by the Wagner 6-item
Mastery Scale)61 and the extent to which they felt stigmatised because of epilepsy (as measured by
Jacoby’s Stigma Scale of Epilepsy)62 that were found to best predict ED use. These factors held similarly
sized associations with ED use, with lower confidence (incidence rate ratio 0.86) and increased feelings
of stigma (incidence rate ratio 1.32) being associated with more ED use.
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‘Mastery’ refers to a state of confidence in which a person feels able to independently overcome the
challenges with which they are faced.63 The mastery measure captured the degree to which participants
perceived themselves to have an internal or external locus of control, with example items from the
scale including ‘I often feel helpless in dealing with my seizures’ and ‘Sometimes I feel that my epilepsy
controls my life’.61 Evidence suggests that when a person feels more confident in their ability to cope and
manage their illness effectively they are more likely to put self-management behaviours into practice.64
Epilepsy self-management and support currently offered to people with epilepsy and their
significant others
The findings from Ridsdale et al.’s study27,31,32 are in keeping with prior evidence: coping with life in
the context of epilepsy requires an individual to accept their diagnosis and learn and adopt specific
self-management behaviours to prevent seizures and manage consequences. These tasks together
constitute what Corbin and Strauss65 labelled the ‘work’ of living with a chronic condition.
It is for these reasons that NICE49 recommends self-management support for PWE. Epilepsy specialist
nurses form an important part of the way in which this support is delivered. However, it is known that
current care models in the UK and beyond continue to fail some PWE and mean that these PWE have
less than optimal levels of self-management confidence. In contrast to some other chronic conditions,
there exists no routine course that PWE can go on to learn about their condition once diagnosed, and
there is limited time in routine care appointments for advice on self-management.66–68 Patients have
previously summarised the lack of information and support that they were given following diagnosis as
‘I was left high and dry’.69,70 It is PWE with lower levels of formal education who have been found to
have the least epilepsy knowledge.71,72
The role that Ridsdale et al.’s study27,31,32 found a patient’s family and friends to play when a seizure
occurs also accords with wider evidence: despite greater social isolation, up to 90% of PWE can still
identify a SO who acts as an informal carer.73 These SOs are not always trained in the management of
seizures, including in the use of emergency medications.
One reason that SOs have been largely missing from discussions about the causes for ED visits for
epilepsy is that it has widely been thought that such visits primarily occur because the person with
epilepsy was alone in a public place, had a seizure and an ambulance was called by a bystander, and
because a lack of information about the person’s medical history (such as from an epilepsy identification
card) meant that paramedics transported the person to ED as a precaution.74,75 Consequently, the focus
has often been on how the public, rather than SOs, can be supported and educated.76 Although ED visits
for epilepsy certainly do occur via this route,77,78 this seems to be the minority.
Reuber et al.23 examined attendances at a large ED in Leeds, UK. They found that, in this area of the
UK, only 15% of ED visits by PWE occurred because the person was alone and had a seizure in a
public place. Most seizures leading to an ED visit instead occurred in the patient’s home23 and most
(70%) 999 calls for seizures are made by relatives or friends rather than by members of the public.34
Given the indications that seizure management skills and confidence have an important role in emergency
service use, a promising idea that has emerged is to offer PWE who frequently attend ED and their SOs a
self-management intervention to improve their confidence and competence in managing seizures.45,79 The
objectives of self-management interventions are to facilitate patients taking an active role in their own
health care by encouraging autonomy and providing accurate information on symptom management.80
They are different from traditional educational approaches because, as well as educating, they seek to
empower those living with chronic health-care conditions.81 It is asserted that when people are supported
to become more activated they benefit from better health outcomes and improved health-care
experiences and make fewer unplanned health-care admissions.80
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What is the evidence that self-management skills, including seizure management,
can be modified?
Evidence from adult and paediatric literature at the time of project design
Evidence from the literature on self-management interventions for people living with other chronic
conditions such as diabetes,82,83 arthritis84–86 and asthma87–89 indicates that it is possible to elicit
improvements in self-management. Consequently, in these fields self-management support has become
well established.90–96 In the UK, self-management courses have become freely accessible to people with
diabetes.97,98 The evidence base on improving self-management skills in PWE is more limited.
A Cochrane review by Bradley et al.99 examined care delivery and self-management strategies for
adults with epilepsy. It found four self-management studies focusing on adults with epilepsy.100–103
None of the trialled programmes focused exclusively on seizure management or those attending EDs or
systematically involved SOs, and none had been trialled in the UK. However, the review did conclude
that there was tentative evidence that such interventions can improve epilepsy self-care skills.
Helgeson et al.’s100 small US RCT is noteworthy because it evaluated an intervention that included
some discussion of seizure first aid. The intervention, the Sepulveda Epilepsy Education programme, is
a psychosocial 2-day group course.100 At follow-up at 4 months, participants receiving the intervention
demonstrated a statistically significant increase in their understanding of epilepsy, a decrease in seizure
fear and a decrease in hazardous medical self-management practices compared with wait-list controls.
However, health service utilisation was not measured and no significant changes were found in relation
to anxiety or confidence managing epilepsy.
As the number of trials conducted with adults with epilepsy is small, Lindsay and Bradley’s104 Cochrane
review of self-management interventions for children with epilepsy and their parents is instructive.
Lindsay and Bradley identified two RCTs of interventions that contained modules on seizure first aid.
The first, conducted by Tieffenberg et al.,87 evaluated a Spanish group-based programme, the Civil
Association for Research and Development in Health (ACINDES in Spanish), for children aged 6–15 years
and delivered by teachers to educate children and parents about epilepsy. It consists of five weekly 2-hour
sessions, followed by a reinforcement session 2–6 months later. At follow-up at 12 months, children in the
intervention arm showed statistically significant improvements in epilepsy knowledge compared with
children in the control arm. There was also a significant reduction in ED visits. The mean number of ED
visits made by children in the intervention arm in the 12 months prior to randomisation was 0.90. This
reduced to 0.22 at follow-up at 12 months. For the TAU arm the mean number of ED visits made by
children went from 0.83 to 0.46.
The second RCT was by Lewis et al.,105,106 and examined the effect of another Spanish intervention
called the Children’s Epilepsy Programme. This intervention taught children and parents about seizures,
living with epilepsy, and communication. Children and parents separately attended four 1.5-hour group
sessions and met together at the end of each session to share learning. At follow-up at 5 months,
children in the Children’s Epilepsy Programme arm had significantly improved epilepsy first aid
knowledge compared with children in the control arm.105 Their parents also showed significantly
greater reductions in anxiety than parents in the control arm.106
That training in self-care is associated with reduced service utilisation in the paediatric epilepsy
population, without compromising patient outcome, concords with the larger, higher-quality evidence
base on interventions to reduce ED use by children with asthma, which is another chronic, relapsing
condition.88,89,107 Boyd et al.,89 for example, completed a Cochrane review of 17 RCTs of educational
interventions for children (and their parents) at risk of asthma-related ED attendances. Data from
> 3000 children who presented to an ED for acute exacerbations and were then followed for an
average of 10 months were included. Educative interventions led to a 37% reduction in the relative
INTRODUCTION
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risk of reattendance at an ED in the treatment arm compared with the control arm, and a 21%
reduction in the relative risk of subsequent hospital admission in the treatment arm compared with the
control arm.
Conclusions from trials regarding the ability of self-management interventions to elicit behaviour change in
PWE do, however, need to be tempered, because most trials have been found to be of low methodological
quality.108–110 Such trials are at a higher risk of bias and potentially overestimate effects (see Savovic et al.).111
In Helgeson et al.’s100 trial of the Seizures and Epilepsy Education programme, for instance, no information
was provided regarding random sequence generation or allocation concealment, only 38% of those
randomised to the intervention completed it and outcome assessments were not blinded.110
Development of the SAFE intervention
On the basis of the evidence so far presented, we hypothesised that PWE who frequently visit ED for
epilepsy (here operationalised as two or more visits in the previous year) might benefit from an intervention
that improves their own and their SOs’ confidence and ability in managing seizures and empowers them
to be able to tell others from their wider support networks about how to help if a seizure occurs. In the
absence of an existing intervention it was necessary to develop one. This was done by adapting a broader
intervention that was in existence and used by the ES for different purposes.
Offering such a programme to the target population is supported by the NHS policy of empowering
and supporting people with long-term conditions to understand their own needs and self-manage
them.112–114 Indeed, the Keogh Urgent and Emergency Care Review115 identified that better supporting
people to self-care for their condition is one way that EDs could become sustainable.
Background to the existing seizure management course and its development
The ES is an English charity with a 120-year history that has assumed an important role in the voluntary
sector in producing informative materials for PWE and in offering epilepsy training for different audiences
(see www.epilepsysociety.org.uk/training-courses-epilepsy#.XSR5AutKj3g; accessed 27 August, 2019).
In 2012–13, > 2000 people attended ES training courses (Joanne Fox, Learning and Development Manager,
ES, 2014, personal communication). Of relevance here was their training course entitled ‘Epilepsy
awareness and seizure management’, which they had been offering since 1998 to a fee-paying audience.
Recipients included teachers, health and social care staff, PWE and SOs. The course was developed
iteratively, with the involvement of neurologists, psychologists and social workers.
The course was delivered by a single educational facilitator. To deliver a course, a facilitator needed
to follow a training programme developed by the ES, and a quality assurance component of ongoing
internal assessment promoted consistency in delivery. The professional background of facilitators was
not fixed; although they did require experience of working with PWE. Facilitators were typically people
with a nursing or social care background.
Although not formally evaluated, the course was considered of interest because one of its aims was to
increase recipients’ confidence in seizure management, emphasising how most seizures are self-limiting,
and providing a practical understanding of when seizures do and do not require emergency treatment.
Michie et al.’s116 Affordability, Practicality, Effectiveness and cost-effectiveness, Acceptability, Side-effects/
safety and Equity (APEASE) framework, which is intended to help guide choices about intervention
development and selection for evaluation, emphasises the importance of considering, from the outset,
issues such as the affordability and practicability of an intervention to ensure that the intervention is
positioned to achieve its intended outcome once rolled out. With this in mind, what was also considered
advantageous about the ES’s course was that its delivery did not depend solely on those with specialist
training in epilepsy. The UK has fewer neurologists per head than other developed nations117,118 and only
≈ 55% of its acute trusts have access to an epilepsy nurse specialist.119,120 Therefore, a care model that
depends solely on such people may not be sustainable and generalisable.
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The course in its original form
The ES’s course was delivered to groups of 10–20 people. It lasted ≈ 3 hours, with breaks included.
Educational aims for course recipients are specified and outlined in Table 1. Materials for the course
included slides, professionally produced video clips of seizure types and first aid and additional
information booklets on topics such as risk management and emergency medication. An information
pack provided participants with a permanent record of the material and included space for notes to
promote active processing of material as well as participation.
The intention was for learning to be elicited rather than taught, with the behaviour of the educational
facilitator seeking to promote a non-didactic approach. Course participants were encouraged to share
experiences and ask questions. To some extent there is therefore meant to be tailoring of the
information that is presented so that it aligns with the needs of the group being taught (i.e. is patient
centred). This, and that the course consists of a number of interacting components that may act both
independently and interdependently, means that it is what the Medical Research Council refers to as a
‘complex intervention’.121,122
Justification for developing seizure management training: a policy and service
user response
The ES course is not informed by detailed theoretical modelling or a clear behaviour change model.
Having reviewed and observed the intervention, our multidisciplinary research team nevertheless
identified several ways by which receipt of the intervention (or a suitable adaption) could plausibly
support PWE to make fewer ED attendances and improve patient and SO outcomes. These are detailed in
full in Appendix 1. In brief, it was considered that it might increase patients’ and SOs’ practical understanding
of seizure management, increase their knowledge of how to make appropriate care and lifestyle decisions
(including the need for ED attendance) and reduce fears about risk, thereby increasing self-confidence
and empowerment.
Importantly, the aims of the programme also broadly aligned with what PWE and their SOs had
generally said they wanted and how they wanted to receive it. For example, studies consistently show
that PWE and their SOs want more information about living with epilepsy.27,31,123–129
Adapting SAFE
To maximise acceptability, benefit and behaviour change potential, it was recognised that the ES’s
course would probably require adaptation for the target audience. To this end, the ES agreed for their
course to form the basis of a new, adapted course, entitled SAFE, for PWE who frequently attend EDs
and their SOs. To identify the changes required we utilised a collaborative framework underpinned by
a philosophy of experience-based co-design.130 This is an approach to improving health-care services
that combines participatory and user experience design and processes to bring about quality
improvements in health care.130
TABLE 1 Epilepsy training materials
Scope Content
l Aim: to provide practical understanding of seizure management
l Audience: broad based, including teachers, patients, care home staff
l Time frame: single 3-hour session
l Delivery: one educational facilitator with knowledge of epilepsy
l Format: group (10–20 participants)
l Style: interactive
l Materials: standardised slides, videos, information booklet
l What is epilepsy?
l Causes and triggers
l Diagnosis
l Seizure types
l Potential post-seizure symptoms
l Management
l When to call an ambulance
l Recovery position
l Status epilepticus
l Treatment, medication, side effects
l Risk management
l Accessing support and information
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The need for a pilot randomised controlled trial of the SAFE intervention
Having adapted the ES’s course, it would be necessary to evaluate SAFE’s efficacy to determine
whether or not its use in routine practice was appropriate. A definitive RCT is the most reliable
methodology for determining efficacy, including of complex interventions. However, RCTs can be costly
and time-consuming, especially when the trial is evaluating change in health-care service contact and
when the follow-up period needs to be reasonably long. Recruitment of participants for RCTs is often
slower or more difficult than expected, thus jeopardising the ability of the trial to answer its intended
research question. For example, only 56% of the trials funded between 2004 and 2016 by the NIHR’s
Health Technology Assessment programme met their final recruitment target.131 Before proceeding to
a definitive RCT, the expenditure therefore needs to be justified, the trial deemed feasible and its
design optimised.132
Because the adapted intervention was new and the target population not studied to a great extent,
important process, management, resource and scientific uncertainties existed concerning the feasibility
and optimal design of a full RCT of SAFE. The uncertainties were as follows:
l No estimates of likely recruitment, consent and follow-up rates for a definitive trial were available.
l Acceptability of randomisation to participants was unknown.
l Annual rate of ED visits in the TAU arm and the likely dispersion parameter were unknown.
l It was unclear whether or not SAFE could be delivered as intended in a trial context (fidelity).
l The resources/costs required to deliver SAFE in a trial context were unclear.
l Estimates of the effect of SAFE on primary and secondary outcome measures and their precision
were lacking.
For these reasons, and informed by Lancaster et al.’s133 guidance, an external pilot RCT was considered
appropriate. Resembling a full RCT in many respects, such a pilot would allow us to resolve the above
uncertainties and permit an informed decision to be made about whether or not and how to proceed
to a definitive trial. In advance of the pilot we specified two criteria against which we would primarily
judge the pilot to help evaluate the feasibility of a definitive trial:
1. At least 20% of eligible patients need to agree to participate in the pilot RCT. This was based
on results from previous evaluations of self-management interventions, including the diabetes
programmes that have since been commissioned by the NHS. A participant uptake rate of < 20%
was deemed to raise significant concerns regarding external validity and could have implications for
trial duration, recruitment centres required and feasibility.
2. Twelve-month primary outcome data need to be secured for at least 75% of participants in the pilot
RCT. This figure was based on results from previous evaluations of self-management interventions
that reported rates of 70–80%.109,110,134
Depending on the results from the pilot, one of the following judgements, based on Thabane et al.’s132
decision framework, would be made regarding the feasibility of a definitive trial:
l stop – the main study is not feasible
l continue, but modify the protocol (feasible with modifications)
l continue without modifications, but monitor closely (feasible with close monitoring)
l continue without modification (feasible as it is).
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Chapter 2 Part A: intervention development
Introduction
Part A sought to develop SAFE for both PWE who frequently visit hospital EDs and their SOs. To do
this, the ES’s existing course ‘Epilepsy awareness and seizure management’ was adapted and its
behaviour change potential optimised.
Many self-management interventions to date have been derived from limited expert opinion and have not
involved PWE and other stakeholders in the planning process.129 By contrast, and to help ensure maximum
benefit and acceptability to users, we used an experience-based co-design approach.130 Such an approach
allows researchers to work collaboratively with people from the target population to identify their specific
learning needs, clarify their delivery preferences and adapt the intervention to match these.
We were mindful of the need for SAFE to be viable for delivery within the NHS. 112–114 Examples
abound of the importance of ensuring that any new intervention is supported by those who will be
asked to ultimately refer their patients to it, deliver it or allocate resources to it, including in the
context of epilepsy.135 Therefore, representatives from different key professional bodies involved in the
support of PWE were also consulted as part of our co-design approach.
Methods
The co-design process used comprised three iterative stages, namely (1) qualitative interviews with
health-care professionals about the existing intervention, (2) optimisation of its behaviour change
potential and (3) focus group (FG) discussions with service users. The process is outlined in Figure 1.
Health
professional
consultation 
Analysis
Development
panel
Revisions
Behaviour
change
Service user
consultation  
Analysis
Development
panel Revisions
Stage 1
Stage 2
Stage 3
ES
baseline
intervention 
Finalised
SAFE
course
FIGURE 1 Intervention development process.
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Participant settings and samples
Stage 1: recruitment of health-care professional representatives
Different health disciplines can be involved in the care of PWE. Some patients will identify a general
practitioner (GP) as the main provider of their ambulatory care whereas others will identify a specialist, such
as a neurologist or epilepsy.The voluntary sector is also an important support structure for many PWE.
When someone seeks emergency care for a seizure, other parts of the health system come into contact with
PWE, including paramedics and ED staff. All parties were considered as being positioned to be able to offer
insights into the support needs of PWE who attend for seizures.We therefore chose to adopt purposeful
sampling for the identification and selection of information-rich cases136 from the main parts of the care
pathways encountered by PWE.This involved identifying and selecting individuals who were especially
knowledgeable about or experienced with the phenomenon of interest.137 In addition to knowledge and
experience, participant availability and willingness to participate were key considerations.138,139
Seven professional organisations (Table 2) identified a representative potentially interested in participating.
Each representative was sent a participant information sheet (see Appendix 2), and those taking part
signed a consent form. Interviews were conducted by a qualitative researcher (Adwoa Hughes-Morley;
see Acknowledgements) and took place at a time and in a format convenient for the representative, be that
via telephone, Skype™ (Microsoft Corporation, Redmond,WA, USA) or face to face at the representative’s
office. Each representative was offered a consultancy fee of £200.
Ultimately, a consultative group comprising nine health-care professionals from seven different
disciplines was established to provide feedback on the content of the ES course. This group included
two consultant neurologists (one with a specialist interest in epilepsy), two consultants in emergency
medicine, a consultant paramedic, a epilepsy nurse specialist, a GP with a specialist interest in epilepsy,
a service commissioner with a health-care background and an educational representative from an
epilepsy charity other than the ES.
TABLE 2 Health-care professional consultation: groups supporting PWE
Group Details
l International League Against Epilepsy – British branch l URL: https://ilaebritish.org.uk (accessed
11 June 2020). London, UK
l Royal College of Emergency Medicine l URL: www.rcem.ac.uk (accessed 11 June 2020).
London, UK
l GPs with a specialist interest in epilepsy l None
l Epilepsy Nurses Association l URL: www.esna-online.org.uk (accessed
11 June 2020)
l North West Ambulance Service NHS Trust l URL: www.nwas.nhs.uk (accessed 11 June 2020).
Bolton, UK
l Cheshire Merseyside Strategic Clinical Networks
(commissioning representative)
l Bromborough, UK
l SUDEP Action (formerly Epilepsy Bereaved) user group l URL: https://sudep.org (accessed 11 June 2020).
Wantage, UK
PART A: INTERVENTION DEVELOPMENT
NIHR Journals Library www.journalslibrary.nihr.ac.uk
12
Stage 3: recruitment of service user representatives
Feedback on the intervention was obtained from a purposive sample of service user representatives.
PWE were eligible to participate in SAFE training if they met the following inclusion criteria:
l established diagnosis of epilepsy (≥ 1 year)
l currently prescribed antiepileptic drug(s)
l age ≥ 16 years (no upper age limit)
l visited an ED for epilepsy at least once in the past 2 years (as reported by the patient)
l living in the north-west area of England
l able to provide informed consent and participate in SAFE course in English.
People with epilepsy were excluded from participating in SAFE training if they reported:
l acute symptomatic seizures
l severe current psychiatric disorders
l life-threatening medical illness.
Patient participants could take part with or without a SO. SOs with the following characteristics were
eligible to participate in SAFE training:
l a SO to the patient (e.g. family member, friend) who the patient identifies as providing
informal support
l age ≥ 16 years (no upper age limit)
l living in the north-west area of England
l able to provide informed consent and participate in SAFE course in English.
Significant others were excluded from participating in SAFE training if they reported:
l severe current psychiatric disorders (e.g. acute psychosis)
l life-threatening medical illness.
The service user representatives were identified via adverts circulated (via newsletters and websites
and at meetings) to the affiliates of user groups, including the Mersey Region Epilepsy Association
(Liverpool, UK), the Brain & Spine Foundation (London, UK), NeuroSupport Services Ltd (Nottingham,
UK) and the ES. This approach enabled the recruitment of ‘experts’, defined as informed individuals
with knowledge or experience of a specific subject.140,141 Eligible patients and SOs interested in taking part
were sent a participant information sheet (see Appendix 3) and those taking part signed a consent form.
A total of 23 service user representatives were ultimately recruited, comprised 13 PWE (seven men
and six women) and 10 SOs (four men and six women). Each received a £10 shopping voucher.
Intervention development panel members
The process was overseen by an intervention development panel. The panel considered and discussed
the findings from the interviews and FGs and made required adaptations to the intervention. The panel
included patient and SO representatives [Mike Perry (MP) and Linda Perry (LP)], a psychologist (AN), a
neurologist (LR), a medical sociologist (MM), a research nurse with specialist qualitative research training
(DS) and a representative from the ES’s training division. Patient and SO representatives were active in
all aspects of the decision-making and were reimbursed in line with guidance.142
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Developing the intervention
Stage 1: consultation with health-care professional representatives
Consensus exists regarding what constitutes appropriate seizure first aid.143–145 Thus, the purpose of
this stage was to interview representatives from the main professional bodies caring for PWE to
ascertain whether or not the medical information presented by the programme was correct and
whether or not SAFE could be an intervention they could, in the future, support. It was considered
important to seek feedback from professionals in the first instance to prevent PWE (and SOs) being
exposed to possibly incorrect information. Moreover, it would allow us to identify from the start what
sort of seizure first aid intervention was considered feasible for delivery in the context of the NHS.
The health-care professional representatives each conducted a baseline document and audiovisual
review of the course materials for the ES’s existing intervention.
In advance of their interviews, each representative was provided with the course materials.
Approximately 2 weeks later, data from each of the nine representatives were collected via audio-
recorded semistructured interviews. A topic guide was developed to reflect the intended purpose of
the stage and on the basis of the literature (see Appendix 4). It was refined through the iterative
process of the interviews.146,147 The exact questions varied depending on the representative’s area of
expertise, but all health-care professional interviews included key discussions on:
l identifying inaccuracies in the content of the existing ES programme
l likes/dislikes and the appropriateness of the current content and delivery
l suggestions about how to make the programme more helpful
l how SAFE might be best rolled out in the NHS if a future trial found it to be effective.
Stage 2: optimisation of the intervention’s behaviour change potential
A significant component of the ES’s intervention consisted of health-related information provision.
It was anticipated that the provision of such information could reassure service users and increase
seizure management confidence and competence. However, for some PWE the information might
actually highlight that their prior use of ED conflicted with medical guidance. From a psychological
perspective, this could be construed as a threat to self-integrity. As a consequence, these people might
be at risk of rejecting or denigrating the information provided by the SAFE intervention, which may
compromise its ability to elicit behaviour change. According to self-affirmation theory,148 people are
fundamentally motivated to preserve a positive, moral and adaptive self-image and to maintain
self-integrity. Consequently, health messages that threaten one’s sense of self-image can be subject to
defensive processing (e.g. motivated scepticism, unrealistic optimism).149
To mitigate against this and maximise the behaviour change potential of SAFE, the intervention
development panel decided to introduce a self-affirmation exercise, namely Reed and Aspinwall’s150
kindness questionnaire, which individuals would complete at the start of SAFE training. The rationale
was that evidence indicates that having a person complete an exercise such as recalling one’s acts
of previous kindness prior to receipt of health risk messages reduces resistance to threatening or
dissonant health risk information. This is because theory indicates that a person’s self-image can be
maintained by self-affirming in one domain (e.g. recalling one’s acts of kindness) even if one is being
threatened in another domain (e.g. health), because people can defend their global sense of self-worth
rather than (for example) against the threat directly attributable to health risks.151,152
The kindness questionnaire was considered ideal because it is brief (taking ≈ 5 minutes to complete)
and effective150,153 and does not need to be delivered by specialists. It consists of 10 questions that
participants work through by themselves, including ‘Have you ever been concerned with the happiness
of another person?’ and ‘Have you ever forgiven another person when they have hurt you?’, with yes/no
response options. The intention was that PWE and SOs would each complete it at the start of SAFE.
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Their questionnaires were not to be collected by any member of the intervention team and the
participant would not be asked how they answered.
Stage 3: consultation with service user representatives
To allow service user representatives to critically feed back on SAFE, two practice courses were run in
November 2015 using the intervention that resulted from the first two stages. These were followed by
FG discussions.
The courses took place in a local hospital’s education centre and were delivered on weekdays to groups
of ≈ 10 patient–SO dyads. A facilitator from the ES (Juliet Bransgrove; see Acknowledgements), who was
an epilepsy nurse specialist with experience of delivering the ES’s course, delivered the courses. She
underwent a period of familiarisation with the adapted intervention by reviewing the new materials and
a trainers’ manual (see Report Supplementary Material 1) and meeting the intervention development panel.
The FGs, which lasted ≈ 60 minutes each, were conducted by a trained qualitative researcher (DS)
to explore participant views. The researcher observed each course and recorded impressions of
participants’ engagement with the materials, the group and the facilitator. A topic guide (see Appendix 5)
reflecting the discrete sections of the course guided the FGs. Participants were asked about issues
related to the course content and delivery as well as for views around its perceived strengths and
barriers to its successful implementation.
Analytic process
The interviews, practice course events and FGs were recorded (with participants’ consent) and
transcribed verbatim. Transcripts were checked for accuracy by the researcher (DS) who conducted the
data collection. A comprehensive inductive and deductive approach was used, with NVivo version 10
(QSR International, Warrington, UK)154 being used to provide a transparent account of the work. Nodes
(codes) were created to mark relevant concepts and topics in the text documents. Lower-level nodes
were then grouped into themes. An account of the process of analysis was logged in the memos
attached to categories and interview and FG documents, including the questions used to interrogate
the data, and thoughts and decisions about what themes to focus on. These capabilities and the
associated process fit with the iterative goals of the development stages of the training intervention.
Direct quotations are provided in the text as a means to verify interpretation and illustrate themes.
Results
Health-care professionals
Analysis of health-care professionals’ responses highlighted three key themes, namely (1) initial impressions,
(2) areas of intervention in need of revision to promote effective participation and (3) course delivery.
Initial impressions
There was consensus on the need for such an intervention and its potential for cost-effectiveness.
As one representative noted:
[I]t will be a powerful tool to upskill and reassure [. . .] The clearer they are about what constitutes that
person’s normal epileptic fit and what maybe a bit unusual, the more [. . .] appropriate the response the
better their [. . .] overall experience, privacy, dignity and everything to follow [. . .] [I]t’s a fairly easy case to
make for the commissioners [. . .] Resources directed by commissioners to pay for this really unnecessary
attendance could be redirected [. . .] win–win.
ED consultant
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The existing intervention was seen to provide a useful starting point for adaption and professionals
liked the videos and associated information booklets:
There’s a solid foundation in there which you can build on to then create the course to make sure it
reaches the kind of outcomes that you are after [. . .] It’s just making sure that it hits all those objectives
along the way.
User group representative
The practical challenges of hosting a group-based course were highlighted by many; it was thought
that ‘getting people together may be a difficulty’ (epilepsy specialist nurse) that would require careful
consideration, especially in relation to ‘distance and timing’ (epilepsy specialist nurse). It was important,
therefore, to ‘think about local delivery and minimising travel time’ (epilepsy nurse specialist).
It was also felt that substantial changes were needed to make the intervention appropriate for its new
audience and to achieve the aim of attenuating unnecessary/avoidable ED use.
Areas of intervention in need of revision
It was deemed important to better emphasise the benefits of the course to PWE and SOs with a more
focused and ‘clear message’ at the start on the need or not for ED attendance after a seizure. Language
level was highlighted as an area that required revision in line with the average UK literacy level. There
were also suggestions, as presented below, to revise the style of presentation so that it was less for
people who might be involved in epilepsy because of their profession:
[I]t’s written in quite a wordy way and probably a few more pictures and a few less words [. . .] would be
better. This is probably a very good presentation to new health-care professionals [. . .] but probably not
great for people that [. . .] have no training whatsoever.
Consultant paramedic
It was considered that a behavioural change focus (emergency medicine consultant 1) should be
brought to the fore and that the benefits to the participant and SO of avoiding unnecessary ED visits
should be emphasised. As explained by the GP representative:
It’s about helping people manage their epilepsy better. What will the course do for you? What can you get
out of the course? [. . .] The course should focus on behavioural change, but the impression should not be
given that the focus is about reducing A&E [accident and emergency department] admissions – that
would be counterproductive. Rather, it is about highlighting the benefits, such as better management will
reduce inconvenience in having to go to A&E.
GP
A recurring theme was the need to better elicit and address patient concerns and that patient and SO
participation should be promoted through more interactive exercises, the inviting of questions and
the discussing of fears, because this was when ‘true education happens’. This was summarised by
one representative:
[S]eizure management, what you should do and what you wouldn’t do [. . .] I’d make that part interactive
[. . .] get them to tell you, get their opinion and their views before and then you show them what they
probably should do afterwards but find out. Because you’ll probably [. . .] challenge them [. . .] that’s the
point where you really get them I think.
Consultant neurologist
A number of participants pointed out that, when seizures happen in public places, the decision to seek
emergency care is not necessarily the patient’s or their SO’s. Therefore, it was recommended that the
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intervention should support patients to develop and carry with them personalised care plans on paper
or on their smartphones, which could be used inform decision-making by paramedics:
[I]f we [the ambulance service] tip up and we don’t know anything about you we are taking you to hospital
[. . .] We’re tipping up to what we consider to be a first-time fit until proven otherwise [. . .] Have a care plan
written or something on you that says ‘I’m an epileptic and this is what happens to me normally’.
Consultant paramedic
Course delivery
Participants observed that, to make the course suitable for delivery in the NHS and to promote quality
and consistency among trainers, the intervention should become fully standardised and a trainer’s
manual, including recommended times for each topic/activity, developed.
With respect to attributes and skills of an ideal facilitator to deliver the course, some identified
epilepsy nurse specialists. However, others felt that the epilepsy voluntary sector was well developed
and, therefore, related commissioning organisations could help avoid shortfalls where specialist staff
were not available. It was considered that the following should be true in any circumstance:
The facilitator is someone who should have knowledge of epilepsy and be good at leading groups. They need
the ability to keep the course on track and to time, especially when participants may want to talk a lot!
Epilepsy nurse specialist
Changes made by intervention development panel to create version 1.1
There was agreement in the intervention development panel that the intervention’s content needed to
be revised to be better directed towards the goal of attenuating unnecessary ED use. Therefore, the
aims for the new intervention were specified as helping participants to:
l feel more confident to manage their seizures/the seizures of someone they know
l know how to tell others how to help
l know some things that may reduce the chances of a seizure
l know some things that may reduce the chances of injury from a seizure.
There was also agreement in the intervention development panel that more interactive activities
were needed. Interactivity was considered important as it permits participants to share and learn
from each other, can foster a sense of empowerment and means that participants ask questions and seek
clarification to ensure that the intervention is tailored to their needs. As part of the discussion, evidence
from the diabetes self-management literature was reflected on, which suggests that interaction between
participants and the facilitator can be important in promoting behaviour change. Skinner et al.155 calculated
the ratio of facilitator talk to participant talk during a group-based education intervention for diabetes and
found that lower facilitator talk ratios predicted greater improvements in participants’ metabolic control
and beliefs about diabetes.
In line with these requirements, Adam Noble and Darlene Snape revised the intervention, generating
new presentation materials, introducing new content and generating a training manual for facilitators.
In doing this, attention was given to presenting information in an easy-to-understand style, with
feedback from the ‘plain English’ section of the ES’s information department being obtained. Table 3
details the changes made to the ES’s intervention at this stage.
To promote more interaction, four new activities were introduced. One involved practising the
recovery position; another required subgroups to find answers to different questions concerning
seizure first aid from among a group of acetates and to present these. This was designed to identify
participant beliefs and fears and for these to be discussed. The final two activities centred on case
studies. These involved participants being read illustrated stories of patients and asked to consider what
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TABLE 3 Content of original course and revisions made following feedback
Original course: version 1.0
Post stage 1: version 1.1 (post professional consultation
and discussion by intervention development panel;
subsequently presented to users)
Post stage 2: version 1.2 (post pilot training sessions, user
FGs and discussion by intervention development panel;
delivered as the intervention in study phase B pilot RCT)
Title
Epilepsy awareness and seizure management Epilepsy Seizure First Aid Training Managing seizures: epilepsy first aid training, information
and support
Duration (hours)
3 3 4
Materials
Slide projector, flipchart, video, information packs
(including wallet-sized first aid instructions cards,
paper epilepsy ID cards, contact details for further
information) and certificates of attendance
Slide projector, flipchart, video, information packs (including
wallet-sized first aid instructions cards, paper epilepsy ID
cards, instructions for IDs on telephone, contact details for
further information) and certificates of attendance
Slide projector, flipchart, video, information packs (including
wallet-sized first aid instructions cards, paper epilepsy ID
cards, instructions for IDs on telephone, contact details for
further information, web address for copies of the course
materials) and certificates of attendance
Order Learning topic
Learning
activity
Minutes
allotted Order Topics
Learning
activity
Minutes
allotted Order Topics
Learning
activity
Minutes
allotted
1 Aim of this
session
Slide – 1 Welcome Slide 5 1 Welcome Slide 5
2 Objectives Slide – 2 Taking on information
(kindness questionnaire)
Interactive 10 2 Goals of this course Slide 2
3 Session outline Slide – 3 Goals of this course Slide 2 3 What would you like
from today?
Interactive 20
4 Myth or truth? Interactive – 4 What would you like
from today?
Interactive 5 4 True or false? Interactive 12
5 What is
epilepsy?
Slide – 5 True or false? Interactive 8 5 Taking on information
(kindness questionnaire)
Interactive 10
6 The brain . . . Slide – 6 Epilepsy, seizures and
how the brain works
Video 10 6 Epilepsy, seizures and
how the brain works
Video 10
7 Lobes of the
brain
Slide – 7 First aid for convulsive
seizures
Interactive 10 7 First aid for convulsive
seizures
Interactive 10
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Order Learning topic
Learning
activity
Minutes
allotted Order Topics
Learning
activity
Minutes
allotted Order Topics
Learning
activity
Minutes
allotted
8 How the brain
works . . .
Slide – 8 What can you do to
help someone during
a seizure?
Slide 5 8 What can you do to
help someone during
a seizure?
Slide 5
9 Seizures
happen when
. . .
Slide – 9 What not to do during
a seizure
Slide 5 9 What not to do during
a seizure
Slide 5
10 Seizures are . . . Slide – 10 What to do after the
seizure has stopped
Slide 5 10 What to do after the
seizure has stopped
Slide 5
11 Possible causes
of epilepsy
Slide – 11 When to call an
ambulance
Slide 10 11 Questions or comments? Interactive 10
12 Diagnosis Slide – 12 Questions or comments? Interactive 5 12 Post-seizure states Slide 15
13 Triggers Slide – 13 Refreshment break Networking 10 13 Injuries Slide 2
14 Seizure types
and first aid
Video 15 14 Recovery position Slide 2 14 When to call an
ambulance
Slide 10
15 Seizure
management
Interactive – 15 Recovery position Video 2 15 Questions or comments? Slide 10
16 Recovery
position
Slide – 16 Let’s practice the
recovery position
Interactive 8 16 Refreshment break Networking 10
17 Maintain
airway
Slide – 17 Questions or comments? Interactive 5 17 Recovery position Slide 2
18 When to call
an ambulance?
Slide – 18 Who needs to know how
to help?
Interactive 3 18 Recovery position Video 2
19 Most seizures
are . . .
Slide – 19 What they need to know
and why
Slide 5 19 Let’s practise the
recovery position
Interactive 15
20 Status
epilepticus
Slide – 20 How to get this
information to them:
family, friends and work
colleagues
Slide 5 20 Questions or comments? Interactive 5
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TABLE 3 Content of original course and revisions made following feedback (continued )
Order Learning topic
Learning
activity
Minutes
allotted Order Topics
Learning
activity
Minutes
allotted Order Topics
Learning
activity
Minutes
allotted
21 Sudden
unexpected
death in
epilepsy
Slide – 21 How to get this
information to them:
members of the public
and health workers
Slide 5 21 Who needs to know how
to help?
Interactive 5
22 Treatment with
drugs
Slide – 22 Questions or comments? Interactive 5 22 What they need to know
and why
Slide 5
23 Medications Slide – 23 Refreshment break Networking 10 23 How to get this
information to them:
family, friends and work
Slide 5
24 Medication Slide – 24 Personal stories:
introduction
Slide 2 24 How to get this
information to them:
members of the public
and health workers
Slide 5
25 Possible side
effects of
medications
Slide – 25 Ben’s story Slide 5 25 Questions or comments? Interactive 5
26 Other possible
treatments
Slide – 26 How to change what
happened to Ben
(carrying medical ID;
triggers)
Interactive 5 26 Refreshment break Networking 5
27 Minimising risk Slide – 27 Triggers Slide 5 27 Personal stories:
introduction
Slide 2
28 Keeping safe Slide – 28 Knowing your triggers Slide 5 28 Ben’s story Slide 6
29 Supporting the
‘whole person’
Slide – 29 Some ways of dealing
with triggers
Slide 10 29 How to change what
happened to Ben
(carrying medical ID;
triggers)
Interactive 5
30 To the future
. . .
Slide – 30 Questions or comments? Interactive 5 30 Triggers Slide 5
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things the patient in the story might have done to have achieved a better outcome. The carrying of
epilepsy identification was one way in which the outcome of one of the stories could have been changed.
It was estimated that, in the revised intervention, 114 minutes (47.5%) was dedicated to interactional/
networking elements, 114 minutes (47.5%) to slides and 12 minutes (5%) to video.
Service users
Having received version 1.1 of the adapted course, three key themes emerged from the analysis of
service users’ responses. These included ‘the need to know’, ‘barriers to and drivers of effective
participation in training’ and ‘course delivery’.
The need to know
All patient and SO participants identified the need for such a course, with lack of prior support in
self-management as a recurring topic of discussion. For example, participants explained as follows:
It can be quite overwhelming I think for partners. It’s like ‘all on their shoulders’ what happens. I think
your carer needs a lot of support too.
Patient 3, male (M), FG 1
The consultants they just presume that you know [about epilepsy] [. . .] but for all the years he got put on
tablet or tablets [. . .] you didn’t see or hear any of this [information presented on the course]. So it’s
suddenly all of an eye-opener and talking here you realise we are not on our own.
SO 1, female (F), FG 1
Similarly, another SO noted:
I always think of epilepsy as the poor relation [. . .] not much on TV or adverts about epilepsy support
[. . .]. A course like this helps to develop that sense of support as well as improve knowledge.
SO 2, M, FG1
Concerns expressed by SOs centred on the ‘need to know I’m doing the right thing’ (SO 4, F, FG 1).
PWE expressed concerns about disclosure and how best to tell others around them how they should
help if a seizure happened; they wanted information and advice on how best to manage this. Overall,
service user participants described three areas of perceived need: knowledge acquisition around
epilepsy, emotional and/or practical support, and dealing with isolation and stigma.
Taken as a whole, the content of the revised course (version 1.1; see Table 3) was felt to be ‘excellent’
(patient 3, M, FG 2) and appropriate. Of particular importance to the users was the straightforward
guidance that an ambulance was required when seizures lasted for 5 minutes or longer. This
information alone was found to be helpful and reassuring, and some said that they would no longer
always call immediately for an ambulance: ‘I think I will wait longer [to call an ambulance] than I did
before picking up the phone’ (SO 3, F, FG 2); ‘I will wait [to call an ambulance] rather than when he has
a seizure going for the phone straight away’ (SO 7, F, FG 2).
Concerns with regard to how to tell others about epilepsy and how to help if a seizure happens
were expressed:
Like when you go somewhere you need to remember to like tell people that you have seizures.
Patient 1, M, FG 1
I need to know how best to share with others [family/friends/colleagues] the implications of
having epilepsy.
Patient 2, F, FG 1
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To this end there was consensus, for the most part, that the need to feel informed and reassured on
what to do when seizures occurred had been met. Participants expressed how they had ‘learned a lot’
(SO 5, F, FG 1) from the session.
The balance between taught and interactive components was felt to be appropriate. The provision of
information was viewed as reassuring and the opportunity to practise the recovery position was
valued. As one patient asserted:
Watching a video would just go straight over me head, but actually putting [patient name] on the floor
and putting him in the right position will help. For me that’s very useful [. . .] something like that I
won’t forget.
Patient 5, F, FG 1
The training session was considered to cover more than implied by its title. Participants said that the
‘wider remit’ (patient 10, F, FG 2) was desirable but that a more accurate title was needed to engage
future service users. ‘Managing seizures: epilepsy first aid training, information and support’ was
identified as more suitable for the purposes of advertising.
Barriers to and drivers of effective participation in training
Service users’ perceptions of barriers to and drivers of successful training were explored. One was the
self-affirmation kindness questionnaire.149 Its positioning and purpose in the session were not understood
by most participants: ‘[. . .] just coming into the session the questionnaire seemed inappropriate’ (SO 3, F,
FG 1). It was also found by some to be threatening: ‘It felt like a test and a bit off-putting’ (SO 4, F, FG 1).
Some service users reported that another barrier was that there was ‘a lot of information to take in’
(patient 4, M, FG 1), and issues relating to memory difficulties were highlighted. Therefore, participants
supported the use of handouts and requested an online copy of the materials that they could access
and share with others.
With respect to content, important feedback from service users was that they appreciated that
attention was given to the different types of seizures and how to manage them and that the focus was
not simply on ‘grand mal seizures’ (SO 5, F, FG 1). However, they suggested that more time be given to
exploring triggers and auras and to explain that not everyone has triggers, which in itself is a potential
risk. It was also suggested that new sections should be included to discuss the risks associated with
post-ictal states and how best to deal with them. Finally, some suggested that ‘dealing with an injury as
well as dealing with the seizure can be difficult’ (SO 7, F, FG 2), and, therefore, information and advice
on how to deal with common seizure injuries were needed.
Course delivery
The size of the group (up to 20 people) was considered to be appropriate and encouraged discussion.
Indeed, peer support and a sense of feeling ‘less isolated’ was highlighted as a key training experience.
Many patients had not previously discussed their epilepsy with people other than their immediate
family members and/or health-care professionals. They valued the group format and described how
they appreciated being able to meet others who were ‘in the same boat’ and ‘realising you are not on
your own with it’ (patient 6, M, FG 1). One SO noted:
[R]eally glad I came. I think it’s just being around people who know exactly, exactly how you feel and
that’s why this should have been put on a long, long time ago.
SO 1, F, FG 1
DOI: 10.3310/hsdr08390 Health Services and Delivery Research 2020 Vol. 8 No. 39
© Queen’s Printer and Controller of HMSO 2020. This work was produced by Noble et al. under the terms of a commissioning contract issued by the Secretary of State for
Health and Social Care. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in
professional journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial
reproduction should be addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House,
University of Southampton Science Park, Southampton SO16 7NS, UK.
23
In terms of who would be best to facilitate the course, many felt that it should be a health-care
professional because they believed that this would make the course ‘credible’ (patient 8, F, FG 2) and
promote uptake. Others, however, argued that it could be facilitated by a representative from a user
group because what was most important was that the trainer was knowledgeable and empathetic and
had the skills to facilitate discussions. Either way, it was argued that standardised training for the
facilitators was important.
Changes made by the intervention development panel to create version 1.2
The user feedback led to a refashioning of a number of details in the way that SAFE was to be delivered
(as version 1.2; see Table 3). To increase the acceptability to users of the self-affirmation kindness
questionnaire, it was agreed that this would not be introduced to participants until ≈ 30 minutes into
the session and would follow the ‘icebreaker’ rather than being introduced immediately.
Given that the main aim of SAFE was to help patients and SOs manage uncomplicated seizures, the
panel revised SAFE so that information on managing common post-ictal states was included. However,
for the same reason, training PWE and SOs in dealing with seizure injuries as requested was deemed
to be beyond SAFE’s scope. Therefore, SAFE was modified to simply acknowledge the possibility of
injuries and direct participants to external resources on this.
The length of version 1.2 of SAFE was extended from ≈ 3 to ≈ 4 hours. The increased duration meant
that more time could be allocated to the interactive elements of SAFE. Finally, a password-protected
website (www.seizurefirstaid.org.uk/Intervention/; accessed 15 June 2020) that provided a copy of
SAFE’s content was developed in an effort to mitigate potential memory difficulties in the target
population. It also provided a means by which participants could share SAFE’s content with others in
their social network.
Discussion
The focus of part A was to develop an epilepsy first aid training intervention that met the needs and
preferences of both PWE who frequently visit hospital EDs and their SOs. To promote adequate
development and piloting156 we worked collaboratively with service users and other key stakeholders.
This activity was underpinned by the Medical Research Council’s complex intervention guidance.156
The process enabled us to access the unique perspectives of service users and health-care professionals.
Clear, tangible changes to the ES’s course were made in response to the feedback received; the developed
SAFE intervention is substantially different in content and form. By making these changes, the acceptability
of SAFE in the target population has been increased. Stakeholder collaboration has maximised SAFE’s
potential benefit and positioned it well for sustained use in the NHS, should this ultimately prove
warranted. We described the process we followed and detailed the content of the finalised intervention
that will be used within the pilot trial. Such an account is rare, with outcome papers frequently being
criticised for not providing readers with sufficient information to interpret trial results.157
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Chapter 3 Part B: pilot RCT – methods
Introduction
Part B of this project was an external pilot RCT of SAFE plus TAU versus TAU only. It sought to:
l estimate the eligibility rate
l estimate the consent rate
l estimate the recruitment rate
l estimate the retention rate
l determine the acceptability of randomisation to participants
l determine the speed of recruitment
l estimate completion rates of study assessment tools
l estimate rates of unblinding
l estimate the annual rate of ED visits in the TAU arm and the likely dispersion parameter
l generate summary statistics to measure the effect of SAFE on the proposed primary and secondary
outcome measures for a future definitive trial and the precision of such estimates at the
post-treatment time points
l determine the feasibility of measuring the primary outcome measure (ED use) by means of
routine data.
Design
The trial was as a multicentre, parallel-arm pilot RCT. Participants were PWE with or without a SO.
PWE (and their SO if participating with one) were randomised at an intervention-to-control ratio of
1 : 1 and followed up for 12 months. The intervention arm received TAU and was offered the SAFE
course and the control arm received TAU. To maximise recruitment, the TAU arm was offered the
intervention once all scheduled 12-month follow-up assessments had been completed. The study also
contained an evaluation of the fidelity with which SAFE was delivered (see Chapter 5) and an economic
evaluation of the cost of delivering it (see Chapter 7). The trial’s design and the intended flow of
participants are shown in Figure 2.
The trial protocol received the favourable opinion of the National Research Ethics Service Committee
North West — Liverpool East (reference: 15/NW/0225) and Health Research Authority (reference:
166241). Its sponsor was the University of Liverpool (reference: UoL001108). The trial was registered
on an open access system (Current Controlled Trials ISRCTN13871327).
Trial progress and conduct was monitored by an independent Trial Steering Committee composed in
line with National Institute for Health Research guidelines. In line with these oversight guidelines,
a Data Monitoring and Ethics Committee was not required.
Study setting and population
Centres
Participants were retrospectively identified from the EDs of three NHS hospitals in Merseyside –
namely, Aintree University Hospital, Arrowe Park Hospital and the Royal Liverpool University Hospital.
Together, these EDs serve a local population of ≈ 827,000 people among whom the prevalence of adult
epilepsy is 0.98%.26 At each site, an ED consultant acted as a local principal investigator.
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EDs generate list of potentially eligible PWE
Patients sent opt-out invitation letter by ED (3 weeks to
opt out of further contact)
Proportion of patients opt out 
Patients telephoned by research team. Study explained,
interest determined and eligibility verified
Proportion of patients not contactable, not eligible and/or 
decline participation
Face-to-face enrolment appointment: consent and baseline measures
Randomised 1 : 1
(stratified)
Arm 1 
SAFE plus TAU. To be given within ≈ 4 weeks of randomisation
n = 40 dyads 
Arm 2
TAU alone
n = 40 dyads
Follow-up (postal, with telephone reminder/assistance) 6 months post randomisation
Follow-up (face to face) 12 months post randomisation
Follow-up (postal, with telephone reminder/assistance) 6 months post randomisation
Follow-up (face to face) 12 months post randomisation
Delayed seizure first aid training
Adverse events screening (telephone) 3 months post randomisation Adverse events screening (telephone) 3 months post randomisation
FIGURE 2 Schematic of planned design for part B of the project: trial approval and monitoring.
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The EDs were selected as research sites because they would probably be similar to those sites that
would be most appropriate for a definitive trial. Specifically, the EDs serve a population characterised
by high levels of social deprivation,158,159 a level of epilepsy control that has been documented to be
worse than the national average and rates of emergency admissions for epilepsy that are among the
highest in England (Liverpool is ranked as the ninth highest and Wirral is ranked as the twelfth
highest).41 Epilepsy control is defined here – on the basis of the Quality and Outcomes Framework
2012–13160 domains – as the percentage of PWE prescribed one or more antiepileptic drugs in the
local population who have been seizure free in the previous 12 months. When the trial was being
designed, 70.9% of PWE from the Clinical Commissioning Group areas served by the hospitals were
seizure free. The national average at the time was 75.4%.41
Participant inclusion criteria
Patients with the following characteristics were eligible:
l established diagnosis of epilepsy (for ≥ 1 year)
l any epilepsy syndrome and any type of focal or generalised seizures
l currently being prescribed one or more antiepileptic drugs
l aged ≥ 16 years (no upper age limit)
l visited an ED for epilepsy on two or more occasions in the previous 12 months (as reported by patient)
l living within 25 miles of any of the three ED recruitment sites
l able to provide informed consent, participate in SAFE and independently complete questionnaires
in English.
Significant others with the following characteristics were eligible:
l a SO to the patient (e.g. family member, friend) whom the patient identifies as providing informal support
l aged ≥ 16 years (no upper age limit)
l living in the north-west area of England
l able to provide informed consent, participate in SAFE and independently complete questionnaires
in English.
Participant exclusion criteria
Patients with the following characteristics were excluded:
l actual or suspected psychogenic non-epileptic seizures alone or in combination with epilepsy
l acute symptomatic seizures related to acute neurological illness or substance misuse (e.g. alcohol or
drug induced)
l severe current psychiatric disorders (e.g. acute psychosis) or life-threatening medical illness
l enrolment in one or more other epilepsy-related non-pharmacological treatment studies.
Significant others with the following characteristics were excluded:
l severe current psychiatric disorders (e.g. acute psychosis) or life-threatening medical illness
l enrolment in one or more other epilepsy-related non-pharmacological treatment studies.
Screening
Stage 1
There is no central, ‘live’ system that can be accessed and searched to identify PWE who have made
visits to NHS EDs in England. Well-documented challenges to information sharing between NHS
services also mean that specialist services and GPs are not necessarily aware of ED attendances made
by PWE for whom they care.20,21 However, hospitals in the UK do maintain local electronic records of
attendances at their EDs. For each attendance, a local record contains the patient’s contact details and
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a number of searchable fields, including date of attendance, patient age, home postcode, presenting
complaint and, if provided, a discharge diagnosis. These attendance systems of the EDs were used to
identify PWE who had attended the EDs in the last 12 months for invitation to the trial.
Searches of the local systems for PWE were completed by the business intelligence units of the
hospitals. We had envisaged that an independent expert panel of neurologists and ED clinicians would
determine the search criteria to be used (e.g. presentation and diagnosis codes). During study set-up it
became apparent that the architecture of the systems and the coding processes at each of the sites
were sufficiently different that local knowledge of the system was required to have confidence that
the criteria used would allow for a sufficiently sensitive and specific search to occur. Therefore, we
instead worked with the local principal investigators at each site to identify the optimal search
strategy. The search terms used are detailed in Appendix 6.
Stage 2
The ‘triage cards’ of the patients captured by the searches during stage 1 were reviewed by the local
principal investigator and their team to identify persons who were and were not eligible to invite. This
level of detailed screening was necessary because (1) no symptom presentation is pathognomonic of
epilepsy (e.g. a presentation coded as ‘blackout/faint’ or ‘fit/seizure’ could be attributable to syncope,
diabetes, head injury or stroke rather than epilepsy) and (2) the discharge diagnosis field was often empty.
In 2016/17, ≈ 35% of ED attendances in England were not allocated a valid primary diagnosis code.161
Those patients who, following review of their triage card, were considered ostensibly eligible by the
local principal investigator were sent an invitation pack, which included a covering letter from the ED
consultant and a patient participant information sheet (see Appendix 7). The letter informed the patient
that, unless they opted out of further contact within 3 weeks or sent notification that they were ineligible,
they would be telephoned by the research team with more information about the study. Patients could
opt out by e-mail, telephone or by returning a Freepost slip. Those opting out were encouraged to detail
any reasons. Those interested in taking part were asked to await contact by the research team and
consider whether or not they would like to take part with a SO.
Stage 3
Interested patients were telephoned to answer questions the patient had, confirm whether or not the
patient wanted to participate and verify their eligibility (including that they had made two or more
ED visits for epilepsy in the last 12 months). If a person was confirmed as eligible and wanted to
participate, consent in principle was taken over the telephone and the research worker arranged a
baseline/enrolment appointment at which informed signed consent was to be obtained from them and
from their SO if they were taking part with one.
Multiple telephone calls were attempted with patients who had not opted out. Attempts to call
participants were made on different days of the week and at different times. A total of three calls per
unresponsive patient were attempted, typically one in the morning, one in the afternoon and one in
the evening. It was important to do this to minimise the influence of work status on ability to consider
participation in the study. If a person could not be contacted (e.g. a correct number was unavailable or
they did not answer), they were posted a letter asking them to contact the team if they were interested in
participating. The sending of a letter was not in the original protocol; this was a substantial amendment
and, with funder and governance approval, incorporated into protocol 1.2 (9 June 2016).
Randomisation
Computer-generated randomisation was conducted remotely by the Liverpool Clinical Trials Centre
[Clinical Trials Unit (CTU) registration number 12]. Following consent and completion of the baseline
measures, the research worker entered the participant’s information into an online system and sent a
request for randomisation to the CTU. This ensured that randomisation was performed independently
of the trial’s research and statistical teams.
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Patient participants were randomised to either the SAFE plus TAU or TAU only arm. If they were
taking part with an SO, the patient and SO were randomised as a dyad. The unit of randomisation was
the individual patient. Patients were randomised to intervention or control at a ratio of 1 : 1 and
randomisation used a web-based minimisation program with a built-in random element utilising
stratification factors that were not made known to the researcher (DS) involved in data collection to
minimise any potential for predicting allocation.
Like most trials using stratification,162 we limited stratification to two factors. We selected factors based
on evidence of their potential importance in influencing ED use and also pragmatic considerations. The
factors chosen were recruitment site from which a patient participant was identified and whether or not
the patient reported, at baseline, feeling stigmatised by epilepsy.
The reason for stratifying by recruitment site was that people who reside in more socially deprived
areas are found to be more likely to use EDs46,47 and because the catchment areas of the three ED
recruitment sites were not completely equal in deprivation. The reason for stratifying by felt stigma
was because, as reported in Chapter 1, Ridsdale et al.27,31,32 found felt stigma to be a possible predictor
of ED use and that it held a similarly sized relationship with subsequent ED use as mastery/confidence
managing epilepsy.27,128 It was not considered ideal to stratify by mastery/confidence in epilepsy
because mastery/confidence in epilepsy is typically measured on a quasi-continuous rather than
categorical scale and so stratifying patients would have required transformation of scores prior to
randomisation by the research worker (DS), whom we sought to keep blind to stratification factors.
Blinding and protection from bias
This was a single-blind (outcome assessors blinded) pilot trial. All participants were aware of their
treatment allocation. The trial statistician (SN), senior trial statistician (CTS) and the research worker
(DS) responsible for consent, data collection and the conducting of outcome assessments were not.
Participants were asked not to inform the research worker of their treatment allocation and were
reminded of this at the start of each data collection point.
Allocation concealment was maintained by e-mail confirmations being automatically generated each time
a participant randomisation was requested by the research worker and these being sent to relevant staff
with or without details of the treatment allocation included, depending on their role in the study. The
research worker submitting the request received only confirmation of successful randomisation, whereas
an administrator was notified of persons randomisation to SAFE. The administrator liaised with patients
(and their SOs) to arrange attendance at a SAFE course. Participants’ usual care providers were informed
of the patient’s involvement in the trial but not of treatment allocation.
To evaluate how the blinding process worked, the research worker completed a ‘research worker
treatment guess’ form after the follow-up assessment at 12 months or after withdrawal, and reported
the circumstances of any unblinding.
People with epilepsy attending SAFE courses did so outside their routine clinic appointments and so
we did not expect transfer of SAFE-related knowledge (and therefore contamination of the TAU arm)
between those in the SAFE plus TAU and TAU only arms at a single site.
Intervention delivery
The SAFE intervention has been fully described in Chapter 2. Materials for the course included
Microsoft PowerPoint (Microsoft Corporation, Redmond, WA, USA) presentation slides, videos
illustrating seizure types, the recovery position and appropriate first aid. Patients took copies of the
slides and additional information booklets (such as on risk management and emergency medication)
away with them and could access and share a website of the course’s content.
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For the purposes of the pilot RCT, a single facilitator (Juliet Bransgrove; see Acknowledgements),
recommended by the ES, was trained to deliver SAFE — She is a registered nurse with 30 years’
experience (18 months as an epilepsy nurse) who delivered the ES’s original course. Her training in
the delivery of the revised intervention involved her familiarising herself with the trainer manual,
delivering two practice courses with participants outside the trial and receiving feedback from the
intervention development panel.
The SAFE courses were delivered in the education centre of a local teaching hospital, chosen because
it was accessible and limited the distance participants needed to travel (i.e. it was near a major
transport hub and centrally located), familiar to the patients and had access to emergency care
services, if required.
To facilitate group interaction, chairs were arranged in a semicircle. A flip chart was set up for writing
notes and discussion points. Workbooks, pens and name badges were ready for participants on arrival.
An administrator was present at each course to support its running. This included audio-recording the
sessions and noting participant attendance. If a participant was present at the start and end of the
course, it was considered that they had received the intervention in full. If a participant was unable to
attend their scheduled course, the administrator attempted to contact them to identify the reason(s)
and offer an alternative course date if appropriate and available.
All data on attendance and the communications between the administrator and participants to arrange
attendance were inputted by them into a secure electronic database. These data were not accessible to
the researcher responsible for participant recruitment and follow-up.
Data collection tools and follow-up visits
Primary
The proposed primary outcome measure for a definitive trial of SAFE would be subsequent ED use.
This would require data on the number of ED visits each participant made over the 12 months
following recruitment. In the pilot trial these data were sought from the NHS’s Hospital Episode
Statistics (HES) system. This system is theoretically able to identify, among other things, the number of
attendances a patient has made at all EDs in England. It is primarily an administrative system, but, with
explicit patient consent, governance approvals and payment of a fee, it is possible to apply to NHS
Digital for this HES system to be interrogated for research purposes. For the pilot RCT a request was
thus submitted for the HES system to be searched for ED attendances within specified time periods by
the patient participants (using their unique NHS numbers). Because evidence was available at the time
that indicated that for ≈ 30% of ED visits no diagnosis is recorded,161 we requested data on the total
number of ED visits made for any reason by individual patient participants during specified periods.
Information on the number of visits each person had made over the 12 months prior to randomisation
was also sought for the purpose of adjustment within the analyses and to allow comparison of
self-reported ED use with routine data.
Secondary
The secondary outcome measures (Table 4) were based on participant self-report and collected
using clinical research forms (CRFs). Baseline (T0) and follow-up at 12 months (T3) measures were
completed during face-to-face sessions with a research worker (DS). During these appointments
(and in line with completion guidelines), patient or SO participants completed their questionnaire
by themselves, with the research worker offering assistance only if requested. An abbreviated
questionnaire assessment occurred at follow-up at 6 months (T2); participants were posted a set of
questionnaires for completion and instructed to return them in a pre-paid envelope.
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TABLE 4 Self-reported outcome measures by assessment and participant type
Outcome Participants
Measure and derivation of
outcome
Baseline
(T0)
3 months
(T1)
6 months
(T2)
12 months
(T3)
ED visits PWE At baseline (T0):
How many times have you used
the following hospital and day
care services over the past
12 months for epilepsy?
Casualty/accident and
emergency department
At 6 months (T2):
You last saw our researcher for
a face-to-face appointment
about 6 months ago. Since then,
have you visited a hospital
accident and emergency
(casualty) department for
epilepsy? (No, not at all or yes)
If Yes, how many times in total
have you visited since your last
face-to-face appointment with us?
At 12 months (T3):
During the past 12 months have
you visited a hospital accident
and emergency (casualty)
department for epilepsy?
(No or Yes)
If yes, how many times in total
have you visited during this time?
✓ – ✓ ✓
Fear of seizures PWE; SOs Epilepsy Knowledge and
Management Questionnaire –
fears subscale (five items)163
Total fear score was calculated
as the sum of the scores on the
scale’s five items, ranging from 5
to 30. Higher scores correspond
to greater levels of fear
✓ – – ✓
Knowledge of
what to do when
faced with a
seizure
PWE; SOs Items from Thinking About
Epilepsy questionnaire
(13 questions)164
Knowledge score was calculated
as the number of questions
answered correctly (out of a total
of 13). Only correctly answered
questions were recorded. No
down-weighting was applied for
incorrectly answered questions or
questions not answered
✓ – – ✓
Confidence
managing
seizures/epilepsy
PWE; SOs PWE: Wagner Mastery Scale
(six items)61
Total score was calculated as the
sum of the scores on the scale’s
six items (with reverse weighting
for two of the items), ranging from
6 to 24. Higher scores correspond
to higher levels of mastery
✓ – ✓ ✓
continued
DOI: 10.3310/hsdr08390 Health Services and Delivery Research 2020 Vol. 8 No. 39
© Queen’s Printer and Controller of HMSO 2020. This work was produced by Noble et al. under the terms of a commissioning contract issued by the Secretary of State for
Health and Social Care. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in
professional journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial
reproduction should be addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House,
University of Southampton Science Park, Southampton SO16 7NS, UK.
31
TABLE 4 Self-reported outcome measures by assessment and participant type (continued )
Outcome Participants
Measure and derivation of
outcome
Baseline
(T0)
3 months
(T1)
6 months
(T2)
12 months
(T3)
SO: Parental Response to Child
Illness Scale – condition
management subscale (six items)165
Total score was calculated as the
average of the scores, ranging
from 1 to 5. A higher score
corresponds to a higher level
of confidence
Quality of life PWE QOLIE-31-P (31 items)166
Total QOLIE-31-P score was
calculated, ranging from 0 to 100.
Higher scores correspond to a
better quality of life
✓ – ✓ ✓
Distress PWE; SOs aHADS (14 items)167,168
Total anxiety score and total
depression scores were
calculated, ranging from 0 to 21.
Higher scores correspond to
higher levels of anxiety or
depression, respectively. Anxiety
and depression categories were
defined based on the total
anxiety or depression score as:
l 0–7 – ‘normal range’
l 8–10 – ‘suggestive of
anxiety/depression’
l 11–21 – ‘probable
anxiety/depression’
✓ – – ✓
Seizure control PWE At baseline (T0): Thapar’s seizure
frequency scale169 for the prior
12 months
At 6 months (T2) and 12 months
(T3): patients were asked for
number of seizures (any type)
since the last assessment and
dates of the first and most recent.
(To assist, patients were offered a
seizure diary at baseline)
✓ – ✓ ✓
Felt stigma PWE; SOs Stigma Scale of Epilepsy (9 items)62
Total stigma score calculated as
sum scores on three items of
scale, ranging from 0 to 9. Higher
scores correspond to higher
levels of stigma. Stigma
categories were defined as:
l 0 – ‘no stigma’
l 1–6 – ‘mildly to
moderately stigmatised’
l 7–9 – ‘highly stigmatised’
✓ – – ✓
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The use of routine outcome data in clinical trials is advocated by the NIHR. However, limited evidence
on its utility exists (see, for example, Powell et al.174). The pilot provided an opportunity to explore
the ease and costs of obtaining routine data, the time it took for routine data to be secured, the
proportion of participants the data covered and, finally, how routinely collected administrative data
on ED use compared with self-reported data.
Adverse events
As part of the trial, patient participants did not receive additional medical reviews. Therefore, the
experience of adverse events was monitored by asking them to complete a standardised checklist as
part of the CRF at 3 months (T1; by telephone), 6 months (T2; by telephone) and 12 months (T3; during
a face-to-face appointment) post randomisation.
TABLE 4 Self-reported outcome measures by assessment and participant type (continued )
Outcome Participants
Measure and derivation of
outcome
Baseline
(T0)
3 months
(T1)
6 months
(T2)
12 months
(T3)
Burden SOs Zarit caregiver burden170
Total burden score calculated as
sum of scores on the measure’s
22 items, ranging from 0 to 88.
Higher scores correspond to
a greater burden. Burden
categories were defined as:
l 0–20 – ‘little or no burden’
l 21–40 – ‘mild to
moderate burden’
l 41–60 – ‘moderate to
severe burden’
l 61–88 – ‘severe burden’
✓ – ✓ ✓
Health economics PWE Client Service Receipt171 and
EQ-5D (13 items)172
✓ – – ✓
Feedback on trial
participation
PWE; SOs Adapted from Magpie Trial
(three items)173
1. If time suddenly went backward,
and you had to do it all over
again, would you agree to
participate in the Seizure First
Aid Training trial?
2. Please tell us if there was
anything about the Seizure First
Aid Training Trial that you think
could have been done better
3. Please tell us if there was
anything about the Seizure
First Aid Training Trial, or your
experience of joining the trial,
that you think was
particularly good
– – – ✓
EQ-5D, EuroQol-5 Dimensions; HADS, Hospital Anxiety and Depression Scale; QOLIE-31-P, Quality of Life in Epilepsy
Scale-31-P.
a This measure was used with permission from GL Assessment Ltd (London, UK), granted 17 July 2015.
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Defining the outcomes
Primary
The proposed primary outcome measure for a future definitive trial is the number of epilepsy-related
ED visits patient participants made over the 12 months following randomisation.
Secondary
There is currently no core outcome set for epilepsy.175 A number of measures described in Table 4
were used to assess secondary outcomes considered to be potentially important to capture in a
definitive trial.
Participants in the pilot trial were assessed using the secondary outcome measures to permit the
sample to be fully described according to them at baseline in order to accurately model potential
burden of participation in a definitive trial and to allow us to describe completeness of data on these
measures. A full description on these measures is provided in Appendix 8.
Adverse events
What constituted a serious adverse event (SAE) and how judgements regarding their relatedness to
participation were made are described in Appendix 9.
Sample size
Because this was a pilot RCT, a formal power calculation to permit it to be able to detect a clinically
meaningful difference in the primary outcome between SAFE plus TAU and TAU arms was not
appropriate. Rather, the aim was to provide robust estimates of the likely rates of recruitment, consent
and follow-up and to yield estimates of the ED event rate and dispersion parameter to accurately
inform power calculations for a future definitive trial. To be able to do this, it was considered that
40 patients in each treatment arm would provide these estimates with adequate precision.
We estimated that ≥ 20% of those who have visited an ED on two or more occasions in the prior
12 months would agree to participate. It was anticipated that ≈ 400 eligible PWE would have visited the
three ED recruitment sites over the 12 months preceding our recruitment phase. This was informed by
NHS Digital data on the number of attendances at the sites in 2012/13176 and audit data that show that
≈ 1% of all ED visits are for epilepsy and ≈ 80% are by those with an established diagnosis.23,177 We also
factored in evidence on the proportion of ED visits within 1 year that had been made by the same
individual20 and estimated, using data from Ridsdale et al.,178 the number of PWE that would satisfy the
inclusion/exclusion criteria.
With a sample size of 80, a participation rate of 20% could be estimated to within a 95% confidence
interval (CI) of ± 4% and a drop-out rate of 25% to within a 95% CI of ± 10%. Assuming that data on
the proposed primary outcome measure of ED visits at 12 months were not available for 25% of
patients, outcome data from 60 patients would still allow robust estimation of the ED rate and
dispersion parameter. We considered that one full-time researcher would be able to recruit the
required sample within 8 months.
Completion of follow-ups
A number of evidence-based strategies were used to maximise retention of participants in the trial.179
This included patient and SO participants receiving a £10 shopping voucher after each follow-up
assessment that they completed and delayed access to SAFE for the TAU arm.
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Unless a participant formally withdrew consent to participate in the trial, HES data on them were
requested and up to three attempts were made to contact patients or SO participants each time a
follow-up assessment was due. The research worker also contacted participants by telephone
approximately 2 weeks after the 6-month questionnaires were posted.
When a patient participant did not complete a follow-up assessment, an attempt to monitor SAEs was
made by sending their GP a letter asking them to inform us if the patient was no longer alive and the
circumstances of death.
Data management
With the exception of the routine outcome data on ED use from NHS Digital, all data were collected
on paper-based CRFs by the research worker. The CRFs were kept in locked filing cabinets in a central
research office with restricted access at the University of Liverpool. The paper CRFs were sent to the
CTU for entry into MACRO 4.0 (Elsevier, Amsterdam, the Netherlands) by a data manager. At the point
of data entry, queries were raised. Participant contact information was kept on a secure central
network server with access granted to study staff only.
Data analysis
All statistical analyses were performed with SAS® statistical software (version 9.4) (SAS Institute Inc.,
Cary, NC, USA) (by SN; overseen by CTS). A full statistical analysis plan was developed and approved
prior to conducting the final analysis.
Rates of eligibility, consent, recruitment, retention and unblinding
Derivation and statistical analysis
The eligibility rate is defined as the percentage of patients screened that satisfy eligibility criteria (see
Chapter 3). The consent rate is defined as the percentage of eligible patients who provided informed,
written consent for randomisation. The recruitment rate is defined as the number of participants
recruited per calendar month.
Eligibility and consent rates are presented as percentages with 95% CIs. Recruitment rates are
presented as the actual number of participants recruited per calendar month presented alongside the
expected number of participants recruited per calendar month on recruitment graphs.
The age, sex and social deprivation profiles (available from ED records) of eligible individuals who did
and did not consent to take part in the trial are presented side by side in table columns for visual
comparison to evaluate representativeness of the trial sample.
Retention rate is defined as the percentage of randomised patient and SO participants completing 3,
6 and 12 months of the study without withdrawing (i.e. without formally withdrawing from any further
data collection). Reasons for withdrawal, where known, are presented.
The completion rate of study assessment tools (i.e. the percentage of patient and SO participants completing
each measure outlined in Table 4) is presented as an indicator of retention and participation in the trial.
The unblinding rate is defined as the proportion of correct treatment allocation guesses made by the
research worker at the end of the trial (12 months) or at withdrawal of the participant from the trial.
The unblinding rate is presented with 95% CIs. A Cohen’s kappa statistic for agreement (i.e. the correct
guess of allocation) and 95% CIs are also presented.
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Demographic and baseline characteristics
Baseline characteristics are presented for PWE overall and by treatment arm with comparisons
presented for a subset of characteristics for those individuals identified as eligible and invited to
participate in the trial who did not agree to participate in the trial.
Relevant baseline characteristics are presented descriptively for SO participants.
Categorical data are summarised by numbers and percentages. Continuous data are summarised by
mean, median, standard deviation (SD) and range (minimum and maximum values). Tests of statistical
significance are not undertaken for baseline characteristics; rather, the potential clinical importance of
any imbalance is noted.
Primary outcome: epilepsy-related emergency department visits
Derivation of outcome
The proposed primary outcome of a future trial is defined as the number of epilepsy-related ED visits
made by patient participants over the 12 months following randomisation measured by HES data. As a
secondary outcome, the number of self-reported epilepsy-related ED visits made by patient participants
over the 12 months following randomisation is also presented.
Statistical analysis
Epilepsy-related ED visits are presented at baseline (T0) and at 12 months (T3), and the number of ED
visits made by the end of the 12-month period compared with the number of ED visits made in the
12 months prior to baseline is also presented. Results are presented for all patient participants and by
treatment arm as mean and SDs, in addition to the median, the minimum and the maximum number
of epilepsy-related ED visits. Completeness of data for self-reported epilepsy-related ED visits is
presented and no imputation of missing data was performed.
The difference between the SAFE plus TAU arm and TAU only arm is compared at 12 months with and
without adjustment for baseline ED visits via negative binomial regression (NBR) models for count
data. Overdispersion (i.e. variance larger than the mean) and an excess number of zeros for individuals
who did not visit an ED in the last 12 months was anticipated; therefore, zero-inflated NBR models
were also applied. The preferred model (negative binomial or zero-inflated negative binomial) was
determined by Vuong’s test.180
Between-arm differences are presented as rate ratios with 95% CIs and statistically tested according
to a 5% level of significance. In addition, as per guidance for pilot trials,181 90% and 80% CIs are also
presented to aid interpretation of between-arm differences.
Epilepsy-related ED visits, measured by HES data, were compared with self-reported epilepsy-related
ED visits and Bland–Altman plots and limits of agreement statistics182 were calculated to determine the
agreement of the two measurement methods. A Bland–Altman plot shows the mean number of ED
visits in self-reported and HES data for each patient participant (x-axis) and the difference in the
number of ED visits in self-reported and HES data for each patient participant (y-axis). Bland–Altman
limits of agreement (mean ± 2 SDs) of the difference in the number of ED visits are also shown on the
plot. These limits can be interpreted as the level of agreement that is ‘acceptable’ between the two
measurements of recording ED visits.
Estimation of sample size of a future definitive trial
The average annual rate of ED visits in the SAFE plus TAU and TAU only arms and the likely dispersion
parameter estimated from the preferred NBR model are used to estimate the sample size of a future
definitive trial according to the methods outlined by Keene et al.183 for a negative binomial regression.
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The number of patient participants required per arm in a definitive trial to detect the size of the effect
shown in the pilot study is:
n =
z1−β + z1−α/2
log(µ1/µ2)
 2
×
µ1 + µ2
µ1µ2
+ 2k
 
, (1)
where Z1 – α/2 and Z1 – β are critical values of the normal distribution for specific values of α and β (typically,
α = 0.05 for a 5% significance level and β = 0.2 or 0.1 for 80% or 90% power, respectively), µ1 and µ2 are
the estimated ED rates from the two treatment arms and k is the negative binomial shape parameter
from the associated gamma distribution, which explicitly represents variability between subjects.
Secondary outcome measures
Derivation of outcomes
Details of the secondary outcome measures are described in Table 4.
Total scores for Quality of Life in Epilepsy Scale-31 item-Patient-weighted (QOLIE-31-P) (PWE participants
only), burden (SO participants only), confidence in managing seizures/epilepsy (SO participants only),
mastery (PWE participants only) and fear of seizures (PWE and SO participants) are presented at baseline
(T0), 6 months (T2) and 12 months (T3). The changes in total scores at 6 months (T2) and 12 months (T3)
from baseline (T0) are presented. Burden categories (‘little or no burden’, ‘mild to moderate burden’,
‘moderate to severe burden’ and ‘severe burden’) are presented.
Total scores for stigma (PWE participants only) and distress (anxiety and depression scores; PWE and
SO participants) are presented at baseline (T0) and at 12 months (T3). The changes in total scores at
12 months (T3) from baseline (T0) are also presented and stigma categories (‘no stigma’, ‘mildly to
moderately stigmatised’ and ‘highly stigmatised’) and anxiety and depression categories (‘normal range’,
‘suggestive of anxiety/depression’ and ‘probable anxiety/depression’) are presented.
The ‘knowledge of what to do where faced with a seizure’ score is presented as the number of
questions answered correctly (out of 13) at baseline (T0) and at 12 months (T3), in addition to the
change in knowledge score at 12 months (T3) from baseline (T0).
Self-reported seizure frequency is presented at baseline (T0), at 6 months (T2) and at 12 months (T3)
according to Thapar’s seizure frequency scale.169 The total numbers of seizures between baseline (T0)
and 6 months (T2) and between baseline (T0) and 12 months (T3) are also presented.
Statistical analysis
Total scores and the change from baseline scores of all measures, plus the total number of seizures,
are presented as mean and SD in addition to the median, the minimum and the maximum scores for
each scale. Burden, stigma, anxiety and depression categories are also presented as the number and
percentage of participants in each category. Results are presented for all participants and by treatment
arm and separately for PWE and SO participants where applicable.
Completeness of data for all self-reported scales is presented. Individual missing values in given scales
of the QOLIE-31-P184 and the Hospital Anxiety and Depression Scale (HADS) scale were imputed
according to recommended rules.185 No imputation was performed for other scales. Total scores are
presented separately for all individuals (including those with missing data) and for individuals with
complete data for the scale.
Visual comparison of differences between treatment arms only are made for secondary outcome
measures; no formal statistical testing is performed.
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Chapter 4 Part B: pilot RCT – recruitment,
retention, intervention delivery and participant
baseline characteristics
Introduction
This chapter presents findings from the pilot trial relating to participant recruitment, retention and
attendance at SAFE intervention sessions.
Participant flow through study
Search period
The stage 1 searches were originally set up to identify PWE who had made an ED visit between
1 January 2015 and 31 December 2015. However, recruitment proved more challenging than anticipated
and, with funder and governance approval, the period in which people could be identified as having
attended the EDs was extended by 7 months to 31 July 2016 (minor amendment, incorporated into
protocol version 1.2 on 9 July 2016). A total of 417,381 attendances for any reason were recorded at the
EDs between 1 January 2015 and 31 July 2016.
Eligibility
The stage 1 searches indicated that 6359 (1.5%) of the ED attendances were attributable to epilepsy
or a suspected epileptic seizure. These visits had been made by 4016 individuals. The Consolidated
Standards of Reporting Trials (CONSORT) flow diagram is presented (Figure 3). Following stage 2
review of the triage card associated with these visits, 1220 individuals were considered to have visited
for established epilepsy, with 555 of them being considered eligible for participation in the trial and
sent an invitation.
Having received the letter, no patient opted out, but 122 patients did send notification that they were
ineligible (Tables 5–7). For nine patients the postal address was incorrect or the letter was not sent, in
error. The remaining 424 patients were telephoned to determine their interest in the study and verify
eligibility (stage 3). Based on these figures, the eligibility rate (424 eligible participants out of 4016
unique individuals screened) was 10.6% (95% CI 9.6% to 11.5%).
It took the local principal investigator at each site ≈ 3 full days to complete the stage 2 screening.
Recruitment rates and speed of recruitment
The process of enrolment (i.e. participant consent and baseline assessment, as opposed to the period
within which the participants’ ED visits must have occurred) began in May 2016 and concluded at the
end of December 2016. Among the 424 patients telephoned, 53 agreed to participate and provided
informed consent, thus giving a consent rate of 12.5% (95% CI 9.3% to 15.6%). The reasons
participants offered for not taking part are provided in Table 8.
Regarding consent, successful telephone contact could be made with only 203 out of the 424 (47.9%)
eligible patients. When restricted to those who could be contacted, the consent rate is 26.1% (95% CI
20.0% to 32.2%).
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TABLE 5 Attendance at ED not related to epilepsy
Reason
Number of participants
Site 1 Site 2 Site 3 Total
No confirmed diagnosis of epilepsy/not attending because of epilepsy 737 483 715 1935
Acute symptomatic seizures related to neurological illness or substance abuse 238 240 191 669
Psychogenic non-epileptic seizures 19 55 29 103
Medical record missing 54 5 27 86
Ineligible, no reason givena 2 1 0 3
Total 1050 784 962 2796
a Lack of reason due to patients returning participation slips without stating actual reason for ineligibility.
Visits made by person already identified
in the database
(n = 2343)
Unique individuals
identified as having visited
for a seizure
(n = 4016)
Invitations sent to ostensibly
eligible patients with
epilepsy
(n = 555) 
Explicitly declined invitation
(n = 150)
(See Table 8 for details)
Patients not contactable by telephone who did
not respond to subsequent letter
(n = 221)Number consenting 
to participate
(n = 53)
(with 38 carers) 
ED visits 
identified as relating
to ‘seizures’
(n = 6359)
Number ineligible
(n = 122)
(See Table 7 for details)
Number for whom postal address was
incorrect  or invite letter not sent in error
(n = 9)Eligible and invited to meet
researcher for baseline 
visit and consent
(n = 424) 
Number randomised
(n = 51)
(with 37 carers) 
Attendance not related to 
established epilepsy
(n = 2796)
(See Table 5 for details) 
Individuals visiting for
established epilepsy
(n = 1220) 
Not eligible
(n = 665)
(See Table 6 for details)
Withdrawn prior to randomisation
(n = 2)
[Reason: no consent from carer, n = 1; patient
changed mind, n = 1]
FIGURE 3 The CONSORT flow diagram of eligibility screening for the trial.
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TABLE 6 Other reasons for non-eligibility (individuals visiting for established epilepsy)
Reason
Number of participants
Site 1 Site 2 Site 3 Total
Postcode outside catchment area 148 94 60 302
Learning disability likely to impede individuals’ capacity to provided
signed, informed consent
45 51 52 148
Inability to converse in English and provide signed informed consent 10 24 46 80
Life-threatening medical illness 35 26 10 71
Severe psychiatric disorder 11 3 18 32
No fixed abode 10 6 13 29
Participating in another trial 3 0 0 3
Total 262 204 199 665
TABLE 7 Reasons for non-eligibility (ostensibly eligible individuals)
Reason
Number of participants
Site 1 Site 2 Site 3 Total
Has not visited an ED for epilepsy on two or more occasions in previous
12 months (self-reported)
9 15 24 48
Not able to provide informed consent, participate in SAFE course if
randomised or to independently complete questionnaires in English
9 7 7 23
Ineligible, no reason givena 4 7 4 15
No established diagnosis of epilepsy (< 1 year) 3 2 5 10
Moved out of area; postcode no longer within 25-mile catchment area 4 1 3 8
Actual or suspected psychogenic non-epileptic seizures alone or in
combination with epilepsy
2 1 4 7
Severe current psychiatric disorders or life-threatening medical illness 1 5 1 7
Not currently being prescribed antiepileptic drug 1 0 1 2
Acute symptomatic seizures related to acute neurological illness or
substance misuse
0 1 0 1
Participating in another trial 1 0 0 1
Total 34 39 49 122
a Lack of reason due to patients returning participation slips without stating actual reason for ineligibility.
TABLE 8 Reasons for declining participation (eligible individuals)
Reason
Number of participants
Site 1 Site 2 Site 3 Total
Not interested 30 11 23 64
Too busy 11 12 11 34
No reason given 9 10 8 27
Too ill 5 5 9 19
Too well 3 1 2 6
Total 58 39 53 150
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The process of enrolment lasted 226 days (equivalent to 7.43 months), with an average randomisation
rate of 6.9 patients per month (ranging from 4 to 11 patients per month). Actual rates and expected
rates of recruitment each month are presented in Appendix 10. Because the target sample size of
80 patients was not reached, the speed of recruitment could not be calculated.
Randomisation
Among the 53 consenting patients, 51 were randomised (along with 37 SO participants with whom
they took part). The first was randomised on 19 May 2016 and the last on 31 December 2016.
Two patient participants were not randomised because they withdrew prior to randomisation.
Among the 51 patient participants randomised, 26 (with 18 SOs) were allocated to SAFE plus TAU
and 25 (with 19 SOs) to TAU only. Participant flow through the SAFE trial is outlined in Figure 4.
Receipt of intervention
Seven SAFE intervention courses were run for the SAFE plus TAU arm between June 2016 and
February 2017. No seizures were recorded as having occurred during the courses and there were no
instances of participants in the TAU arm attending a SAFE session by mistake.
We anticipated that SAFE would be delivered to groups of 8–10 people in the pilot trial. In practice,
the average group size was 5, with 20 (76.9%) out of the 26 patient participants and 13 (72.2%) out of
the 18 SOs randomised to the intervention attending a course. No patients or SOs completed only part
of a course.
A total of 33 course bookings were made for the 26 patient participants randomised to SAFE. Most
(n = 18, 90%) of the 20 patient participants randomised to SAFE who actually attended a course
attended the first course that they were booked on. The minority of patients who did not ultimately
attend a course were associated with substantial administrative activity. Specifically, six patient
participants who did not attend a course received, between them, 45 telephone calls from the study
administrator and booked onto 11 course slots. This contrasts with the 34 telephone calls in total that
were made to the 20 patient participants who attended a course. Reasons for non-attendance included
poor health on the patients’ behalf and work commitments on behalf of the SO.
Withdrawals and completion of follow-ups
Formal withdrawals from trial
Among the 51 randomised patient participants, only three (5.9%) withdrew consent to participate and
for routine data to be collected on them over the course of their 12 months in the trial; two withdrew
from the TAU condition and one from the SAFE arm. This meant that consent remained in place for
securing routine outcome ED data for 48 (94.1%) patient participants. The reasons for participant
withdrawal are described in Appendix 11. No withdrawals were initiated on the patient’s behalf by a
health-care provider or a member of the research team. Among the 37 randomised SO participants,
five (13.5%) withdrew.
Participation in questionnaire-based follow-up assessments
A total of 37 (72.5%) of the patient participants and 21 (56.8%) SOs attended their scheduled post-
randomisation primary outcome assessment at 12 months (T3). The 37 patient participants attended
their post-randomisation follow-up visit at 12 months at a median of 286 days (range 252–365 days)
post randomisation. Appointments often took place before 12 months because slower recruitment
meant that time for follow-up within the life of the project was reduced.
With respect to the interim questionnaire assessments, 43 (84.3%) patients returned the 3-month (T1)
follow-up questionnaire and 39 (76.5%) patients and 26 (70.3%) SOs returned their 6-month (T2)
follow-up questionnaire.
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Unique patients assessed for eligibility
(n = 4016)
Excluded
(n = 3965)
• Not meeting inclusion criteria, n = 3583
• Not contacted or not contactable, n = 230
• Declined to participate, n = 152
Patients withdrawn during the study
(n = 1)
• Patients withdrawn at 3-month follow-up, n = 0
• Patients withdrawn at 6-month follow-up, n = 0
• Patients withdrawn at 12-month follow-up, n = 1
    • Reason: too busy, n = 1
Patients completing 12-month follow-up
(n = 25)
Carers withdrawn during the study
(n = 1)
• Carers withdrawn at 6-month follow-up, n = 1
    • Reason missing, n = 1
• Carers withdrawn at 12-month follow-up, n = 0
Carers completing 12-month follow-up
(n = 17)
• Did not receive SAFE plus TAU, n = 6
• Reason: ill health of patient, n = 2
• Reason: patient/carer work commitments, n = 2
• No reason given, n = 2
• Did not receive SAFE plus TAU, n = 5
• Reason: ill health of patient, n = 2
• Reason: patient/carer work commitments, n = 2
• No reason given, n = 1
Patients withdrawn during the study
(n = 3)
• Patients withdrawn at 3-month follow-up, n = 1
    • Reason: not interested any more, n = 1
• Patients withdrawn at 6-month follow-up, n = 1
    • Reason: wife has cancer, n = 1
• Patients withdrawn at 12-month follow-up, n = 1
    • Reason: moved away to work, n = 1
Patients completing 12-month follow-up
(n = 22)
Carers withdrawn during the study
(n = 4) 
• Carers withdrawn at 6-month follow-up, n = 3
    • Reason: not interested any more, n = 1
    • Reason: too ill, n = 1
    • No longer friends with person with epilepsy,
        n = 1
• Carers withdrawn at 12-month follow-up, n = 1
    • Reason: moved away to work, n = 1
Carers completing 12-month follow-up
(n = 15)
Patients allocated to TAU
(n = 25)
Carers allocated to TAU
(n = 19)
Allocation
Follow-up
Randomised patients
(n = 51)
Randomised carers
(n = 37)
Enrolment
SAFE plus TAU TAU
Patients allocated to SAFE plus TAU
(n = 26)
Carers allocated to SAFE plus TAU
(n = 18)
• Did not receive allocated intervention: NA
• Did not receive allocated intervention: NA
FIGURE 4 The CONSORT flow diagram for the SAFE trial. NA, not applicable.
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Securing outcome data and their completeness
Primary outcome: emergency department data from Hospital Episode
Statistics system
Completeness of data
Hospital Episode Statistics data on ED use were secured by the research team from NHS Digital for
each of the 48 (94.1%) randomised patient participants for whom consent to participate and secure ED
outcome data on them remained.
Process of securing the data
After delays in being granted permission to access NHS Digital’s application form, the research team
submitted the application for the data on 16 February 2018. To minimise cost, a single application,
rather than one relating to the baseline period and one for follow-up, was submitted. The data were
ultimately received by the research team on 31 October 2018 at a direct cost of £6960.00 [inclusive of
value-added tax (VAT)].
Prior to starting the trial and submitting the application, the research team communicated with NHS
Digital and ensured that the participant information sheet and consent form were consistent with its
requirements. Despite this, it took 7 months for the application to be reviewed and approved by NHS
Digital and an additional 1.5 months for the data file to be produced and transferred.
During these periods, substantial effort was required by the research team to respond to queries raised
by NHS Digital and to request progress updates once responses had been submitted. A log of all
correspondence was kept by the research team. The team typically responded to queries raised by NHS
Digital within 1 day; key milestones are outlined in Appendix 12. In one instance, the research team
needed to successfully appeal – 5 months into the application process – against a decision by NHS
Digital to reject it because of, among other things, apprehensions regarding the project’s scientific merit.
The team was notified it was being rejected because of ‘concerns [over . . .] whether this pilot would yield
findings that were statistically valuable to achieve the stated aims given the small numbers involved’.
Secondary outcome data
The extent to which the secondary outcome measures were fully completed by the patient participants
who participated in the follow-up assessments varied by assessment point, by measure and by participant
type (Tables 9 and 10). Self-reported ED use at 12 months post randomisation (T3) by patient participants
was the secondary means by which ED use was captured and so, arguably, the most important of the
secondary outcome measures. Self-reported ED use data at 12 months (T3) were available for 34 (66.7%)
out of the 51 randomised patient participants.
Baseline characteristics
Patient participants
Demographics
The mean age of the 51 randomised patient participants was 39.9 years (SD 15.6 years, range 16–71 years);
29 (56.9%) were female and 94.1% identified themselves as being of ‘white’ ethnicity (Table 11).
The Index of Multiple Deprivation (IMD) (URL: www.gov.uk/government/statistics/english-indices-of-
deprivation-2015; accessed 27 August 2019), measuring levels of deprivation according to participants’
home postcode, indicated that most (74.4%) patient participants lived in areas of high deprivation;
49% (n = 25) lived in areas in the top 10% most socially deprived in the country. Most (53%) patient
participants had attained a basic level of formal education only [i.e. Ordinary levels (O levels)/General
Certificate of Secondary Educations (GCSEs)/Level 1 or 2 National Vocational Qualification (NVQ)].
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TABLE 9 Number of patient participants fully completing study assessment tools at each time point
Study assessment tool
Treatment arm, n (%)
Total, n (%)SAFE plus TAU TAU
Baseline (T0) (N = 26) (N = 25) (N = 51)
ED self-report 24 (92.3) 21 (84.0) 45 (88.2)
Thapar’s seizure frequency scale:169 seizure control 26 (100.0) 25 (100.0) 51 (100.0)
QOLIE-31-P184 23 (88.5) 16 (64.0) 39 (76.5)
aHADS167,168 23 (88.5) 24 (96.0) 47 (92.2)
Stigma Scale of Epilepsy62 24 (92.3) 24 (96.0) 48 (94.1)
bClient Service Receipt Inventory171 19 (73.1) 17 (68.0) 36 (70.6)
EQ-5D172 21 (80.8) 25 (100.0) 46 (90.2)
Wagner 6-item Mastery Scale61 26 (100.0) 21 (84.0) 47 (92.2)
Epilepsy Knowledge and Management questionnaire:163 fear of
seizures subscale
16 (61.5) 9 (36.0) 25 (49.2)
6 months (T2) (N = 26) (N = 23) c (N = 49)c
QOLIE-31-P184 16 (61.5) 12 (52.2) 28 (57.1)
Wagner 6-item Mastery Scale61 21 (80.8) 15 (65.2) 36 (73.5)
Thapar’s seizure frequency scale:169 seizure control 16 (61.5) 15 (65.2) 28 (57.1)
12 months (T3) (N = 25)d (N = 22)d (N = 47)d
ED self-report 17 (68.0) 17 (77.3) 34 (72.3)
Thapar’s seizure frequency scale:169 seizure control 20 (80.0) 14 (60.9) 34 (72.3)
QOLIE-31-P184 10 (40.0) 8 (36.4) 18 (38.3)
aHADS167,168 18 (72.0) 17 (77.3) 35 (74.4)
Stigma Scale of Epilepsy62 18 (72.0) 17 (77.3) 35 (74.4)
bClient Service Receipt Inventory171 13 (52.0) 10 (45.5) 23 (48.9)
EQ-5D172 18 (72.0) 17 (77.3) 35 (74.4)
Wagner 6-item Mastery Scale61 18 (72.0) 16 (72.7) 34 (72.3)
Epilepsy Knowledge and Management questionnaire:163 fear of
seizures subscale
8 (32.0) 5 (22.7) 13 (27.7)
Feedback on participation 17 (68.0) 15 (68.2) 32 (68.1)
EQ-5D, EuroQol-5 Dimensions.
a Completeness of the whole HADS scale (both anxiety and depression subscales).
b Only six mandatory questions counted. Conditional questions (e.g. ‘if yes, then’) were not counted towards
total completion.
c Two patient participants from the TAU arm had withdrawn by the 6-month visit.
d Four patient participants (three from the TAU arm and one from the SAFE plus TAU arm) had withdrawn by the
12-month visit.
Although some participants did not fully complete all items in a questionnaire, this does not mean that their data
would automatically need to be excluded from analysis of a change in that domain because for some measures test
developers permit imputation when the number of missing items is small and follows a specific pattern. Information on
the number of items completed for the specific assessment tools is presented in Appendix 13.
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TABLE 10 Number of SO participants fully completing study assessment tools at each time point
Study assessment tool
Treatment arm, n (%)
Total, n (%)SAFE plus TAU TAU
Baseline (T0) (N = 18) (N = 19) (N = 37)
Zarit caregiver burden170 17 (94.4) 17 (89.5) 34 (91.9)
aHADS167,168 17 (94.4) 18 (94.7) 35 (94.6)
Parent Response to Child Illness scale186 18 (100.0) 19 (100.0) 37 (100.0)
Epilepsy Knowledge and Management questionnaire:163
fear of seizures subscale
6 (33.3) 4 (21.1) 10 (27.0)
6 months (T2) (N = 17)b (N = 16)b (N = 33)b
Zarit caregiver burden170 15 (88.2) 8 (50.0) 23 (69.7)
Parent Response to Child Illness scale186 16 (94.1) 9 (56.3) 25 (75.8)
12 months (T3) (N = 17)c (N = 15)c (N = 32)c
Zarit caregiver burden170 11 (64.7) 10 (66.7) 21 (65.6)
aHADS167,168 11 (64.7) 10 (66.7) 21 (65.6)
Parent Response to Child Illness scale186 11 (64.7) 10 (66.7) 21 (65.6)
Epilepsy Knowledge and Management questionnaire:163
fear of seizures subscale
6 (35.3) 2 (13.3) 8 (25.0)
Feedback on participation 11 (64.7) 9 (60.0) 20 (62.5)
a Completeness of the whole HADS scale (both anxiety and depression subscales).
b Four SO participants (one in the SAFE plus TAU arm and three in the TAU arm) had withdrawn by the 6-month visit.
c Five SO participants (one in the SAFE plus TAU arm and four in the TAU arm) had withdrawn by the 3-month visit.
Although some participants did not fully complete all items in a questionnaire, this does not mean that their data
would automatically need to be excluded from analysis of a change in that domain because for some measures test
developers permit imputation when the number of missing items is small and follows a specific pattern. Information on
the number of items completed for the specific assessment tools is presented in Appendix 13.
TABLE 11 Demographic characteristics of patient participants
Demographic characteristic
Treatment arm
TotalSAFE plus TAU TAU
Sex, n (%) (N = 26) (N = 25) (N = 51)
Male 10 (38.5) 12 (48.0) 22 (43.1)
Female 16 (61.5) 13 (52.0) 29 (56.9)
Missing 0 (0.0) 0 (0.0) 0 (0.0)
Age (years) at presentation to the EDa (N = 26) (N = 25) (N = 51)
Mean, years 39.2 40.7 39.9
SD, years 13.96 17.52 15.66
Minimum, years 18.9 16.5 16.4
Median, years 37.1 41.4 38.8
Maximum, years 69.9 71.3 71.3
Missing, n (%) 0 (0.0) 0 (0.0) 0 (0.0)
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TABLE 11 Demographic characteristics of patient participants (continued )
Demographic characteristic
Treatment arm
TotalSAFE plus TAU TAU
IMDb (N = 26) (N = 25) (N = 51)
Decile 1
n (%) 11 (42.3) 14 (56.0) 25 (49.0)
Minimum rank 44 48 44
Median rank 574.0 1231.5 673.0
Maximum rank 3202 2166 3202
Deciles 2 and 3
n (%) 7 (26.9) 6 (24.0) 13 (25.4)
Minimum rank 4649 3989 3989
Median rank 6785 6665 6785
Maximum rank 8281 7816 8281
Deciles 4–6
n (%) 2 (7.7) 4 (16.0) 6 (11.8)
Minimum rank 9881 11,480 9881
Median rank 12,836 11,924 11,924
Maximum rank 15,791 16,004 16,004
Deciles 7–10
n (%) 5 (19.2) 1 (4.0) 6 (11.8)
Minimum rank 24,971 32,724 24,971
Median rank 27,642 32,724 28,876
Maximum rank 31,002 32,724 32,724
Decile missingc
n (%) 1 (3.8) 0 (0.0) 1 (2.0)
Ethnicity, n (%) (N = 26) (N = 25) (N = 51)
White 25 (96.2) 23 (92.0) 48 (94.1)
Asian/Asian British 0 (0.0) 0 (0.0) 0 (0.0)
Black/African/Caribbean/black British 1 (3.8) 1 (4.0) 2 (3.9)
Mixed/multiple 0 (0.0) 0 (0.0) 0 (0.0)
Other 0 (0.0) 1 (4.0) 1 (2.0)
Missing 0 (0.0) 0 (0.0) 0 (0.0)
Other significant medical history, n (%) (N = 26) (N = 25) (N = 51)
No, none 13 (50.0) 10 (40.0) 23 (45.1)
Yes, another medical condition(s) 10 (38.5) 13 (52.0) 23 (45.1)
Yes, a psychiatric condition 1 (3.8) 0 (0.0) 1 (2.0)
Yes, both medical and psychiatric conditions 2 (7.7) 2 (8.0) 4 (7.8)
Missing 0 (0.0) 0 (0.0) 0 (0.0)
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Epilepsy characteristics
Patient participants had been diagnosed with epilepsy for a median of 21 years. Most participants
(62.8%) reported having had ≥ 10 seizures in the previous year. Most participants (54.9%) reported
having another health condition. The median time since their last seizure was 14 days. Most participants
(n = 38; 74.5%) reported having seen a neurologist in the 12 months prior to their assessment (Table 12).
TABLE 11 Demographic characteristics of patient participants (continued )
Demographic characteristic
Treatment arm
TotalSAFE plus TAU TAU
Education, n (%) (N = 26) (N = 25) (N = 51)
O levels/GCSEs/Level 1 or 2 NVQ 13 (50.0) 14 (56.0) 27 (53.0)
A levels/Level 3 NVQ 5 (19.2) 3 (12.0) 8 (15.7)
University degree/graduate certificate or diploma 5 (19.2) 5 (20.0) 10 (19.6)
Postgraduate university degree (e.g. PGCE, MSc, MA, PhD) 2 (7.7) 0 (0.0) 2 (3.9)
Missing 1 (3.9) 3 (12.0) 4 (7.8)
A level, Advanced level; MA, Master of Arts; MSc, Master of Science; PGCE, Postgraduate Certificate in Education;
PhD, Doctor of Philosophy.
a Four participants (7.8%) had missing ages recorded from CRF data; therefore, date of birth and date of presentation
recorded in the bespoke screening database were used to calculate age at presentation to the ED.
b The IMD ranks every small area in England from 1 (most deprived area) to 32,844 (least deprived area). Decile and
rank missing for one recruited participant because they resided in Wales.
TABLE 12 Baseline disease characteristics and key health service use of patient participants
Disease characteristic
Treatment arm
TotalSAFE plus TAU TAU
Time (years) since epilepsy diagnosis
n (%) 26 (100.0) 25 (100.0) 51 (100.0)
Mean, years 19.9 22.6 21.2
SD, years 14.85 18.38 16.57
Minimum, years 1.8 1.7 1.7
Median, years 16.8 19.3 17.3
Maximum, years 53.9 64.9 64.9
Missing, n (%) 0 (0.0) 0 (0.0) 0 (0.0)
Time (days) since last epileptic seizure
n (%) 23 (88.5) 22 (88.0) 45 (88.2)
Mean, days 53.6 40.1 47.0
SD, days 101.10 61.21 83.34
Minimum, days 1 0 0
Median, days 14.0 10.5 14.0
Maximum, days 340 235 340
Missing, n (%) 3 (11.5) 3 (12.0) 6 (11.8)
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TABLE 12 Baseline disease characteristics and key health service use of patient participants (continued )
Disease characteristic
Treatment arm
TotalSAFE plus TAU TAU
Number of epileptic seizures in the last 12 months
n (%) 26 (100.0) 25 (100.0) 51 (100.0)
0 1 (3.8) 0 (0.0) 1 (2.0)
1 1 (3.8) 0 (0.0) 1 (2.0)
2 0 (0.0) 2 (8.0) 2 (3.9)
3 2 (7.7) 1 (4.0) 3 (5.9)
4 0 (0.0) 0 (0.0) 0 (0.0)
5 0 (0.0) 2 (8.0) 2 (3.9)
6 1 (3.8) 3 (12.0) 4 (7.8)
7 1 (3.8) 1 (4.0) 2 (3.9)
8 2 (7.7) 2 (8.0) 4 (7.8)
9 0 (0.0) 0 (0.0) 0 (0.0)
≥ 10 18 (69.2) 14 (56.0) 32 (62.8)
Missing, n (%) 0 (0.0) 0 (0.0) 0 (0.0)
HES health-care use in the last 12 months
ED attendance
n (%) 25 (96.2) 23 (92.0) 48 (94.1)
At least one attendance, n (%)a 23 (88.5) 18 (72.0) 41 (80.4)
Mean 2.1 3 2.5
SD 2.22 2.76 2.51
Minimum 0 1 0
Median 1 2 2
Maximum 10 12 12
Missing, n (%) 1 (3.8) 2 (8.0) 3 (5.9)
Self-reported health-care use in the last 12 months for epilepsy
ED attendance
n (%) 24 (92.2) 21 (84.0) 45 (88.2)
At least one attendance, n (%)a 23 (88.5) 18 (72.0) 41 (80.4)
Mean 4.3 9.8 6.7
SD 2.83 24.38 16.27
Minimum 1 1 1
Median 4 4 4
Maximum 12 107 107
Missing, n (%) 2 (7.8) 4 (16.0) 6 (11.8)
Neurology outpatient appointment
n (%) 25 (96.2) 22 (88.0) 47 (92.1)
At least one attendance, n (%)a 21 (80.8) 16 (68.0) 38 (74.5)
Mean 2.6 3.1 2.8
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TABLE 12 Baseline disease characteristics and key health service use of patient participants (continued )
Disease characteristic
Treatment arm
TotalSAFE plus TAU TAU
SD 1.78 2.26 2.00
Minimum 1 1 1
Median 2 2 2
Maximum 8 10 10
Missing, n (%) 1 (3.8) 3 (12.0) 4 (7.8)
Emergency ambulance called (whether or not the ambulance took the patient to the ED)
n (%) 21 (80.8) 21 (84.0) 42 (82.4)
At least one attendance, n (%)a 18 (69.2) 18 (72.0) 36 (70.6)
Mean 3.2 4.1 3.6
SD 2.87 2.86 2.86
Minimum 1 1 1
Median 2 3 3
Maximum 12 12 12
Missing, n (%) 5 (19.2) 4 (16.0) 9 (17.7)
GP contact
n (%) 23 (88.5) 23 (92.0) 46 (90.2)
At least one contact, n (%)a 16 (61.6) 13 (52.0) 29 (56.9)
Missing, n (%) 3 (11.5) 2 (8.0) 5 (9.8)
Number of contacts (if used)a
Mean 3.7 4.3 4.0
SD 2.02 3.03 2.50
Minimum 1 1 1
Median 3.5 4.0 4.0
Maximum 6 12 12
Epilepsy nurse contact
n (%) 22 (84.6) 23 (92.0) 45 (88.2)
At least one contact, n (%) 12 (46.2) 12 (48.0) 24 (47.0)
Missing, n (%) 4 (15.4) 2 (8.0) 6 (11.8)
Number of contacts (if used)a
Mean 2.4 2.1 2.3
SD 1.37 1.56 1.45
Minimum 1 1 1
Median 2.0 1.5 2.0
Maximum 6 6 6
a Mean, SD, minimum, median and maximum number of attendances calculated for those with at least one attendance
or contact.
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Emergency department use in 12 months prior to enrolment
Hospital Episode Statistics emergency department data
Hospital Episode Statistics ED data for the 48 patients for whom consent were maintained over the
trial show that they together made 122 ED visits in the 12 months before randomisation. Frequency of
ED use among them was positively skewed (Figure 5). The median number of visits was 2 (range 0–12)
(see Table 12).
As described in Chapter 3, patient identification centred on the use of NHS ED attendance records and
only patients who, when telephoned, said that they had made two or more ED visits for epilepsy in the
prior 12 months were recruited. Despite this process, data from the HES system indicated that four
(8.3%) patient participants had not made any ED visits during the 12 months prior to recruitment and
a further 19 (39.6%) were noted to have made only one ED visit.
Self-reported emergency department data
Self-reported data were available for 45 (88.2%) patient participants. The median number of visits was
four (range 0–107) (see Table 12). Again, despite the screening processes, four (8.9%) patient participants
responded on the questionnaire completed subsequent to telephone screening that they had not made
any visits during the prior 12 months and 3 (6.7%) reported that they had made only one visit.
Relationship between Hospital Episode Statistics and self-reported data
There were 42 patient participants who had self-reported ED data at baseline (T0) and for whom
consent remained in place for obtaining their HES ED data. Bland–Altman plots of the agreement
between self-reported and HES data on ED visits were produced.
Primary focus is given to the plot shown in Figure 6. This is based on data from 41 rather than 42 patient
participants. This is because the distribution of self-reported ED use was particularly influenced by one
patient participant who self-reported 107 visits in the prior 12 months. We can confirm that that report
of 107 visits was checked against the participant’s answer on the questionnaire and did not reflect a data
entry error. Given that only one ED visit in the 12 months was recorded for this patient participant in
HES data, we considered the self-report of 107 ED visits to be an outlier and excluded this in the plot
shown in Figure 6 (Appendix 14 presents a Bland–Altman plot without any exclusions).
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FIGURE 5 Histogram of the number of ED attendances in the previous 12 months by patients according to HES system.
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FIGURE 6 Bland–Altman plot of agreement between self-reported and HES data on ED visits at baseline (n = 41; excludes outlier).
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Figure 6 shows that disagreement existed between self-reported and HES data for most patient
participants. Most (76.2%) participants self-reported more ED visits than were indicated by the HES
system. Only three (7.1%) participants reported the same number of ED visits as were recorded by
HES. Figure 6 shows that the limit of agreement was –5.0 visits (i.e. five fewer visits in self-reported
data than in HES data) to 7.7 visits (i.e. 7.7 visits more in self-reported data than in HES data).
Psychosocial measures
Compared with a maximum possible score of 100, the mean QOLIE-31-P score was 48.3 (SD 17.3),
with a large range (17.1–79.5). Twenty-six (50.9%) participants had ‘probable’ anxiety and 11 (21.6%)
had ‘probable’ depression. Assessment of self-stigma revealed that most (n = 42; 82.3%) felt at least
some stigma because of epilepsy and 15 (29.4%) felt highly stigmatised.
Comparability of treatment arms, including in emergency department use
Considering the small sample size, the process of randomisation was largely successful in generating
two treatment arms broadly similar in demographics and scores on the baseline assessment tools (see
Tables 11 and 12). Some differences were apparent in their ED use prior to randomisation (as measured
by HES and self-report); ED use was slightly higher in the TAU arm than in the SAFE plus TAU arm
(see Table 12).
Representativeness
The age, sex and social deprivation profile of the randomised patient participant sample was compared
with that of the patients who were eligible to participate but who declined to participate or were not
contactable. This showed that the two groups were comparable in age and social deprivation profile
but that females were slightly over-represented in the recruited sample (Table 13).
Significant other participants
Most (72.5%) patient participants took part in the trial with a SO. SOs were typically a partner or
spouse (43.2%), a parent (21.6%), or a son or daughter (16.2%). Most (75.5%) SOs lived in the same
household as the patient and had contact with them every day of the week (89.2%). Their mean age
was 43.2 years (SD 17 years, range 17–79 years) and most (59.5%) were female. Among the SOs,
32.4% reported having a medical condition themselves.
Anxiety levels among SOs were high, with 15 (40.5%) of the SOs having a score indicating ‘probable’
clinical anxiety. Only three (8.1%) had a score indicating ‘probable’ clinical depression. The mean Zarit
caregiver burden score170 was 18.9 (SD 12.51), with most being categorised as reporting either little or
no burden (n = 23; 62.2%) or mild to moderate burden (n = 11; 29.7%). Further characteristics of the
SOs, including by treatment arm, are provided in Appendix 15.
Researcher unblinding
The researcher correctly stated the treatment allocation of 35 out of the 51 patient participants, giving
a rate of unblinding of 68.6% (95% CI 54.1% to 80.9%). The chance-corrected Cohen’s kappa statistic
for this level of agreement is 0.37 (95% CI 0.12 to 0.63), indicating ‘fair’ agreement. For SO participants,
the researcher correctly stated the treatment allocation of 24 out of the 36 SOs (estimate missing for
one SO), giving a rate of unblinding of 66.7% (95% CI 49.0% to 81.4%) and a Cohen’s kappa statistic for
agreement of 0.33 (95% CI 0.02 to 0.64). For only three (5.8%) patient participants and three (8.3%)
SO participants did the researcher report that they strongly thought that they knew the patient
participant’s treatment allocation because of comments participants had made.
Summary
A successful pilot trial was completed in terms of a largely representative sample being recruited and
randomised and most patients randomised to SAFE receiving it. There were no protocol deviations
and the research worker completing the outcome assessments remained blind to treatment allocation.
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TABLE 13 Demographic characteristics of eligible participants by agreement to participate in the trial
Demographic characteristic Agreed to participate Did not agree to participate
Sex, n (%) (N = 51) (N = 379)a
Male 22 (43.1) 192 (50.7)
Female 29 (56.9) 187 (49.3)
Missing 0 (0.0) 0 (0.0)
Age (years) at presentation to the ED
n (%) 51 (100.0) 379 (100.0)
Mean, years 39.9 40.6
SD, years 15.66 16.83
Minimum, years 16.4 16.2
Median, years 38.8 37.5
Maximum, years 71.3 84.4
Missing, n (%) 0 (0.0) 0 (0)
IMDb (N = 51) (N = 379)
Decile 1
n (%) 25 (49.0) 188 (49.6)
Minimum rank 44 28
Median rank 673.0 924.5
Maximum rank 3202 3107
Deciles 2 and 3
n (%) 13 (25.4) 82 (21.6)
Minimum rank 3989 3291
Median rank 6785 5309
Maximum rank 8281 9835
Deciles 4–6
n (%) 6 (11.8) 59 (15.6)
Minimum rank 9881 10,277
Median rank 11,924 14,459
Maximum rank 16,004 19,659
Deciles 7–10
n (%) 6 (11.8) 50 (13.2)
Minimum rank 24,971 19,826
Median rank 28,876 22,673
Maximum rank 32,724 32,396
Decile missing
n (%) 1 (2.0) 0 (0)
a Includes seven patients who could not be contacted owing to an incorrect postal address and two patients who
were not sent an invite letter in error.
b Decile and rank missing for one recruited participant because they resided in Wales. The IMD ranks every small area
in England from 1 (most deprived area) to 32,844 (least deprived area).
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However, only one of the two predetermined ‘stop/go’ criteria for a definitive trial was met. Specifically,
the criterion of securing primary outcome data for ≥ 75% of participants was satisfied (in that it was
secured for 94%), but the criterion regarding the percentage of eligible patients agreeing to participate
was not: only 12.5% rather than ≥ 20% agreed to take part. The low consent rate, as well as fewer
patients being found to be eligible to take part and contactable than anticipated, meant that the target
sample size for the pilot RCT was not achieved. The pilot RCT also revealed that identifying patients
from local ED records could be resource intensive and that securing routine outcome data on ED use
via the HES system requires substantial time.
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Chapter 5 Intervention fidelity
Introduction
Seizure first Aid training For Epilepsy is a group-based intervention comprising multiple interacting
components and requires a number of behaviours on behalf of those delivering and receiving SAFE.
These features create opportunity for variation in its delivery. To permit accurate interpretation of the
estimates of its effect generated by the pilot RCT, as well as to help determine whether or not SAFE
can be delivered as intended in a trial context, information on its implementation fidelity in the pilot
RCT is required. Implementation fidelity refers to the extent to which the core content of SAFE was
delivered (adherence) as intended and with what sort of skill (competency). Such monitoring is
recommended by the Template for Intervention Description and Replication (TIDieR) extension to the
CONSORT statement.187
Assessing for both adherence and competence is important because the two are not necessarily
equivalent (e.g. a facilitator can be highly adherent to treatment manual procedures but not be
competent in deploying them). An aspect of competence that appears important when delivering
group-based complex interventions155 is interactivity between facilitator and recipients – namely,
the degree of ‘didacticism’.155,188 Although some didacticism is needed to ensure that certain information
is provided and participants remain oriented to the goals of the intervention, interaction means that
participants are asking questions and obtaining clarification and so are ensuring that the intervention is
tailored to their needs. It also permits participants to share and learn from one another.
In the light of the above information, we therefore report how we (1) developed a measure of
adherence for SAFE and evaluated its reproducibility, (2) used an existing method for assessing
didacticism and evaluated its reproducibility when applied to SAFE and (3), using audio-recordings
of intervention sessions, determined the extent of adherence and didacticism demonstrated in the
delivery of SAFE in the pilot RCT.
Methods
All seven courses run for the SAFE plus TAU arm of the pilot RCT were audio-recorded and assessed
for implementation fidelity. Because SAFE is brief and it is not known which components are its key,
active, behaviour-changing ingredients, all parts of SAFE were evaluated for their fidelity. The
facilitator was aware that course recordings were to be rated.
Developing the intervention fidelity measurement instruments
Adherence
A checklist of SAFE’s intended content was developed on the basis of the facilitator’s manual (see
Report Supplementary Material 1), which lists the 37 items that were meant to be delivered across
SAFE’s six modules. The checklist asked a rater to report the extent to which each item was delivered
(0 = not delivered; 1 = partially delivered; 2 = fully delivered).
The number of items in each module differed (range 4–10). To allow adherence in the different course
modules to be compared, average adherence ratings were calculated.
DOI: 10.3310/hsdr08390 Health Services and Delivery Research 2020 Vol. 8 No. 39
© Queen’s Printer and Controller of HMSO 2020. This work was produced by Noble et al. under the terms of a commissioning contract issued by the Secretary of State for
Health and Social Care. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in
professional journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial
reproduction should be addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House,
University of Southampton Science Park, Southampton SO16 7NS, UK.
57
Competence
The intention was that learning would be elicited rather than taught via SAFE, with the behaviour of
the educational facilitator seeking to promote a non-didactic approach. It was not known what level of
didacticism represented the optimum and would be associated with the greatest improvement in
patient outcomes. It was nevertheless important to gauge what balance between adherence and
didacticism was being achieved when SAFE was being delivered in the pilot.
Therefore, using a method previously developed by our team,189 didacticism was assessed using Eudico
Linguistic Annotator 5.1 software (Max Planck Institute for Psycholinguistics, Language Archive,
Nijmegen, Netherlands).190 This software permitted a rater to listen to the audio-recording of a SAFE
course and simultaneously code when the facilitator was speaking. The total amount of facilitator
speech, as a proxy measure of how didactic the course was, was then calculated. This was divided by
the duration of the course to generate the percentage of course time during which the facilitator was
speaking. Filler words (e.g. ‘oh’, ‘OK’ and ‘yeah’) were not considered instances of facilitator speech.
Testing the measures
To assess reliability of the implementation fidelity measures, two independent raters individually
evaluated each course using the fidelity measures. The raters were final-year students completing a
Bachelor of Science degree in psychology. Their training consisted of completion of practice adherence
and didacticism ratings on two courses not delivered as part of the trial.
Data analysis
Testing the measures
Inter-rater agreement was calculated using MedCalc 18.2.1 (MedCalc Software Ltd, Ostend, Belgium).
The intraclass correlation coefficient191 evaluated agreement between the two raters’ didacticism
ratings. For the adherence measure, the ratings from the two raters were tabulated and simple
percentage agreement first calculated. Inter-rater reliability was then assessed using the chance-
corrected weighted kappa statistic.
Because paradoxical values of kappa can occur owing to bias or skewed prevalence,192 the influence of
these factors was considered by calculating a prevalence index and a bias index and by comparing the
change in kappa when the prevalence-adjusted bias-adjusted kappa for ordinal scales (PABAK-OS) was
calculated using a PABAK-OS calculator (URL: www.singlecaseresearch.org/calculators/pabak-os;
accessed 27 August 2019). The prevalence index can range from −1 to 1 (0 indicates equal probability)
and the bias index ranges from 0 to 1 (0 indicates equal marginal proportions and so no bias).193
Course fidelity
The raters’ adherence and didacticism scores for each course were averaged and described using
descriptive statistics.
Results
Testing the fidelity instruments
Adherence scale: inter-rater reliability
For 96% of adherence items, the raters made the same judgement about the extent to which the item was
delivered but the weighted kappa statistic was only 0.66 (95% CI 0.50 to 0.83). This was a consequence
of prevalence bias (–0.83; bias index 0.06), with 94.6% of the raters’ ratings using the category ‘fully
delivered’. Given this, the PABAK-OS statistic of 0.91 (95% CI 0.85 to 0.97) (which equates to ‘substantial
agreement’) provided a more accurate reflection of rater concordance.
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Didacticism measure: inter-rater reliability
With a coefficient of 0.96 (95% CI 0.78 to 0.99), the intraclass correlation coefficient indicated that the
two raters’ judgements regarding didacticism were highly correlated.
Course fidelity
Adherence
Adherence was high. Among the 259 items meant to be delivered across the seven courses, 228
(88.0%) were ‘fully delivered’. Only eight (3.1%) were ‘not delivered’ (Table 14). The average adherence
rating (with a maximum of 2) given to the items across the SAFE courses was 1.88 (SD 0.11, range
1.65–1.97) (see Appendix 16).
The mean and range of adherence scores given to the individual intervention items showed that no item
proved too challenging to be fully delivered at least once. The mean score of only one intervention item
(namely, requiring the facilitator to inform the participants about when the demonstrated recovery
position should and should not be delivered) fell below 1 (i.e. to 0.79).
Didacticism
The mean percentage of facilitator speech across the courses was 55% (SD 5.4%), with a range of
49–64% (see Table 14).
Summary
The SAFE intervention was found to have been delivered as intended across the pilot RCT. The
adherence measure indicated that the facilitator delivered almost all the items prescribed by the
treatment manual. Moreover, they were able to do this while maintaining a high degree of interactivity.
In the light of these findings, we do not expect the estimate of intervention effect found in the pilot
RCT to be influenced by poor implementation fidelity.
TABLE 14 Characteristics of the courses
Course number
Adherence rating
Didacticism rating: percentage
(SD) of time facilitator speaking
Number (%) of items
fully delivered
M rating (SD) across
37 items
1 35 (94.6) 1.97 (0.11) 54.45
2 33 (89.2) 1.91 (0.35) 57.57
3 33 (89.2) 1.92 (0.25) 63.94
4 35 (94.6) 1.95 (0.22) 54.48
5 32 (86.5) 1.86 (0.40) 49.59
6 27 (73.0) 1.65 (0.69) 48.87
7 33 (89.2) 1.88 (0.39) 59.42
Across all seven courses 228 (88.0) 1.88 (0.11) 55.47 (5.35)
Each course consisted of six modules. Together these contained 37 items that were to be delivered. The extent of each
of these items delivered was rated using the following scale: 0= item not delivered; 1= item partially delivered;
2= item fully delivered.
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Chapter 6 Outcomes of the pilot randomised
controlled trial and implications for a
definitive trial
Introduction
Primary and secondary outcome measures were captured/completed to varying degrees at baseline
and at 3-, 6- and 12-month follow-up. This chapter outlines the findings from these assessments.
Outcome measures
Proposed primary outcome: emergency department use measured by the Health
Episode Statistics system
Routinely collected data on ED use from the HES system were secured for 48 (94.1%) of the randomised
patient participants. The mean number of visits recorded over the 12 months following randomisation to
the SAFE plus TAU arm was 1.8 (SD 3.14) and the median was 1 (range 0–12). For the TAU arm, the
mean was 3.4 (SD 4.78) visits and the median was 2 (range 0–20) visits. Compared with the 12 months
prior to randomisation, mean ED use over the follow-up period reduced for the SAFE plus TAU arm by
0.3 (28%) visits. For the TAU arm, it increased by 0.4 (11%) visits over the follow-up period (Table 15).
Emergency department use was overdispersed. However, there was not an excess of zeros (Vuong’s
test:180 z = –0.17; p = 0.87). For this reason, NBR compared the effect of treatment arm on ED use,
which showed that the estimated rate of ED visits following randomisation was around 46% lower in
the SAFE plus TAU arm than in the TAU arm (rate ratio = 0.54). This difference was not statistically
significant at the 5% alpha level (95% CI 0.24 to 1.18), nor at the 10% level (90% CI 0.28 to 1.04).
The difference was statistically significant at the 20% level (80% CI 0.32 to 0.90; p = 0.12) (Table 16).
Owing to a slight imbalance between treatment arms in ED use in the 12 months prior to randomisation
(i.e. ED visits at baseline), we also applied an adjusted NBR, including SAFE plus TAU arm and baseline
ED visits. The results showed that an increased number of ED visits pre randomisation was associated
TABLE 15 Number of ED visits patient participants made according to HES data
Number of ED visits
Treatment arm
TotalSAFE plus TAU TAU
During the 12 months prior to baseline
n (%) 25 (96.2) 23 (92.0) 48 (94.1)
Mean 2.1 3 2.5
SD 2.22 2.76 2.51
Minimum 0 1 0
Median 1 2 2
Maximum 10 12 12
Missing, n (%) 1 (3.8) 2 (8.0) 3 (5.9)
continued
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TABLE 15 Number of ED visits patient participants made according to HES data (continued )
Number of ED visits
Treatment arm
TotalSAFE plus TAU TAU
During the 12 months following randomisation
n (%) 25 (96.2) 23 (92.0) 48 (94.1)
Mean 1.8 3.4 2.6
SD 3.14 4.78 4.05
Minimum 0 0 0
Median 1 2 1
Maximum 12 20 20
Missing, n (%) 1 (3.8) 2 (8.0) 3 (5.9)
Change from baseline at 12 months
n (%) 25 (96.2) 23 (92.0) 48 (94.1)
Mean –0.3 0.4 0.1
SD 1.99 3.81 2.99
Minimum –4 –5 –5
Median 0 0 0
Maximum 5 16 16
Missing, n (%) 1 (3.8) 2 (8.0) 3 (5.9)
TABLE 16 Differences between groups in number of HES-recorded ED visits: SAFE plus TAU vs. TAU alone
Model and parameter Value
CI
p-value95% 90% 80%
12 months following randomisationa
Negative binomial
SAFE plus TAU, rate ratio 0.54 0.24 to 1.18 0.28 to 1.04 0.32 to 0.90 0.12
Dispersion parameter 1.53 0.67 to 2.39 0.80 to 2.25 0.96 to 2.09 NA
Vuong’s testb –0.17 NA NA NA 0.87
12 months following randomisation with adjustment for baseline ED visits
Negative binomial
SAFE plus TAU, rate ratio 0.62 0.33 to 1.17 0.36 to 1.06 0.41 to 0.94 0.14
Baseline ED visits, rate ratio 1.33 1.18 to 1.52 1.20 to 1.49 1.23 to 1.45 < 0.001
Dispersion parameter 0.69 0.17 to 1.21 0.26 to 1.13 0.35 to 1.03 NA
Vuong’s testb –0.13 NA NA NA 0.90
NA, not applicable.
a Analysis based on 48 patient participants.
b Vuong’s test180 p-value interpretation: a significantly negative parameter value favours the negative binomial model
and significantly positively favours the zero-inflated negative binomial model. A non-significant value indicates no
significant difference between the models; therefore, the simpler negative binomial model is preferred.
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with an increased number of post-randomisation ED attendances (rate ratio 1.33, 95% CI 1.18 to 1.52).
With the adjustment, the estimated effect size for treatment arm reduced, with the rate of ED visits for
the SAFE plus TAU arm being around 38% lower than that for the TAU arm (rate ratio 0.62). In this
adjusted analysis, treatment arm was not significantly associated with ED use at the 5% (95% CI 0.33 to
1.17) or 10% (90% CI 0.36 to 1.06) level; the treatment arm was statistically significant at the 20% level
(80% CI 0.41 to 0.94; p = 0.14).
Secondary outcome data
Emergency department use: self-reported
Self-reported data on ED use during both the 12 months prior to and the 12 months following randomisation
were available for 34 (66.6%) of the randomised patient participants.The mean number of ED visits reported
by patient participants in the SAFE plus TAU arm was 1.2 and the median was 0.0.The mean number of
ED visits reported by patient participants in TAU arm was 2.9 and the median was 1.0. Compared with
the 12 months prior to randomisation, mean ED use over the follow-up period reduced by 2.6 visits
for participants in the SAFE plus TAU arm. For the TAU arm, this reduced by 0.3 visits (see Appendix 17).
Negative binomial regression with (rate ratio 0.34, 95% CI 0.11 to 1.07; p = 0.10) and without
(rate ratio = 0.42, 95% CI 0.15 to 1.20; p = 0.06) adjustment for ED use over the 12 months prior to
randomisation indicated that the estimated rate of ED visits following randomisation was around 66%
and 58% lower in the SAFE plus TAU arm and in the TAU arm, respectively (Table 17).
Relationship between Hospital Episode Statistics and self-reported data
Among the 34 patient participants who had self-reported ED data at 12 months (T3) and for whom
consent remained in place and HES data were secured, 11 (32.4%) had the same number of ED visits
recorded in HES and self-reported data: seven (41.2%) from the TAU arm and four (23.5%) from the
SAFE plus TAU arm. A total of 13 patient participants (38.27%) had more ED visits recorded in HES
data than in self-reported data and 10 (29.4%) self-reported more ED visits than were recorded by
HES data; proportions were similar across the two treatment arms (Table 18).
TABLE 17 Differences between groups in number of self-reported ED visits: SAFE plus TAU vs. TAU alone
Model and parameter Value
CI
p-value95% 90% 80%
12 months following randomisation
Negative binomial
SAFE plus TAU, rate ratio 0.42 0.15 to 1.20 0.17 to 1.01 0.21 to 0.83 0.10
Dispersion parameter 1.85 0.50 to 3.20 0.72 to 2.98 0.97 to 2.73 NA
Vuong’s testa 0.49 NA NA NA 0.62
12 months following randomisation with adjustment for baseline ED visits
Negative binomial
SAFE plus TAU, rate ratio 0.34 0.11 to 1.07 0.13 to 0.88 0.16 to 0.72 0.06
Baseline ED visits, rate ratio 1.15 0.83 to 1.60 0.88 to 1.52 0.93 to 1.43 0.39
Dispersion parameter 1.87 0.38 to 3.36 0.62 to 3.12 0.89 to 2.84 NA
Vuong’s Testa –0.13 NA NA NA 0.90
NA, not applicable.
a Vuong’s test180 p-value interpretation: a significantly negative parameter value favours the negative binomial model
and significantly positively favours the zero-inflated negative binomial model. A non-significant value indicates no
significant difference between the models; therefore, the simpler negative binomial model is preferred.
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Figure 7 shows a Bland–Altman plot of the agreement between the mean number of self-reported and
HES-recorded ED visits for the 34 patient participants; the limits of agreement were –5.3 visits (i.e. 5.3
fewer visits recorded in self-reported data than in HES data) to 4.4 visits (i.e. 4.4 visits more recorded
in self-reported data than in HES data). Compared with baseline (see Figure 6), this Bland–Altman plot
demonstrates a relatively even spread of self-reported versus HES-recorded ED visits.
Other secondary outcome measures
As per the statistical analysis plan, differences between the two treatment arms on the remaining secondary
outcome measures were not formally statistically tested. For completeness, summary statistics for the arms
on these measures at 6 months’ (T2) and 12 months’ (T3) follow-up are reported in Appendix 18.
Safety and adverse events
A total of 18 (35.3%) patient participants reported adverse events over the course of their follow-up
(see Appendix 19). In the SAFE plus TAU arm, six adverse events were reported by six participants;
13 adverse events were reported by 12 participants in the TAU arm. Only one SAE occurred during
the study: a diagnosis of previous status epilepticus. This was reported by one SAFE plus TAU arm
participant. On medical review, it was considered unlikely to be related to SAFE or participation in the
trial because it arose from investigations that the participant had been having before they began
participating in the trial.
Participant feedback
A total of 32 (68.1%) patient participants and 20 (62.5%) SOs completed the participant feedback
questionnaire at 12 months (T3). All but one said that they would participate in the trial again
(Tables 19 and 20).
When asked to explain why, the limited burden associated with participating was mentioned, as was a
sense of duty to help improve things for others. Some SAFE plus TAU arm participants mentioned the
benefit they perceived themselves to have derived from SAFE. Illustrative quotes included the following:
I found that the study was not an issue or an inconvenience and I was happy to participate and would
happily take part in any future studies.
PWE participant
I’m more than happy to help in a study that helps towards epilepsy.
PWE participant
Before we done it [participated in the research] we didn’t have a clue [. . .] Sometimes we would have
gone to the hospital if we needed [. . .] but now we don’t need to go.
SO
TABLE 18 Comparison of HES-recorded and self-reported ED visits during the 12 months post randomisation
HES-recorded vs. self-reported ED visits
Treatment arm, n (%)
Total, n (%)SAFE plus TAU TAU
More HES recorded than self-reported 7 (41.2) 6 (35.3) 13 (38.2)
Equal 4 (23.5) 7 (41.2) 11 (32.4)
More self-reported than HES recorded 6 (35.3) 4 (23.5) 10 (29.4)
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Some participants provided comments relating to recruitment. No concerns were raised regarding
randomisation, indicating that the process was acceptable. A point made by a number of participants
was that, although they valued the intervention, they felt the offer seemed somewhat reactive and that
a more preventative approach to self-management support might be valuable. They said that taking
part in SAFE had been their primary source of education since being diagnosed, with health-care
encounters having previously focused on ‘medication and never about education or management’
(SO participant) and that there was a need to offer such an intervention to those who have been
recently diagnosed with epilepsy.
In terms of continued participation in the trial, a number of participants reported that they had
experienced challenges in completing the questionnaires during the course of the study owing to
instances of being unwell. Several participants from the TAU arm noted that memory problems and
the gap between data collection episodes meant that they had forgotten about their participation in
the study and so their motivation to take part when contacted had reduced.
TABLE 19 Feedback on participation in the SAFE trial: patient participants
Feedback on participation in the SAFE trial
Treatment arm, n (%)
Total,
n (%)
SAFE plus
TAU TAU
If time suddenly went backward, and you had to do it
all over again, would you agree to participate in the trial? (N = 26) (N = 25) (N = 51)
Definitely yes 15 (57.7) 10 (40.0) 25 (49.0)
Probably yes 2 (7.7) 4 (16.0) 6 (11.8)
Probably no 0 (0.0) 1 (4.0) 1 (2.0)
Definitely no 0 (0.0) 0 (0.0) 0 (0.0)
Not sure 0 (0.0) 0 (0.0) 0 (0.0)
Missing 9 (34.6) 10 (40.0) 19 (37.2)
TABLE 20 Feedback on participation in the SAFE trial: SO participants
Feedback on participation in the SAFE trial
Treatment arm, n (%)
Total,
n (%)
SAFE plus
TAU TAU
If time suddenly went backward, and you had to do it
all over again, would you agree to participate in the trial? (N = 18) (N = 19) (N = 37)
Definitely yes 11 (61.1) 9 (47.4) 20 (54.1)
Probably yes 0 (0.0) 0 (0.0) 0 (0.0)
Probably no 0 (0.0) 0 (0.0) 0 (0.0)
Definitely no 0 (0.0) 0 (0.0) 0 (0.0)
Not sure 0 (0.0) 0 (0.0) 0 (0.0)
Missing 7 (38.9) 10 (52.6) 17 (45.9)
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Sample size calculation for future trial
The proposed primary outcome measure for a definitive trial is ED use as measured by HES. The pilot
RCT found a reduction of around 47% in ED use in the SAFE plus TAU arm in the 12 months following
randomisation compared with the TAU arm.
Table 21 shows the number of patient participants that would be required per arm for a definitive trial.
Depending on the estimate of the dispersion parameter from the pilot trial that is used and the statistical
power required, the number of patient participants needed per arm in a definitive trial ranges from
123 to 451.
If the central value of the estimate range for the dispersion parameter (k) of 0.69 is used, 90% power
stipulated and 9.4% of recruited patients eventually withdraw consent to access their HES data
(as observed in the pilot), a sample of 674 patients [(308 × 2) + 58] would need to be recruited for a
definitive trial of SAFE. Using the estimates for eligibility and consent from the pilot trial, it would be
anticipated that the triage cards of > 51,000 patients would need to be screened and > 7000 patients
invited to secure a sample of 674 patients.
For the pilot RCT, three type 1 EDs acted as recruitment sites. These EDs generated, on average,
17.6 patient accruals each from 19 months of attendances (i.e. ≈ 1 per month). The EDs were similar in
size to EDs in England, with the mean number of attendances (for any reason) being in line with the
average for English EDs.194 It can therefore be estimated that a definitive trial would require around
39 average-sized ED sites to recruit the necessary sample. This would equate to about half of England’s
type 1 EDs.
Summary
Using data from the 94% of patient participants on whom primary outcome data were secured,
estimates for the effect of SAFE plus TAU on ED use were generated. Feedback from participants on
trial participation was also secured. Participation in the trial was not associated with adverse effects
and participants for the most part welcomed taking part and receiving the intervention. Using the
estimate of effect and evidence from the pilot RCT on eligibility and uptake, it was calculated that a
large definitive trial, in terms of recruitment sites and starting sample, would be needed to definitively
judge the efficacy of the SAFE intervention.
TABLE 21 Required sample size for a definitive trial to detect estimated effect of SAFE plus TAU on ED use
(measured using HES data)
Dispersion parameter (k)
≈ 47% reduction (from 3.4 to 1.8 visits) in 12 months compared with TAU
n per arm (α= 0.05; 80% power; β= 0.2) n per arm (α= 0.05; 90% power; β= 0.1)
0.17 123 164
0.5 191 255
0.69 230 308
1 293 393
1.21 337 451
Dispersion parameter taken from the adjusted NBR model in the pilot RCT (k = 0.69, 95% CI 0.17 to 1.21). See Table 16.
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Chapter 7 Economic evaluation
Introduction
When the feasibility of a definitive trial is being considered, an important part of the decision calculus
is the cost of delivering the intervention to be trialled. Cost is important because it will affect the ease
with which ‘excess treatment costs’ can be secured and would be fundamental to future cost-effectiveness
analysis. It is also important because stakeholders will want to consider the budget impact and scalability
of the intervention to be tested should it be found to be cost-effective. In contrast to health technologies,
the costs of complex interventions such as SAFE are often less well characterised and may vary depending
on the context of use. Microcosting is a method that provides detailed, bottom-up cost data based on each
component of the delivery of an intervention.195
We performed a microcosting to calculate the fixed and variable costs of delivering SAFE in the
context of the pilot RCT. The cost of developing the SAFE intervention via the processes described
in Chapter 2 was also determined. Such information is rarely provided but can be helpful for those
planning similar endeavours and for research funders.
Methods
The microcosting adopted the perspective of an academic non-profit-making institution and was
conducted in three stages: (1) identification of resources; (2) measurement; and (3) valuation.196
Step 1: identification of resources
A health economics researcher (EH) met with staff central to the development of the SAFE intervention
(academic staff AN and DS) and delivery (epilepsy nurse specialist and SAFE facilitator Juliet Bransgrove
and project administrator Gail Moors; see Acknowledgements) to map out the courses run for the project.
The work and resources required for each were attributed to one of three categories according to the
primary purpose of the course: inform intervention design, participants in the SAFE plus TAU arm and
participants in the TAU only arm (Figure 8).
Preparatory
work
Practice
session 1
FG 1
Practice
session 2
FG 2
Preparatory
work
Intervention
arm 1
Intervention
arm 2
Intervention
arm 3
Intervention
arm 4
Intervention
arm 5
Intervention
arm 6
Intervention
arm 7
Preparatory
work
TAU 
arm 1
TAU 
arm 2
Website access
Website access
FIGURE 8 Workflow. Light blue shading signifies research and development.
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The resources and items required to deliver SAFE were also differentiated as fixed or variable. Fixed
resources were constant regardless of the number of people attending the course (e.g. room hire,
facilitator). Variable resources were those that changed depending on the number of attendees (e.g.
patient/SO take-away information packs, travel expenses). Participant involvement was costed from the
point at which they were invited to attend a SAFE session to more accurately reflect routine practice.
Step 2: measurement
The quantity of use of the resources identified in stage 1 was measured. To capture this information we
used the ‘time and motion method’.197 This involved the completion (by AN, DS, Juliet Bransgrove and
Gail Moors; see Acknowledgements) of electronic data collection forms on which they self-reported the
time that they dedicated to different activities. The research team (AN and DS) also recorded details of
the number of participants invited and attending each of the SAFE sessions and non-staff resources.
Staff time and costs
Time was split into preparatory work (time in meetings, designing the SAFE intervention, administration
of SAFE’s content, planning and organising practice sessions, attending practice sessions, reviewing
and editing SAFE’s content) and programme delivery (time spent inviting participants, organising and
attending SAFE sessions, packing up, and administration of participant expenses and the website).
Staff recorded their time against each task for each SAFE session.
Travel time and costs
Staff involved in SAFE’s delivery recorded estimates of time spent travelling to sessions and any travel
costs. Travel costs were recorded for participants and taken from the study finance records as the total
claimed per group.
Other costs
The two academic staff central to adapting the intervention (AN and DS) recorded all resources and
items required to complete the activities identified in stage 1. This included office space for staff
involved in course preparation and administration, telephone calls, stationery, printing and postage,
leaflets for patients/SOs, advertising, participant remuneration (practice sessions only), venue hire,
refreshments, equipment, and website domain and administration costs.
Step 3: valuation
A monetary value was attached to the quantities of resources used that were measured in step 2. Unit
costs and details of suppliers were obtained using local data from the finance office of the University
of Liverpool or national sources [e.g. Royal Mail (Royal Mail Group Ltd, London, UK)] as applicable
(Table 22). Costs were calculated using price year 2017/18 and as Great British pounds. VAT was
applied to equipment and consumables at a rate of 20%.
Details of staff job titles, employer and salary bands were obtained. Academic staff costs were calculated
using University of Liverpool salary scales 2017/18 (hourly rates). Salary costs for the epilepsy nurse
specialist delivering the training and the administrative assistant were calculated using hourly rates for
casual workers and included 12.07% holiday pay. The epilepsy nurse specialist completed her role on the
SAFE pilot study on an honorary contract with University of Liverpool at an hourly rate equivalent to
band 6 in NHS England or Wales (Royal College of Nursing 2018). All salary costs were converted into
cost per minute for the purpose of valuing time on activities. The staff costs per minute were multiplied
by the time spent on each activity, then summed to obtain total staff costs.
Analysis
Resource use and costs were analysed to calculate the cost of developing the intervention, the fixed
and variable costs of delivering the training sessions (SAFE plus TAU or TAU) and the mean cost per
participant or patient (which includes the cost of attending with or without an SO). The cost of developing
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TABLE 22 Unit costs
Category Unit cost (£) Source
Staff (per minute)
Lecturer (grade 8) 0.46 University of Liverpool198
Administrative assistant 0.23
Research fellow (grade 8) 0.40
Epilepsy specialist nursea 0.25
IT technician (grade 8) 0.47
Delegate expenses (per group)
Practice group (travel) 55.00 Research study financial statement. Practice
group remuneration: £10 shopping voucher per
FG participant. Disaggregated travel expense
data not available
Practice group (remuneration) 135.00
SAFE plus TAU arm (travel) 40.00
TAU arm (travel) 46.40
Telephone (per minute, including VAT)
Office line to UK mobile 0.06 BT (London, UK)199
Office line to UK landline 0.05
Advertising (per advert)
Practice group recruitment 45.00 Liverpool Daily Echo (Liverpool Daily Post &
Echo Ltd, Liverpool, UK)
Venue costs
Room hire (per course; 0.5 days, room capacity
20 delegates, includes PC and projector)
80.00 Royal Liverpool Academy200
Refreshments (per head; tea and coffee) 1.50 Royal Liverpool Academy200
Equipment (including VAT)
Dictaphone (DM-650; Olympus, Tokyo, Japan) and
boundary microphone (ME33; Olympus)
355.98 Research study financial statement
Study laptop 592.87 Desk Top Publishing Microsystems Ltd (Leeds,
UK); purchased via University of Liverpool
Annual fees (including VAT)
Website domain 20.94 Fasthosts Internet Ltd (Gloucester, UK)
Freepost licence fee 116.40 Royal Mail201
Delegate packs (including VAT)
Invite pack (1 black and white, single-sided
A4 page; envelope; second-class post; Freepost
reply envelope)
1.12 Lyreco (Marly, France); University of Liverpool
printing rates; Royal Mail
Reminder pack (1 black and white, single-sided
A4 page; envelope; second-class post; Freepost
reply envelope)
1.12
FG consent form (1 black and white, single-sided
A4 page)
0.04
continued
DOI: 10.3310/hsdr08390 Health Services and Delivery Research 2020 Vol. 8 No. 39
© Queen’s Printer and Controller of HMSO 2020. This work was produced by Noble et al. under the terms of a commissioning contract issued by the Secretary of State for
Health and Social Care. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in
professional journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial
reproduction should be addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House,
University of Southampton Science Park, Southampton SO16 7NS, UK.
71
SAFE was calculated as the sunk cost of designing the intervention (incurred and independent of future
training courses) plus the total fixed annual set-up cost. Calculations were based on an assumption of
11 groups per year and an equipment life of 1 year.
The epilepsy nurse specialist who facilitated the SAFE courses was not based locally but located in the
region of the ES offices. This meant that she travelled to Liverpool to deliver the course. For this reason,
a scenario analysis that excluded the travel time and travel expenses of the epilepsy nurse specialist
facilitating the groups was conducted to explore a more realistic scenario of employing a local nurse.
The means and SDs of observed data were calculated. The 95% central range (CR) for costs and
differences was generated using 10,000 bootstrap replications. All data were managed and analysed in
Microsoft Excel® 2010 (Microsoft Corporation, Redmond,WA, USA).
Results
Over the course of the project, 11 SAFE intervention courses were run. Two were run to inform
intervention design, seven were run for participants in the SAFE plus TAU arm and two were run after
the trial was completed for the TAU arm. Data were collected from the four noted members of staff,
with all data collection forms being complete and no missing data.
The total cost of developing the training was £9947, which included two practice SAFE courses
attended by 27 people (Table 23); 88.72% of the development cost was a sunk cost independent of
future training courses.
To deliver SAFE in the pilot RCT, the fixed cost (SAFE plus TAU arm or TAU arm) was £263 per group,
which represented the cost of course facilitation and venue hire. The mean variable cost per group
(n = 9) was £922 (SD £131, 95% CR £887 to £1085). There were no statistically significant differences
in the mean cost per group between SAFE plus TAU and TAU only (SAFE plus TAU arm: mean £903,
SD £134; 95% CR £760 to £1087; TAU arm: mean £986, SD £140, 95% CR £887 to £1085; difference
in CR –£324 to £119).
TABLE 22 Unit costs (continued )
Category Unit cost (£) Source
Delegate booking confirmation (1 colour,
double-sided A4 page; envelope; first-class)
0.80
Delegate course pack (SAFE plus TAU) (slide
handouts: 10 colour, single-sided A4 pages;
certificate; folder)
0.89
Delegate course pack (TAU) (slide handouts:
20 black and white, single-sided A4 pages;
certificate; folder)
0.89
Name badge 0.60
Leaflet 1.00 ES
Convener packb (4 acetates; 4 answer cards;
10 pens; flip chart; trainer manual;c clipboard;c
2 whiteboard markers;c 12 coloured marker pensc)
4.96 Lyreco
IT, information technology; PC, personal computer.
a Epilepsy specialist nurse: honorary contract with University of Liverpool; ≈ band 6 in NHS England or Wales.
b Convener pack calculation uses mean cost per group.
c Single purchase, reused throughout 11 groups.
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TABLE 23 Total observed costs and cost per delegate to deliver SAFE
Description
Design and
set-up
SAFE delivery course
Practice session
Treatment arm
SAFE plus TAU TAU
1 2 1 2 3 4 5 6 7 1 2
Fixed costs (£)
Equipment 928.85 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Website 77.12 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Freepost licence 116.40 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Venue 0.00 80.00 80.00 80.00 80.00 80.00 80.00 80.00 80.00 80.00 80.00 80.00
Facilitator (staff cost) – 192.79 192.79 177.96 177.96 177.96 177.96 177.96 177.96 177.96 177.96 177.96
Facilitation resources – 4.96 4.96 4.96 4.96 4.96 4.96 4.96 4.96 4.96 4.96 4.96
Total (fixed) 1122.37 277.75 277.75 262.92 262.92 262.92 262.92 262.92 262.92 262.92 262.92 262.92
Variable costs (£)
Staff costs 4243.41 612.88 1158.56 591.19 521.84 429.37 429.37 318.41 318.41 318.41 299.96 416.03
Staff travel expenses 44.10 279.87 279.87 274.67 274.67 265.43 265.43 265.43 265.43 265.43 233.63 265.41
Participant expenses 0.00 180.00 200.00 40.00 40.00 40.00 40.00 40.00 40.00 40.00 92.80 0.00
Office costs (including
telephone)
589.33 33.00 105.50 81.63 85.23 92.60 88.70 89.00 86.60 89.00 57.17 70.13
Stationery/print/postage 0.00 156.35 196.96 57.44 93.68 68.93 68.93 34.46 22.98 45.95 182.73 298.44
Refreshments 0.00 72.25 72.25 41.80 41.80 32.81 32.00 41.00 26.60 18.50 21.00 34.50
Advertising 45.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total (variable) 4921.84 1334.34 2013.13 1086.73 1057.22 929.13 924.42 788.30 760.01 777.29 887.28 1084.51
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TABLE 23 Total observed costs and cost per delegate to deliver SAFE (continued )
Description
Design and
set-up
SAFE delivery course
Practice session
Treatment arm
SAFE plus TAU TAU
1 2 1 2 3 4 5 6 7 1 2
Fixed and variable costs (£)
Total 6044.21 1612.09 2290.88 1349.65 1320.14 1192.05 1187.34 1051.22 1022.93 1040.21 1150.20 1347.43
Delegates and arms
Delegates (patient : SO
ratio)
– 12 15 2 : 3 4 : 4 3 : 3 4 : 2 3 : 0 1 : 1 2 : 2 4 : 4 8 : 5
Mean cost (£) per
delegate
– 134.34 152.73 269.93 165.02 198.68 197.89 350.41 511.47 260.05 143.78 103.65
Mean cost per arm, £ (SD; 95% CR)a 1166 (134.22; 1023 to 1350) 1249 (139.46; 1150
to 1347)
Mean cost per delegate, £ (95% CR)a 240 (211 to 278) 119 (110 to 128)
Mean cost per patient (with or without SO), £ (95% CR)a 408 (358 to 472) 208 (192 to 225)
a CRs generated from 10,000 bootstrap replications.
Two academic researchers, one epilepsy specialist nurse delivering the training, and administrative support.
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On average, the TAU arms involved six more participants than the SAFE plus TAU arms. The mean cost
per participant was £119 (95% CR £110 to £128) in the TAU arm; this was significantly lower than the
cost per participant in the SAFE plus TAU arm, which was £240 (95% CR £211 to £278; difference in
CR –£1137 to –£872); both estimates exclude fixed annual set-up costs of £1122.
The average ratio of patients to SOs was 3 : 2. The mean cost per patient (with or without SO) was
£208 (95% CR £192 to £225) in the TAU arm; this was significantly lower than the cost per patient in
the SAFE plus TAU arm, which was £408 (95% CR £358 to £472).
When including the cost of developing SAFE (£181 per person), the mean cost per participant, based
on all 55 participants in SAFE plus TAU or TAU arms, was £375 (95% CR £348 to £402). This reduced
to £214 (95% CR £188 to £241) when excluding sunk costs that would not be incurred again in
the future.
Staff time accounted for 50.01% of the cost of the delivering SAFE and almost 70.21% of the development
cost. Staff travel expenses accounted for an additional 21.10%. Travel expenses were high as a
consequence of the specialist nurse delivering SAFE not being based locally.
Office, stationery, printing, postage and venue hire costs were relatively low. A scenario analysis of
facilitator costs without travel expenses (time and cost) reduced the mean cost by 21.08%, from £194
(95% CR £167 to £221) to £152 (95% CR £124 to £179) per delegate or from £333 (95% CR £288 to
£380) to £261 per patient.
Discussion
Delivering SAFE was estimated to cost £333 per patient (with or without a SO) and it is plausible that
it could be delivered for as little as £261 per patient or £152 per delegate. The main cost contributors
are staff costs and associated travel expenses and office costs. The annual fixed cost of setting up and
running SAFE is £1122 (plus £35.07 per patient, based on 32 patients per year attending with or
without a SO).
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Chapter 8 Discussion
Principal findings
Part A: intervention development
A novel co-production approach enabled us to achieve our objectives of (1) optimising the content,
delivery and behaviour change potential of the ES’s existing course for PWE attending ED and their
SOs and (2) developing a seizure management intervention that had support from representatives from
the target service user population and from professional groups involved in their care.
The finalised intervention – SAFE – was brief, manualised, supported by the inclusion of a theory of
behaviour change and based on a delivery method considered by stakeholders to be sustainable for the
NHS. Feedback from service users who received the test version of the intervention was positive. This is
despite it focusing on sensitive areas, such as potentially unnecessary hospital service by them and their
own beliefs about epilepsy. Participants valued the straightforward guidance offered by SAFE and liked
its group format. This concurs with previous observations, with PWE previously reporting that the
format helps them ‘feel less alone’ and able to share and learn from others.127 Our participants did
identify potential barriers to intervention effect (e.g. memory difficulties) and we sought to ameliorate
these (e.g. by providing participants with access to hard copies and online copies of the course materials).
Triallists have often been criticised for not describing complex interventions sufficiently for
replication.202 This is not the case for SAFE. Its content and the origin of each of its elements are
clearly documented. A TIDieR checklist187 is also available (see Report Supplementary Material 2).
The microcosting of intervention development activity is rare. At just under £10,000, the cost of
developing SAFE is arguably low. This was, in part, because SAFE was adapted from an existing
intervention and because the owners of the original course (the ES) did not charge for access to it or
its materials. Our findings are important to disseminate because they could help those considering
similar endeavours to accurately forecast activity, timelines and costs. They also provide funders with a
benchmark against which to judge applications.
Part B: pilot randomised controlled trial
A pilot RCT comparing SAFE plus TAU with TAU only was successfully completed. As planned, it
provided estimates of key parameters, including recruitment and retention, and allows an informed
decision regarding the feasibility and optimal design of a definitive trial of SAFE to be made. In this
chapter we discuss the estimates, their relation to the two progression criteria established at project
outset and the implications.
Positives for feasibility of a definitive trial
The pilot demonstrated that it is possible to identify, consent, randomise and largely retain people
from the target population and their SOs in a RCT. This was not a given at the outset because, to our
knowledge, no previous trial had focused recruitment on this population and because this population is
potentially vulnerable.
No safety concerns arose from the trial’s conduct and no protocol deviations occurred. Strategies in the
trial to conceal treatment allocation worked. It was possible to get most (76.9%) patient participants
who were randomised to the SAFE plus TAU arm to a SAFE session and for it to be delivered as
intended (i.e. with high fidelity). This is in line with previous RCTs of complex interventions with the
epilepsy population.71,72,203–205
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Feedback from participants indicated that they valued SAFE and the perceived benefits from receiving
it. The SAFE intervention was perceived as being outside current epilepsy service provision. Most said
that they would participate in such a trial again if invited.
Importantly, by using routine outcome data on ED use as the basis for the proposed primary outcome
measure, it was possible to secure 12-month outcome data for 94% of the randomised patient participants.
This means that the second progression criterion – that 12-month follow-up data could be obtained for
at least 75% of patient participants – was satisfied. The direct cost for these data was ≈ £10,000. The
progression criterion would not have been met had the trial relied on patients self-reporting on ED use
because only 67.7% of participants were available and/or able to provide this information. Routine
data would thus make a definitive trial less vulnerable to the effect of attrition. By way of context,
the proportion of randomised patient participants with primary outcome data in recent NIHR Health
Technology Assessment programme trials (conducted between 2005 and 2017) was 89% (IQR 79–97%),
but these typically had shorter follow-up periods (median 6 months post randomisation).131
Our pilot also revealed that relying on self-reported data would expose a definitive trial to what
appears to be recall bias by patients relating to their use of ED. At baseline, 76.2% of patients reported
more ED visits during the 12 months prior to recruitment than indicated by routine data for them
(on average by 3.8 visits). It has often been claimed that recall bias is not such an issue for ‘big ticket’
items such as hospitalisations as it is for more routine lower-cost service items (e.g. ambulatory
outpatient clinic visits).206,207 Our findings indicate that caution should be exercised in using
self-reported data on ED use.
The proportion of patients who self-reported a different number of ED visits to that recorded by HES
was slightly smaller at 12-month follow-up (i.e. 29.4% reported more visits and 38.2% reported fewer).
The reason for the greater congruence between the two data sources at this assessment point is not
clear. The provision to patient participants at recruitment of seizure diaries by the trial team in which
they were encouraged to record seizures and associated events might have attenuated bias.
The apparent bias and the smaller proportion of patients with self-reported ED outcome data meant
that the effect size estimate for SAFE differed substantially depending on whether the calculation
used self-reported or HES data. When looking at the unadjusted NBR models, the self-reported data
indicate that the estimated rate of ED use in the SAFE plus TAU arm was 58% lower than for the TAU
arm. HES data indicate that the rate of ED use was around 46% lower.
A microcosting exercise indicated that the cost per attendee (when excluding facilitator travel costs)
of attending a SAFE course was ≈ £152. Accurately identifying the cost of an intervention’s delivery
allows excess treatment costs for a definitive trial to be forecast and helps with assessments regarding
the potential for an intervention to be offered in clinical practice. The figure also allows for a simple
and preliminary evaluation to be made of the potential for savings to be generated by comparing the
cost of the intervention to the direct cost of the health service contact that the intervention seeks to
reduce. The average cost of an ED attendance for a suspected seizure in 2007–13 was £123, with an
additional £1651 being incurred if the visit resulted in hospital admission (which it did in around half
of cases).34
Microcosting of complex interventions remains rare. However, it is helpful to note that the NIHR-
funded Self-Management education for adults with poorly controlled epILEpsy (SMILE) UK trial did
include a microcosting of a self-management education for adults with poorly controlled epilepsy,208
where the 2014/15 price was estimated to be £56.05 per session. However, the SMILE intervention
required multiple sessions, bringing the mean cost associated with the intervention to £180 (inflated
to 2017/18 prices). By contrast, the SAFE intervention requires a single session at a comparable cost
to the SMILE intervention (between £152 and £194 per delegate). The SAFE cost could be reduced if
course attendance could be maximised to the intended level of ≈ 10 patient–SO dyads per course.
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Negatives for feasibility of a definitive trial
The pilot revealed that only a small proportion of patients attending ED for a suspected seizure were
eligible (10.6%) and willing (12.5%) to participate in a trial. A key reason for ineligibility was intellectual
impairment. The leading reason for not wanting to take part was lack of interest. The low rate of
uptake means that the other progression criterion stated at the project’s outset – that at least 20% of
eligible patients agree to participate – was not satisfied.
Low participant uptake does not preclude a definitive trial from happening. It also may not reflect
the acceptability of the intervention outside the trial context. In the RCT of the self-management
intervention Dose Adjustment for Normal Eating for Type 1 diabetes, which is now offered by the NHS
as part of usual care, only 17% of those eligible participated.97 If the low recruitment rate seen in our
pilot trial did reflect patient support or interest in the intervention outside a trial context, this would
pose challenges to the intervention’s delivery and commission within the NHS since, on average, a single
ED was generating only one eligible patient who was willing to take part for every month of attendances.
One reason we set the consent rate criterion was that, with such low participation, there is an
increased likelihood that those who do and do not agree to take part may differ in important ways,
thus limiting the generalisability of the trial’s findings. We compared eligible patients who did and did
not agree to take part in the pilot RCT by age, sex and deprivation status. We found no obvious
differences in age or deprivation. Females were slightly over-represented. The reason for this is
not known (trials generally tend to under-represent females). When telephoning patients about
participation in the pilot trial we intentionally attempted telephone calls at different times of the day
to minimise the influence of work status on participation.
We do not know if differences existed between participants and non-participants on other indices
because access to the wider medical records of non-participants was not ethically permissible. One
indication that the pilot trial might not have been recruiting a representative sample was that a high
proportion (75.5%) of the recruited patient participants reported having seen an epilepsy specialist
within the 12 months prior to the ED attendance that led to their identification. National audit data28
indicate that most (≈ 65%) PWE attending ED have not done this.
The low uptake seen in the pilot RCT has implication for the likely cost of a definitive trial. In Chapter 6
we calculated that the sample size required for a definitive trial could be ≈ 680 PWE. This was informed
by the pilot trial estimate that SAFE may have only a modest effect on participants’ subsequent ED use,
reducing it on average by 0.3 ED visits over 12 months (compared with an increase of 0.4 ED visits for
the TAU only arm). Based on the participant uptake rate seen in the pilot, 39 recruitment sites could be
needed to secure the required sample. The mean cost of NIHR-funded (Health Technology Assessment
programme) RCT trials is ≈ £1.3M.209 The median number of recruitment sites in these trials was only
15.131 In requiring 2.5 times more sites, a definitive trial of SAFE would be more expensive. This, and the
potential unrepresentativeness of the sample likely to take part, could mean that a definitive RCT of
SAFE would not represent value for money from a funder’s perspective.
It might not even be possible for a definitive trial to secure 39 EDs as recruitment sites. The requirement
for them to release clinical personnel to the extent required in the pilot RCT to complete the screening
work would not seem realistic considering how stretched most EDs already are in meeting their clinical
priorities (e.g. Hassan et al.210). Thirty-nine EDs equates to about half of type 1 EDs in England. A recent
survey210 highlighted that 62% of ED consultants in the UK viewed their current job as unsustainable and
94% regularly worked in excess of their planned activities.
A final negative to emerge from the pilot trial was that securing the routine outcome data on ED use
was not straightforward. For data applications, such as ours, that involve identifiable data and require
linkage across a series of data sets, NHS Digital’s Service Level Agreements state that these should be
processed within ≈ 2 months.211 In practice, for our pilot RCT it was not until 9 months after the last
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participant follow-up assessment at 12 months had been completed that the raw outcome data were
secured. This is despite our research team having communicated with the data provider before and
during the pilot trial to ensure recruitment and consent approaches were consistent with their
requirements. Substantial time from the research team was also required following application
submission to respond to queries from the data provider. In addition, despite the current project being
funded on the basis of external scientific reviews and its potential significance, the research team in
one instance needed to appeal against a decision by the data provider midway through the application
process to reject our data request, primarily because of unfounded concerns regarding the project’s
scientific merit.
Possible modifications to address negatives for progression to definitive trial
Participant uptake
Recruitment of people with uncontrolled epilepsy into evaluative studies has previously been reported to
be challenging. In the SMILE (UK) trial,208 PWE living in the London area who had experienced at least
two seizures in the prior year were invited to a trial of self-management that had a 12-month follow-up
period;212 37% of those invited took part. In a non-randomised trial of self-management for PWE who had
attended ED on one or more occasions in the prior 12 months, the uptake rate was 26%.128 Challenges
can arise owing to the nature of the condition itself (e.g. unpredictable but frequent seizures) and its
consequences (e.g. anxiety about travelling alone, inability to drive, memory impairment). A range of
evidenced-based strategies were therefore used in the pilot RCT to try to maximise recruitment. These
included participant vouchers, first-class postage for invitations, flexibility regarding when and where
research appointments took place, the use of an ‘opt-out’ approach to contacting patients about the study,
multiple contact attempts and all patient-facing documents being developed collaboratively with a patient
and public involvement group. Despite this, a low recruitment rate was experienced.
The characteristics of the recruited patients offers one potential suggestion for the particularly low
participant rate seen in the pilot RCT. Specifically, 82% of participants felt stigmatised by their epilepsy,
21.6% highly stigmatised.This is higher than among those with epilepsy generally, including those with
uncontrolled seizures (63%).212 Epilepsy, for reasons rooted deep in its history, has been called a ‘stigmatising
condition par excellence,’213 and negative beliefs and lack of knowledge about the condition continue to be
present. Consequently, PWE can feel ashamed of their diagnosis, guilty and reluctant to talk about it.214 Those
attending ED appear to be particularly at risk of this.This could be a barrier to participating in research. It is
currently unclear how recruitment could be altered to mitigate the feeling of stigmatisation.
It is also worth considering what changes might be possible to who approaches patients regarding
participation. Local ED clinicians invited PWE to participate in the pilot RCT. In trials it is usually
preferable for a usual care provider with whom a patient has an established relationship to do the
inviting. This was not considered ideal for the pilot RCT because national data indicated that most
from the target population do not have a specialist usual care provider for their epilepsy (at least not
one they have seen recently). Moreover, it was apparent that GPs were often not informed of ED visits
made by PWE on their practice registers. Therefore, neither specialists nor GPs are positioned to
reliably identify PWE for invite. Given the low participant uptake rate, a modification that a definitive
trial could consider making would be for the EDs to identify ostensibly eligible patients from their
records and then request that the identified patients’ GPs do the inviting. What impact this would have
on uptake is not clear. It would require additional NHS support costs and additional approvals to
permit EDs to communicate with general practices on what would be a research matter.
One of the leading reasons that patients gave for not wanting to take part was lack of interest.
Some of this lack of interest might have arisen because of the time that had elapsed between the ED
visit that led to their identification and them receiving the study invite (the median was 9 months).
This could be addressed by shortening the time period between identification and invite, or, even more
drastically, recruiting patients prospectively instead. The latter would have significant implications for
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the resources required by a definitive trial. In addition, the pragmatics of recruiting PWE directly from
the ED requires clarification. For example, patients may often be in a post-ictal state and, furthermore,
a stay in the ED is typically far shorter than a stay on a hospital ward.
We note that it is possible that the serial assessment of participants and the need for them to
complete multiple secondary outcome questionnaires at the assessments might have been seen as
overly burdensome by people considering the invitation to participate in the trial. It might also have
negatively affected retention of the participants who were recruited. If a definitive trial committed
itself to using routine ED data as the source of data for the primary outcome measure, that trial could
theoretically reduce or even totally drop the use of the secondary assessment measures. This might
increase uptake and improve retention. In considering how dramatic the improvements might be, it is
perhaps worth noting that none of the participants who did take part in the trial and who completed
the trial participation feedback questionnaire identified the questionnaire packs as being burdensome
or as an area of the trial that required improvement.
Identifying eligible patients
Identifying eligible patients for the pilot RCT from ED attendance systems required substantial time
and effort on behalf of the local principal investigators at the EDs. This was because of the nature of
the condition, because the ED administrative systems did not code visits in a sufficiently granular way
and because many of the data on patients that was needed to determine eligibility (e.g. presence of
certain comorbidities) was recorded in an unstandardised way in non-searchable, free-text fields.
Consequently, searches of the attendances systems were limited to simply identifying persons who had
attended for a ‘suspected seizure’. The triage cards of these identified persons needed to be accessed
and screened by local clinicians to find people suitable for invitation. This activity could not have been
delegated to research staff, including research nurses, since it is not ethically permissible for a person
outside the patient’s care team to access information on their medical history for the purposes of
research without prior consent.215
Since our pilot RCT took place, a new coding system for EDs – the Emergency Care Data Set216 – has
been phased in. From the perspective of a definitive trial, it brings some advantages because it seeks
to standardise and increase the granularity with which presentations and comorbidities are recorded.
For example, a specific presentation code for seizure caused by a neurological condition now exists.216
The system also asks for diagnosis to be recorded using detailed Systematised Nomenclature of Medicine
(SNOMED) clinical terms; however, the fields ‘discharge diagnosis’ and ‘comorbidity’ in the Emergency Care
Data Set are not mandatory.217,218 Therefore, it remains to be seen how well completed these fields are
before it is possible to conclude that the presence of the new system means that PWE can be more readily
identified for a definitive trial, and demands on local sites reduced to a reasonable level.
Securing routine outcome data on emergency department use
For a definitive trial of SAFE to be well positioned to be funded and for it to be designed optimally,
stakeholders would want to be confident that primary outcome data could be secured and a fairly
precise estimate would be needed as to when the data would be available. Our pilot demonstrated that
the provision of such data is not a given and that the timeline is hard to estimate. Bodies such as the
NIHR have endorsed the use of routine data sources in clinical research. It is possible that, as routine
data are requested more often for trials, NHS Digital’s application processes will be revised and
become more suitable for the research environment. It is notable that our experience is not unique.
The challenges in securing routine outcome data from NHS Digital were described in detail by
Powell et al.174 in 2017, and recommendations for improvements with the system were made.
Effect of the SAFE intervention
Efficacy was not the primary focus of our pilot RCT. No power calculation was completed and, with
such a small sample, imbalance in pre-randomisation covariates between the treatment arms is
possible. The estimated modest effect of SAFE on subsequent ED use – namely, reducing it from
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2.1 visits over a 12-month period to 1.8 (compared with a slight increase in the TAU only arm from 3.0 to
3.4 visits) – was used to inform the sample size calculations for a definitive trial. Therefore, it is important
to consider how realistic this estimate is because a larger effect would probably make a definitive trial
cheaper (i.e. because fewer patient participants and thus recruitment sites would be required).
When the pilot RCT was being designed the empirical evidence on the ability of self-management
interventions to change behaviour in PWE was positive but inconclusive. An updated systematic review
by Luedke et al.219 has since been published. It considered evidence from 13 randomised trials and two
non-randomised trials of self-management interventions for epilepsy published before April 2018. The
review concluded that interventions showed clinically important benefit on only a limited number of
outcome measures. Interventions that primarily sought to increase knowledge changed self-management
behaviours moderately, whereas interventions that included techniques such as cognitive behavioural
therapy or problem-solving treatment improved quality of life only modestly. Overall, self-management
interventions were not found to decrease seizure rates.
One RCT from the USA220 identified by Luedke et al.’s review219 is particularly instructive because it is
the only one to have also considered change in ED use. It focused on what its authors, Sajatovic et al.,220
labelled an ‘at-risk’ population, defined as adults with established epilepsy who had had at least one
negative health event within the past 6 months, be it a seizure, an accident, a self-harm attempt or an
ED visit. The RCT compared the effects of an educational intervention, called ‘self-management for
people with epilepsy and a history of negative health events’, to a wait list control. It comprised eight
sessions, addressed myths surrounding epilepsy and introduced participants to key self-management
tasks. A total of 120 patients were recruited and followed up for 6 months. The trial found no statistically
significant differences between arms in terms of subsequent ED/hospitalisation use. For the intervention
arm it reduced by 0.44 visits from 1.22 visits. For the wait list control arm it reduced by –1.26 visits
from 2.4 visits.
The findings of the updated review suggest that the relatively small estimated effect of SAFE is in the
region of what might be expected of a self-management intervention and thus the estimate from our
pilot trial constitutes a reasonable basis for the sample size calculations for a definitive trial. That a
self-management intervention reduces ED visits by a only small amount also makes sense from a
clinical perspective because we now know that factors beyond low seizure confidence can influence
whether or not an ED visit occurs. One is that studies with the ambulance service show that peripheral
issues, such as performance targets and difficulties accessing information on patient medical history to
determine normality or otherwise of the seizure presentation, can influence whether or not a person is
conveyed to ED following an emergency call.77,78
Progression, feasibility and optimal design of a definitive trial
Thabane et al.132 provide a framework for judging whether or not to proceed to a definitive trial
following a pilot. They describe the options as (1) ‘continue without modification’ (feasible as it is),
(2) ‘continue without modifications, but monitor closely’ (feasible with close monitoring), (3) ‘continue,
but modify the protocol’ (feasible with modifications) and (4) ‘stop’ (main study is not feasible). In satisfying
only one of the pre-specified progression criteria, a definitive trial based on our pilot trial’s design is not
feasible. On the basis of the discussion above, we do not consider that any options are currently available
to modify the protocol in such a way for it to become feasible. Therefore, we recommend not proceeding
to a definitive trial.
Alternative steps to the diffusion of the SAFE intervention
A definitive trial of SAFE is needed to determine its efficacy. This information would help commissioners
understand with confidence whether or not SAFE should be scaled up and rolled out. As noted, our pilot
indicates that such a trial is not currently feasible, although it might be in the future. In the meantime,
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the needs of many PWE who visit ED with respect to seizure first aid will continue to be unmet, with all
the consequences that this has. Because it is not known when any other intervention will become available,
an argument can be made for making SAFE available in some form to the epilepsy population now.
In support of this approach is that SAFE was rigorously produced, including the key information that
health-care professional representatives reported that the target population needs to routinely receive
(but for various reasons often do not). It received positive support from service users, with most who
received it welcoming it. There were also no indications that SAFE had any serious adverse effects and
it might reduce some ED use.
One way of making SAFE available now would be to convert its materials into a free online resource to
which health-care professionals, such as epilepsy nurses and neurologists, and charities could direct
interested people. The conversion could be in the form of a professionally produced video of a SAFE
course that could be run with agreeable service users. To engage those viewing the online resource,
interactive questions could be integrated into recordings.
The conversion would be a relatively straightforward process and allow the investment already made
via this project to be capitalised on. To enable the conversion, only modest funding would be required
to produce the website and maintain and update it over time. For the pilot RCT, a more basic website
was developed for trial participants to allow them to download (rather than interact with) the course
slides and videos of the recovery position. The costs of the former activity provide some guidance as to
the sort of costs required. In 2017–18 the website domain cost the project £20.94 for 5 years and the
hourly rate for an information technology (IT) technician to maintain the site was only £28.09.
It is likely that a full conversion of SAFE would be welcomed by many health-care professionals
because specialist services are currently being asked to innovate, identify and care for those currently
underserved, such as PWE who visit EDs. However, the workforce is small and can already struggle to
achieve waiting time targets and respond to requests for help.
Sharing SAFE in the way described would also present new opportunities to evaluate SAFE’s effect
with a potentially large sample over time, albeit in a less rigorous way than by a full RCT. For instance,
by using a pre–post design, those viewing the materials could be asked to fill in a brief online
questionnaire immediately before and after the intervention to provide a measure of the intervention’s
effect on seizure first aid knowledge and confidence. The same people could be asked for consent for
access to be given to routine data from NHS Digital on its use of ED during the 12 months before and
after completion of the course.
Strengths and limitations
Intervention development
The intervention was co-produced. The process enabled us to access the unique perspectives of health-
care professionals and service users in a non-tokenistic way. Clear, tangible changes to the intervention
were made in response to their views. The APEASE framework116 provides criteria that need to be
considered when considering the utility and potential of interventions. Our project has provided
positive evidence for the SAFE intervention on a number of these criteria, namely acceptability,
practicability, affordability and safety. SAFE is well positioned to be implemented in the NHS should
this ultimately prove appropriate.
We anticipate that the description provided of the co-production process we adopted could also provide
a useful template for the development of interventions by other groups. A concern of some researchers
is that the process of engaging service users and other stakeholders will be unwieldy and it will be
challenging to engage stakeholders.221 To this point we note that this process is not one that should be
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entered into lightly because it requires careful planning, expertise, resources and ethics approval. It took
9 months to complete, with a team including four experienced academics, two at the professorial level.
However, we would argue that the length of the feedback sessions and the quality of consideration given
by the stakeholders goes some way to demonstrating how willing stakeholders can be to contribute to
such processes. In terms of recruitment, we note that those with epilepsy can often have low self-esteem
and confidence.186,213 This meant that we needed to be mindful from the start of the need, when bringing
people into this process, to clearly emphasise to participants what we were doing, why we wanted them
involved and that it was their views, however critical, that we needed to hear.
Pilot trial
The pilot trial was completed in a rigorous manner in accordance with best practice guidelines and
reported according to the CONSORT extension for randomised pilot and feasibility trial222 (see Report
Supplementary Material 3). Randomisation was done remotely by computer and stratification factors and
allocations concealed from those collecting baseline and follow-up data and analysing them. Patients were
also recruited from NHS sites. Some RCTs, including Sajatovic et al.’s trial,220 have focused recruitment on
user group participants. People in such groups might differ in important ways from those who are not.
We also used an opt-out method of recruitment whereby we contacted patients about the study unless
they told us otherwise. The opt-in method, where the onus is on the patient to contact the research team
to express their interest, was not considered ideal for a patient population that frequently reports memory
problems and whose lives can be disrupted by episodic relapses of their condition. Another strength is that
recruitment sites were in areas where social deprivation was high and epilepsy control poor and so similar
to those where a definitive trial would probably need to focus recruitment.
We completed one of the few microcostings of a self-management intervention for epilepsy. We also
described the content of the SAFE intervention in detail and independently monitored its fidelity and
reported the results. A recent review of trials of psychosocial interventions for epilepsy found that
only ≈ 5% of trials did this for ‘adherence’ and ≈ 2% for ‘competence’.223 Indeed, we have also provided
a rare worked example of how to conduct a fidelity assessment and the resources required. Medical
Research Council publications224 note the importance of evaluating fidelity; however, minimal guidance
is provided regarding how to do it. Intervention developers report that this is one reason why they fail
to assess fidelity.225
The pilot trial is not without potential weaknesses. First, despite the trial team identifying PWE for
inclusion on the basis of them having at least one attendance at ED for epilepsy recorded and the
patient, when questioned, reporting at least two visits in the 12 months prior to recruitment, ≈ 40%
of these patients might not have met the inclusion criteria (according to the routine health data
subsequently obtained). The inclusion of these people could affect the external validity of the trial and
attenuate the estimated effect of SAFE because they had less opportunity for a reduction in ED use.
In addition, while 18 (69%) of the 26 patient participants randomised to SAFE took part with an
informal carer, five (28%) of these did not ultimately attend an intervention session. This is comparable
to experience in the SMILE (UK) trial.208 Their non-attendance may have limited the effect of SAFE
because carers can be key to decision-making when a seizure occurs.
Because a diagnostic code is often not recorded for ED visits, we asked NHS Digital to inform us
how many ED visits, regardless of diagnosis, each patient had made during specific periods of time.
Therefore, it is possible that not all of the visits reported for the participants were associated with
epilepsy. UK data on how many ED visits a person with epilepsy has made for reasons other than
epilepsy in a set period is not known. PWE are certainly more likely to have a comorbidity than the
general population and so it is possible that they attend for other reasons.
When calculating the size of sample probably required for a definitive trial of SAFE, the pilot trial’s
estimate of SAFE’s effect on ED use was used. We used the estimate because there is no consensus
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about what constitutes a minimally important clinical reduction in ED visits. We acknowledge that the
estimate from the pilot trial might be lacking in precision133 and that basing the sample size calculations
on a smaller or larger effect size would substantially change the required sample size for a definitive trial.
Implications for NHS service commissioning, policy and practice
l The trial was not designed to determine SAFE’s efficacy. There remains limited evidence to justify
the commissioning of such a service.
l Some PWE are unknown to ambulatory care services and cannot be readily identified. Increasing
the granularity with which attendances at EDs are coded could enable them to be readily identified,
supported and involved in research.
l Using routine data on ED could make trials less vulnerable to losses to follow-up and mean that
they are not exposed to apparent recall bias. Stakeholders need to be given more assurances from
those holding the data that it is likely to be provided and done so in a timely manner.
l Given that SAFE is liked by service users, that it might reduce ED use in a small way and that it
does not appear to have serious adverse effects, there is a case for converting it into an free online
resource that people could be directed to in the short term to go some way to address the
otherwise unmet seizure first aid training needs of PWE who visit EDs and their SOs.
Recommendations for research
l A definitive SAFE trial, with its current design, should not be conducted because it is not feasible
for the reasons given above. We cannot envisage any immediate changes to trial design that could
make it feasible.
l Research is required to understand how people from the target population can be better recruited.
It is possible that the feelings of stigma apparent in the target population might be an important
barrier to recruitment. If this is the case, it is important that recruitment methods are identified or
developed to ensure that participants’ feelings of stigma do not compound the difficulties that they
may already be facing by preventing high-quality research into their condition from being conducted.
l Converting SAFE into a free online resource that people could be directed to could provide an
opportunity for an alternative method of evaluating its effect on some of the primary and secondary
outcome measures used in the pilot RCT. Via a pre–post design, people accessing the online
resource could complete brief measures to assess change in seizure first aid confidence and skills.
They could also be asked for consent to access routine data on their use of EDs in the 12 months
before and after their viewing of the resource.
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Patient data
This work uses data provided by patients and collected by the NHS as part of their care and support. Using
patient data is vital to improve health and care for everyone. There is huge potential to make better use of
information from people’s patient records, to understand more about disease, develop new treatments,
monitor safety, and plan NHS services. Patient data should be kept safe and secure, to protect everyone’s
privacy, and it’s important that there are safeguards to make sure that it is stored and used responsibly.
Everyone should be able to find out about how patient data are used. #datasaveslives You can find out
more about the background to this citation here: https://understandingpatientdata.org.uk/data-citation.
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Appendix 1 Possible ways that the SAFE
course could reduce unnecessary/avoidable
emergency department use
Primary putative mechanisms
Low seizure management confidence and skills How might the course address and reduce ED use?
PWE can have low levels of knowledge of epilepsy and
seizures, have incorrect beliefs concerning first aid, lack
confidence managing seizures and be disproportionately
fearful (e.g. Long et al.70). Consequently, some patients can
routinely call for emergency medical assistance when they
are about to have or have had a seizure, regardless of
whether or not it is medically required
Responsibility for managing epileptic seizures is often
delegated to SOs (Walker et al.73). Some have low levels
of epilepsy knowledge, have incorrect beliefs concerning
seizure first aid, lack of confidence in managing seizures
and can be fearful of seizures and their threat to a
patient’s life (Kobau et al.226). Consequently, some SOs call
for emergency medical attention when the patient has or
has had a seizure, regardless of whether or not it is
medically required
Topics covered in the ES course could increase patients’
knowledge of what seizures are, what seizures’ effects
are and help patients to know when it is necessary to
seek emergency assistance. This could serve to increase
patients’ confidence in managing seizures, including
post-ictal states, and help them to delineate the
circumstances that require emergency services. The
course could also help allay disproportionate fears
The ES course could help increase SOs’ knowledge of
what seizures are, what seizures’ effects are and help
them to know when it is necessary to seek emergency
medical attention and identify alternative pathways of
support. It could also help allay disproportionate fears
held by the SO
The topics covered in the ES course could also help PWE
feel more informed and comfortable with their diagnosis.
This could empower them to have a discussion with
others in their caring network about epilepsy, relay
correct information about how they can be helped if they
have a seizure and what their preferences are regarding
transportation to ED. To help PWE to do this, the ES has
a variety of resources that participants are given or have
their attention drawn to. For example, in the participant
take-away information pack there are a number of free
wallet-sized ‘seizure first aid cards’ that can be given to
friends and family members
Secondary putative mechanisms
Suboptimal medication or risk management How might the course address and reduce ED use?
Evidence that in some cases ED attendance by PWE may
have been precipitated by the person having experienced
a seizure or seizure-related injury because they have
not managed their medication (e.g. have skipped doses)
or epilepsy in an optimum manner or managed risk
(e.g. not taken precaution to avoid a seizure trigger)
(Faught et al.;227 Tan et al.228)
The ES course describes what antiepileptic medications do,
explains why adhering to prescribed regimes is important
and outlines potential seizure triggers. This could promote
better medication and risk management by PWE and so
reduce avoidable seizures and associated complications.
Imparting this information to SOs could also be helpful
and allow them to become powerful supporters of the
development of self-management responsibility in the
PWE they know (e.g. helping PWE with reminders) and
risk management (e.g. helping the PWE to identify and
avoid triggers, such as sleep deprivation and stress)
The ES course also briefly covers issues to do with
the commonality of epilepsy, whom it affects and its
emotional impact, provides participants with the contact
details of support agencies and helps to dispel some
misconceptions and myths about epilepsy (e.g. its causes).
This, along with meeting other PWE, may help reduce
feelings of stigma and shame about the diagnosis.
Stigma can be associated with willingness to accept
one’s diagnosis and antiepileptic treatments
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Lack of emergency seizure medication How might the course address and reduce ED use?
Portable emergency seizure medications (e.g. buccal
midazolam) are suitable for some PWE. They can be
prescribed to PWE who have had a previous episode of
prolonged or serial convulsive seizures (NICE).49 They can
empower patients and families to manage some seizures,
without the need for medical assistance (Mitchell et al.;229
O’Dell et al.230). However, patients and SOs might not be
aware of them or their utility. They may also have incorrect
beliefs about them (e.g. that all need to be rectally
administered), which could act as a barrier to their use
The ES course covers emergency medication. Sources
of further information on this topic are also provided.
The information could enable PWE to start a discussion
with usual care providers about whether or not such
treatment is suitable for them
Lack of epilepsy identification at time of seizure How might the course address and reduce ED use?
In a minority of cases (≈ 15%; Reuber et al.23), ED visits
by PWE occur because the person is alone, has an
uncomplicated seizure in a public place and a bystander
calls for an ambulance. Evidence indicates that it can be
challenging for ambulance staff to know whether or not it
is safe to discharge the patient at the scene because they
do not know the patient’s medical history. The patient may
also be post-ictal; although it is not necessary to transport
them to hospital, they do not have an alternative way of
ensuring patient safety. Some evidence indicates that
low confidence in managing seizures results in some
ambulance staff being insistent about transporting the
patient to ED (Burrell et al.78)
The ES course does not currently cover this topic.
However, with the help of experts and users consulted
during the development phase, it might be feasible to
introduce this as a new topic. This could involve briefly
discussing with PWE and SOs the challenges that
face ambulance crews when managing seizures, the
benefits of patients carrying easily accessible epilepsy
identification cards and the benefits of patients carrying
the contact details of a SO who could be contacted to
look after the patient and explain the patient’s medical
history. Patients could also be advised on the rules and
regulations concerning transportation to ED by paramedics
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Appendix 2 Participant information sheet
for health-care professional representatives
(part A)
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Appendix 3 Participant information sheet for
service user representatives (part A)
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Appendix 4 Topic guide for interviews with
health-care professional representatives
(part A)
Reminder of context of study for interviewer: 
Many visits to hospital emergency departments for epilepsy are clinically unnecessary. This is because they are 
by people with known, rather than new epilepsy, who have experienced an uncomplicated seizure. Research by
our group indicates people with established epilepsy often aend hospital emergency departments for these 
seizures because they and their significant others (SOs) can lack confidence managing seizures. They say they
want more information, are unsure as to what the effects of seizures are, do not know when medical aenon 
is required, and some fear death. To beer support these people, we are developing a seizure first aid training 
course for paents who frequently visit emergency departments, and their family and friends. The course will be
adapted from an exisng seizure management training course that has been delivered on a small scale by the 
Epilepsy Society.
Tools:
To help the interview process, take a copy of the course materials that were sent to the interviewee. The table
of 8 topics covered may be a useful aide memoire for interviewees. The interviewee is also encouraged to
bring any notes with them to the interview.
Areas to be covered by the interview with health professional/ user group stakeholders: 
Briefly, what is their area/ work/ career background?
How are they involved in supporting people with epilepsy?
What were their thoughts on the idea of the course?
How successful/ unsuccessful do they think the course will be in improving paents and SOs seizure 
management skills and confidence? Any parcular groups for which is likely to be most or least useful? 
What did they think from the course was most likely/ least likely to help paents make fewer clinically
unnecessary ED visits? 
Are there any new things that they think the course needs to cover so that it is as helpful as possible?
If so, what and how?
Specific areas to be explored here if not covered spontaneously: 
Some paents may hold disproporonate fears concerning the effects of seizures on the brain and the 
possibility of death. Does the interviewee think some course me should be given to the topic of what
the effects of seizures are and the risks of events, such as status epilepcus and SUDEP? If so, what
informaon do they think the course should provide and how? 
Does the interviewee think evidence on the high proportion of unnecessary ED visits for epilepsy should 
be explicitly presented to parcipants? 
Does the interviewee think some course me should be given to allow participants to discuss fears of
unconsciousness/death in themselves and SOs; and seizure management? 
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Parcipants might not be aware of emergency seizure medicaon and may also have incorrect beliefs
about them. Does the interviewee think some course me should be given to the topic of emergency 
medicaon? If so, what informaon should be relayed and how? 
Some ED visits occur because the person is alone, has an uncomplicated seizure in a public place, and 
a bystander calls for an ambulance. Does the interviewee think some course me be given to the topic 
of how paents and families can help ambulance crews manage seizures in the community when
appropriate, rather than having to transport the paent to ED? If so, what informaon or strategies do
you think the course should provide paents with and how?
Are there any things that they think should be removed from the course? If so, what and why?
To accommodate that addional aspect/s, whilst keep the course length roughly the same, what you 
do they think could be removed and why?
Are there any things currently covered by the course that they think should be changed? If so, what
and how?
What did they think about the way the course is delivered? (Group sizes, seng, educaonal facilitator
background, capacity etc.) 
Do they have any thoughts on how the course will be received by PWE who frequently visit ED? 
Are there any barriers to participang and/or using informaon and training that they idenfy?
Do they have any thoughts on how the course will be received by the family members and friends who 
aend the course?
One specific area to be explored here if not covered spontaneously - Does the interviewee think some course
me should be given to how patients can best discuss their epilepsy and first-aid with friends and colleagues
not on the course?  If so, what informaon or strategies do you think the course should provide paents with 
and how?
Did they idenfy any inaccuracies in the medical informaon that was presented? If so, what/ where?
If the course were ulmately found to be effecve, how do they think it could be best rolled out within
the NHS? (e.g., idenfying who needs it; how oen courses should be provided; who pays for it)  What
would be the barriers and facilitators be?
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Close:
Any other quesons or comments parcipant wishes to make
Thank you for your me
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Appendix 5 Topic guide for focus groups with
service user representatives (part A)
Introducon:
Introduce self and project role 
Well once again I would like to thank you all for taking the me to be here with us today.  
As I menoned previously we are now interested in finding out about your views about today’s training. 
Your comments and suggesons for change are important to us as we want to use those ideas to help
us improve the content and presentation of this training. 
Before we start this discussion I just want to menon a couple of important points: 
o The discussion will work best if everyone feels comfortable to share their opinion and 
somemes personal experiences. It is important that we agree from the start that any 
personal details people speak about during this session are respected by us all and kept
confidenal by not sharing any personal informaon about anybody else outside of this room. 
Does this sound okay to everyone? ...Thank you 
o Please note this FG is being audio recorded for the purpose of data collecon.  The recording
will be transcribed and I will use the findings from this discussion to inform the further
development of this training package 
o Can I just confirm that everyone has signed a consent form? … you will receive a copy of this
form to keep
o Please feel free to speak openly – there are no right or wrong answers.  However it would be
useful if when making a comment you could say whether you are speaking as a PWE/SO. This  
will help me to understand which perspecve your response is coming from.
o Any quesons before we begin?
Ice-breaker - General Overview:
Right, so let’s get started
As you may already know there are lots of different types of epilepsy and everyone is individual. This
probably meant that some of things we talked about today may have been important to some of you,
while some things may not.  Thinking about your impressions overall then: 
o How well was today’s session organised overall? 
EXPLORE,
o What did you parcularly appreciate and/or enjoy about the session? (prompts)
Content
Presentaon 
Timeframe (including start me and duration)
Venue (including access and facilies) 
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Presentaon 
Timeframe (including start me and duration)
Venue (including access and facilies) 
Use previous discussion as the platform to explore follow-on questions: 
Today’s course was designed to give you information about epilepsy first aid:
o In your opinion how well did the taught aspects of the session meet:
This aim / What could we have done differently
Your own expectaons / What would you like to see changed
We also tried to provide people with epilepsy and those who support them with a 
practical view of how to manage seizures, including what to do and what not to when 
seizures occur:
In your opinion how good were the explanation of topics provided in the session 
Was enough me given to these explanations 
Was enough me given to the praccal demonstraons (recovery posion)
What could we have done differently
In the future, we want everyone who takes part in these sessions to contribute as much as possible 
as we believe this will make what is being said more meaningful for the participants. With this in
mind: 
o How comfortable did you feel to: 
Ask quesons about the topics covered
To parcipate in the praccal tasks in the session 
(prompts to explore in turn/ in depth)
Kindness Quesonnaire 
Quiz 
What to do/ what not to do task
Recovery demonstraon/practice 
o In your opinion Does group size/mix, promote / hinder interacon 
Was the group size/mix of PWE/SOs appropriate:
Yes – why?/ No – why?
EXPLORE,
o What changes could we introduce to improve the session? (prompts)
Content
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The session content
Thinking specifically about the content of the session, in your opinion:
o Where the key message(s) from today’s session easy to idenfy?
o Was the amount of material covered was about right?
o Was there anything that was unclear or could have been beer explained?
o Was there anything you wanted to be included that wasn’t? 
If so what was it and why was this important?
If you have had an opportunity to look at the addional information provided today:
o How relevant to the session do you consider them to be?
o What addional informaon, not provided would you have liked to have been included?
I would now like to hear your opinions about how the session was delivered today:
o Was the session leader considered to be knowledgeable / provide quality instrucon?
o  How well did the session leader develop a good rapport with those taking part? 
o Was class parcipaon and interacon encouraged sufficiently / too much
o Where the teaching and learning methods used smulating / interesting?
o How good was the balance between the session leader talking, the group work and the 
discussion?
o Was adequate provided for quesons and discussion?
o Overall, how well organised was the session?
CLOSE
Are there any other comments anyone would like to make about any aspect of today’s session? 
THANKYOU 
This training session, its format and resources were informed by broader seizure management 
training that is currently offered by the Epilepsy Society. In your opinion:
o How well (or not) do you think the session tle reflects the:
The session aims 
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Appendix 6 Search criteria employed at the
different recruitment sites to identify
potentially suitable persons attending
emergency departments for epilepsy
ED site
1 2 3
Identify those people who in the
free-text box ‘presenting complaint’
are recorded as having visited the
ED for a:
l ‘fit’
l ‘epilepsy’
l ‘convulsion’
l ‘seizure’
Identify those people admitted as an
emergency from an ED to a ward
with any of the following primary or
secondary ICD-10 diagnoses:
l ‘G40 Epilepsy’
l ‘G41 Status epilepticus’
l ‘G83.8 Other specified
paralytic syndromes’
l ‘R56.8 Other and
unspecified convulsions’
Identify those people who in the
free-text box ‘reason for visit’ or
‘presenting complaint’ are recorded
as having visited the ED for:
l ‘fit’
l ‘epilep’
l ‘convuls’
l ‘seiz’
Identify those people admitted as an
emergency from an ED to a ward
with any of the following primary or
secondary ICD-10 diagnoses:
l ‘G40 Epilepsy’
l ‘G41 Status epilepticus’
l ‘G83.8 Other specified
paralytic syndromes’
l ‘R56.8 Other and
unspecified convulsions’
Identify those people who attended
the ED and were given any of the
following presenting complaint/
discharge diagnosis profiles:
l ‘AE20 AEPRC Fit’ AND ‘02 AEDIG
Contusion/abrasion’
l ‘AE20 AEPRC Fit’ AND ‘04 AEDIG
Head injury’
l ‘AE20 AEPRC Fit’ AND ‘05
AEDIG Dislocation’
l ‘AE20 AEPRC Fit’ AND ‘06 AEDIG
Sprain/ligament injury’
l ‘AE20 AEPRC Fit’ AND ‘07 AEDIG
Muscle/tendon injury’
l ‘AE20 AEPRC Fit’ AND ‘10 AEDIG
Burns and scalds’
l ‘AE20 AEPRC Fit’ AND ‘15 AEDIG
Near Drowning’
l ‘AE20 AEPRC Fit’ AND ‘33 AEDIG
Facio-maxillary conditions’
l ‘AE20 AEPRC Fit’ AND ‘38 AEDIG
Diagnosis not classifiable’
l ‘241 AEDIG Epilepsy’
Identify those people admitted as an
emergency from an ED to a ward
with any of the following primary or
secondary ICD-10 diagnoses:
l ‘G40 Epilepsy’
l ‘G41 Status epilepticus’
l ‘G83.8 Other specified
paralytic syndromes’
l ‘R56.8 Other and
unspecified convulsions’
ICD-10, International Statistical Classification of Diseases and Related Health Problems, Tenth Revision.
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Appendix 7 Participant information sheet for
patients in the pilot randomised controlled
trial (project part B)
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Appendix 8 Full details of secondary
outcome measures
Quality of life (patients only; baseline, 6 months and 12 months)
Quality of life was measured using the epilepsy-specific quality of life measure QOLIE-31-P.184 This asks
participants to reflect on how they felt over the past 4 weeks. It has seven subscales that reflect the aspects
of living that can be affected by epilepsy (emotional well-being, energy fatigue, cognitive functioning, seizure
worry, medication effects, social functioning and overall quality of life). Scored according to guidelines, a
participant’s total score ranges from 0 to 100, with higher scores indicating better overall perceived quality of
life.The QOLIE-31-P varies from the original version of the tool166 in that at the end of each subscale there is
one additional item that asks the participant to rate the degree of ‘distress’ caused by that particular topic.
Burden (significant others only; baseline, 6 months and 12 months)
No epilepsy-specific measure is available to measure so-called ‘caregiver burden’ in the target
population. Therefore, Zarit caregiver burden scores170 were used to capture the impact of informal
caring on the patient participant’s designated SO. Its 22 items evaluate the effect of a condition on
quality of life, difficulty in social and family relationships, psychological suffering, shame, guilt and
financial difficulty. It is the most widely used, standardised, validated scale and has previously been
used in epilepsy (Stavem et al.231).
Psychological distress (patients and significant others; baseline and
12 months)
The 14-item HADS167,168 was used to measure self-reported distress in patients and SOs. It is a reliable,
valid scale widely used in UK epilepsy research. Anxiety and depression scores are grouped into
symptom categories: ‘normal’ (0–7), ‘suggestive of anxiety/depression’ (8–10) and ‘probable anxiety/
depression’ (11–21).232
Felt stigma (patients only; baseline and 12 months)
Jacoby’s 3-item Stigma Scale of Epilepsy with revised 4-point scoring14,62,233 measured the extent to
which patient participants felt that they are stigmatised because of their epilepsy. Response options
include a four-point Likert scale: ‘not at all’ (0), ‘yes, maybe’ (1), ‘yes, probably’ (2) and ‘yes, definitely’ (3).
A total score of 0 is classified as ‘does not feel stigmatised’ while total scores of 1–6 are classified as
‘mildly to moderately stigmatised’ and total scores of 7–9 are classified as ‘highly stigmatised’. The
scale’s internal consistency (Cronbach’s α = 0.85) is good.14
Fear of seizures (patients and significant others; baseline and 12 months)
Both patients and SOs completed five items from the fears subscale of the 60-item Epilepsy
Knowledge and Management questionnaire.163 They focus on knowledge about seizures and on fears of
death or brain damage. The five items have previously been used in isolation.234
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Confidence managing seizures/epilepsy (patients and significant others;
baseline, 6 months and 12 months)
The epilepsy-specific Wagner 6-item Mastery Scale61 was used to measure patient participants’ perception
of epilepsy and its treatment and the extent to which they felt able to control these. This measure is able
to distinguish between groups of PWE with differing levels of severity. It has adequate internal consistency
(Cronbach’s α = 0.7) and test–retest reliability.235 SOs completed the 6-item Condition Management
subscale from the Parents Response to Child Illness Scale,186 which has been shown to have good internal
consistency.165 SOs respond to each item using a 5-point scale.
Knowledge of what to do when faced with a seizure (patient and significant
others; baseline and 12 months)
Both patients and SOs completed a measure assessing their knowledge of what to do when faced with a
seizure. The standardised questions come from Martiniuk et al.’s Thinking About Epilepsy questionnaire.164
Seizure control (patients only; baseline, 6 months and 12 months)
At baseline (T0), patients were asked to complete Thapar’s seizure frequency scale169 for the prior
12 months. At 6- (T2) and 12-month (T3) follow-up, patient participants were asked for the number of
seizures (of any type) that they had experienced since the last assessment and the date of the first and
most recent seizure (if applicable) since last assessment. To assist patients to be able to provide this
information they were offered a seizure diary at baseline (T0) and instructed on how to complete it.
Health economics (patients only; baseline and 12 months)
The Client Service Receipt Inventory171 enabled measurement of patient participants’ health service
use (including use of ambulance services, regardless of whether or not transfer to ED happened),
informal care (including work time lost by SOs), benefits received and employment status during the
12 months prior to baseline (T0) and at 12 months (T3). The 5-item EQ-5D,172 already shown to be
valid in PWE,153 was also used.
Feedback on participation (patients and significant others and 12 months)
To capture patient and SOs feedback on their experience of taking part in the trial, including
randomisation, we asked both parties to complete three questions at their final assessment. These
were (1) ‘If time suddenly went backward, and you had to do it all over again, would you agree to
participate in the Seizure First Aid Training trial?’ (options: ‘definitely yes’, ‘probably yes’, ‘probably no’,
‘definitely no’ and ‘not sure’, plus a free-text field to explain the response), (2) ‘Please tell us if there
was anything about the Seizure First Aid Training Trial that you think could have been done better’
(options: free-text response) and (3) ‘Please tell us if there was anything about the Seizure First Aid
Training Trial, or your experience of joining the trial, that you think was particularly good’ (options:
free-text response). The questions are based on those used to explore participants’ experience of
participating in Morgan et al.’s Magpie trial.236
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Appendix 9 Serious adverse event protocol
Event
We defined a SAE – adapting the definition in Medicines for Human Use (Clinical Trials) Regulations
2004237 – as an adverse event that:
l resulted in death
l was life-threatening (subject at immediate risk of death, e.g. status epilepticus)
l resulted in a seizure that led to hospital admission for ≥ 24 hours
l resulted in emergency attendance or hospital admission for reason other than seizure
l resulted in persistent or significant disability or incapacity
l was otherwise considered medically significant.
‘Life-threatening’ in the context of ‘serious’ refers to an event in which the patient is at risk of death at
the time of the event; it does not refer to an event that hypothetically might have caused death if it were
more severe. Hospitalisations for a pre-existing condition, including elective procedures that had not
worsened, do not constitute a SAE. Prolongation of hospital stay owing to social factors, for example
geographical location of the participant’s home, which prevented discharge is also not considered a SAE.
Given the characteristics of the subject population being studied, the following events are expected in
this study population and will not be recorded as part of the SAE monitoring process:
l Epileptic seizures with or without injury.
l Emergency or urgent medical attention. This includes a visit to a hospital ED lasting < 24 hours,
attending an NHS out-of-hours primary care service, telephoning for an ambulance, telephoning NHS
111, seeking/having an urgent/fast-tracked appointment with a usual care provider (GP or specialist)
or other registered health-care professional (e.g. a pharmacist).
l Side effects of antiepileptic drug.
l Diagnosis of a comorbid psychiatric condition.
A delegated medically qualified person in the team (AM or LR) will assess each unexpected SAE. This
person will consider information on the temporal and physical relationship between the event and
possible causes and assess whether the event was related or unrelated to the patient’s participation in
the study. Further details on the process follow.
Monitoring
As part of this trial, patient participants will not receive additional medical reviews. There is also no
‘live’ system that can be used to track SAEs such as emergency admissions, and usual care providers
are not systematically informed of them. Therefore, to monitor SAEs the research team will liaise with
patients themselves. A standardised form will be completed as part of the CRF at 3 months (T1, by
telephone), 6 months (T2, by telephone) and 12 months (T3, during a face-to-face appointment) post
randomisation to collect information on patient participants’ experience of unexpected SAEs.
In each instance, a maximum of three attempts will be made to contact the patient participant by
telephone (including trying to contact them via their informal carer if they are taking part with one).
Should the patient not be contactable a letter will be sent the patient’s GP asking them to inform the
research team if the patient is no longer alive and of the circumstances of their death.
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Given the characteristics of the subject population being studied the potential adverse events expected
in this study population are as follows:
l Epileptic seizures with or without injury.
l Emergency or urgent medical attention. This includes a visit to a hospital ED lasting < 24 hours,
attending an NHS out-of-hours primary care service, telephoning for a ambulance, telephoning NHS
111, seeking/having an urgent/fast-tracked appointment with a usual care provider (GP or specialist)
or other registered health-care professional (e.g. a pharmacist).
l Side effects of antiepileptic drug.
l Diagnosis of a comorbid psychiatric condition.
Although they will be captured as outcomes of the trial, they will not be recorded as part of the SAE
monitoring process.
Causality
A delegated, medically qualified person in the team will assess each unexpected SAE. This person will
consider information on the temporal and physical relationship between the event and possible causes
and assess whether the event was related or unrelated to the patient’s participation in the study. In
doing this, they will use the definitions in the table below.
To complete their assessment, the research team may need to obtain medical records, such as
contacting a hospital where a patient was admitted as an emergency. For the following reasons a
window of 10 days will be allowed for a SAE to be reviewed by the medic: information on adverse
events will have been collected by research workers during concentrated follow-up periods, there will
be only one delegated medical assessor and assessment may depend on the timeliness of response
from hospitals for historically distant admissions.
Definitions of causality for serious adverse event
Term Description
Unrelated There is no evidence of any causal relationship. There is an alternative cause for the SAE
Unlikely There is little evidence to suggest that there is a causal relationship (e.g. the event did not occur
within a reasonable time after receipt of the intervention). There is another reasonable explanation for
the event (e.g. the participant’s clinical condition, other concomitant treatment)
Possibly There is some evidence to suggest a causal relationship (e.g. because the event occurs within a
reasonable time after receipt of the intervention). However, the influence of other factors may have
contributed to the event (e.g. the participants clinical condition, other concomitant treatment)
Probably There is evidence to suggest a causal relationship and the influence of other factors is unlikely
Almost
certainly
There is clear evidence to suggest a causal relationship and other possible contributing factors can be
ruled out
Reporting
The main research ethics committee (REC) approving the study and the sponsor will be informed
within 15 days of the team becoming aware of any SAE that in the opinion of the medical reviewers is
both unexpected (that is, the type of event is not listed in the protocol as an expected occurrence) and
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judged to be ‘possibly’, ‘probably’ or ‘almost certainly’ related to participation in the study (that is, it
resulted from administration of any of the research procedures, including the intervention).
Notifications will include the following details: date of the SAE, location, a description of the circumstances
of the event and an assessment of the causal relationship to the SAFE intervention and the implications, if
any, for the safety of study participants and how these will be addressed. Notifications made to the main
REC shall be made using the National Research Ethics Service SAE reporting form for non-Clinical Trials
of an Investigational Medicinal Product. A flowchart is given below to aid the determination of
reporting requirements.
A log of all SAEs that are unexpected and which were judged to be related to participation in the study
will also be reviewed by the Independent Trial Steering Committee and the implications for the study
considered. This information will also be sent to the funder as part of the progress reports and the
chief investigator will include details of the event in the annual progress report to the REC and a copy
sent to the sponsor.
Has a SAE occurred?
Yes No
Medical review for
relatedness
No further reporting
required
Is it ‘possibly’, ‘probably’
or ‘almost certainly’
related to participation?
No
No further
reporting
required
Inform REC and sponsor of SAE
within ≤ 15 days of research
team learning of event and
address implications, 
if any, for study 
Yes
FIGURE Flowchart for determining of reporting requirements for SAEs.
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Appendix 10 Cumulative, actual and expected
recruitment (consented and randomised) to
SAFE trial
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Appendix 11 Reasons for withdrawal from
the pilot randomised controlled trial
Reasons for withdrawal
Treatment arm, n (%)
Total, n (%)SAFE plus TAU TAU
Patient participants withdrawing from the study (N = 1) (N = 3) (N = 4)
Too busy 1 (100.0) 0 (0.0) 1 (25.0)
Not interested any more 0 (0.0) 1 (33.3) 1 (25.0)
Other: moved away to work 0 (0.0) 1 (33.3) 1 (25.0)
Other: wife has cancer 0 (0.0) 1 (33.3) 1 (25.0)
SO participants withdrawing from the study (N = 1) (N = 4) (N = 5)
Too ill 0 (0.0) 1 (25.0) 1 (20.0)
Not interested any more 0 (0.0) 1 (25.0) 1 (20.0)
Other: moved away to work 0 (0.0) 1 (25.0) 1 (20.0)
Other: no longer friends with person with epilepsy 0 (0.0) 1 (25.0) 1 (20.0)
Reason missing 1 (100.0) 0 (0.0) 1 (20.0)
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Appendix 12 Milestones in securing data
from NHS Digital
Period
Project milestone Milestone in obtaining data from NHS Digital
Date Note Date Note
Pre trial 1 July 2015 Project officially
starts
1 August 2015 Intervention
development starts
28 September 2015 Received feedback on draft
participant information sheets
and consent form for trial to
ensure compliance
Trial period 19 May 2016 First trial participant
randomised
11 October 2017 Participated in NHS Digital
training
18 October 2017 Registered as new user of
application system
7 November 2017 Delays experienced. Access
to application form granted
after chasing
December 2017 Final 12-month
follow-up completed
Post trial 16 February 2018 Application submitted to
NHS Digital
28 February 2018 Teleconference with NHS
Digital. Provisional opinion
given that only minor changes
required and likely time frame
for receipt of data 1.5 months
7 March 2018 Received written feedback
from NHS Digital after
chasing on minor changes
required
22 March 2018 Revised application submitted
3 April 2018 NHS Digital submitted
new query (1) to applicants
requesting additional
information (applicants
respond 3 April 2018)
26 April 2018 NHS Digital submitted
new query (2) to applicants
requesting additional
information (applicants
respond 26 April 2018)
30 April 2018 NHS Digital submitted
new query (3) to applicants
requesting additional
information (applicants
respond 30 April 2018)
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Period
Project milestone Milestone in obtaining data from NHS Digital
Date Note Date Note
5 May 2018 NHS Digital submitted
new query (4) to applicants
requesting additional
information (applicants
respond 5 May 2018)
10 May 2018 NHS Digital submitted
new query (5) to applicants
requesting additional
information (in the light of
General Data Protection
Regulation introduced in
May 2018) (applicants
respond 11 May 2018)
30 May 2018 NHS Digital submitted
new query (6) to applicants
requesting additional
information (in the light of
General Data Protection
Regulation introduced in
May 2018) (applicants
respond 30 May 2018)
30 May 2018 NHS Digital submitted
new query (7) to applicants
requesting additional
information (applicants
respond 30 May 2018)
15 June 2018 NHS Digital confirmed that
data approvals owner will
review revised application
27 June 2018 NHS Digital submitted
new query (8) to applicants
requesting additional
information and request
revisions to trial website (in the
light of General Data Protection
Regulation introduced in
May 2018) (applicants respond
28 June 2018)
2 July 2018 NHS Digital submitted new
query (9) to applicants
requesting additional
information (applicants
2 July 2018)
6 July 2018 NHS Digital notified applicants
that data approval owner has
rejected application primarily
because of ‘concerns [over]
whether this pilot would yield
findings that were statistically
valuable to achieve the stated
aims given the small numbers’
10 July 2018 Secured confirmation of right
to appeal and process
20 July 2018 Applicants submitted letter
of appeal
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Period
Project milestone Milestone in obtaining data from NHS Digital
Date Note Date Note
25 July 2018 Appeal accepted by NHS
Digital
15 August 2018 NHS Digital submitted new
query (10) to applicants
following IGARD committee’s
review of application (applicants
respond 16 August 2018)
16 August 2018 Teleconference with NHS
Digital data production team
04 September 2018 NHS Digital sent data-sharing
agreement to applicants
10 September 2018 NHS Digital confirmed receipt
of completed data-sharing
agreement
25 September 2018 Applicants securely transferred
patient participants’ details to
NHS Digital
31 September 2018 NHS Digital released data to
applicants
IGARD, Independent Group Advising on the Release of Data.
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Appendix 13 Completeness of secondary
outcome measures by assessment point, tool
and participant type
Number of questions of study assessment tool completed by patient
participants at each time point
Number of questions of study assessment tool
completed at each time point
Treatment arm, n (%)
Total, n (%)SAFE plus TAU TAU
Baseline (T0) (N = 26) (N = 25) (N = 51)
QOLIE-31-P184
33 0 (0.0) 1 (4.0) 1 (2.0)
35 2 (7.7) 2 (8.0) 4 (7.8)
36 1 (3.8) 6 (24.0) 7 (13.7)
37 (maximum) 23 (88.5) 16 (64.0) 39 (76.5)
aHADS167,168
7 1 (3.8) 0 (0.0) 1 (2.0)
13 2 (7.7) 1 (4.0) 3 (5.9)
14 (maximum) 23 (88.5) 24 (96.0) 47 (92.2)
Stigma Scale of Epilepsy62
0 1 (3.8) 1 (4.0) 2 (3.9)
2 1 (3.8) 0 (0.0) 1 (2.0)
3 (maximum) 24 (92.4) 24 (96.0) 48 (94.1)
bClient Service Receipt Inventory171
2 1 (3.8) 0 (0.0) 1 (2.0)
4 1 (3.8) 0 (0.0) 1 (2.0)
5 5 (19.2) 8 (32.0) 13 (25.5)
6 (maximum) 19 (73.2) 17 (68.0) 36 (70.5)
EQ-5D172
5 5 (19.2) 0 (0.0) 5 (9.8)
6 (maximum) 21 (80.8) 25 (100.0) 46 (90.2)
Wagner 6-item Mastery Scale61
1 0 (0.0) 1 (4.0) 1 (2.0)
3 0 (0.0) 1 (4.0.) 1 (2.0)
5 0 (0.0) 2 (8.0) 2 (3.9)
6 (maximum) 26 (100.0) 21 (84.0) 47 (92.1)
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Number of questions of study assessment tool
completed at each time point
Treatment arm, n (%)
Total, n (%)SAFE plus TAU TAU
Epilepsy Knowledge and Management Questionnaire:163 fear of seizures subscale163
0 3 (11.6) 2 (8.0) 5 (9.8)
1 1 (3.8) 1 (4.0) 2 (3.9)
2 1 (3.8) 5 (20.0) 6 (11.8)
3 1 (3.8) 4 (16.0) 5 (9.8)
4 4 (15.4) 4 (16.0) 8 (15.7)
5 (maximum) 16 (61.6) 9 (36.0) 25 (49.0)
6 months (T2) (N = 26) (N = 25) (N = 51)
QOLIE-31-P184
0 4 (15.4) 8 (32.0)c 12 (23.5)c
16 1 (3.8) 0 (0.0) 1 (2.0)
34 0 (0.0) 1 (4.0) 1 (2.0)
35 0 (0.0) 2 (8.0) 2 (3.9)
36 5 (19.2) 2 (8.0) 7 (13.7)
37 (maximum) 16 (61.6) 12 (48.0) 28 (54.9)
Wagner 6-item Mastery Scale61
0 4 (15.4) 8 (32.0)c 12 (23.5)c
2 1 (3.8) 0 (0.0) 1 (2.0)
5 0 (0.0) 2 (4.0) 2 (3.9)
6 (maximum) 21 (80.8) 15 (60.0) 36 (70.6)
12 months (T3) (N = 26) (N = 25) (N = 51)
QOLIE-31-P184
0 7 (26.9)d 8 (32.0)d 15 (29.4)d
1 1 (3.8) 0 (0.0) 1 (2.0)
31 0 (0.0) 1 (4.0) 1 (2.0)
35 1 (3.8) 4 (16.0) 5 (9.8)
36 7 (26.9) 4 (16.0) 11 (21.6)
37 (maximum) 10 (38.5) 8 (32.0) 18 (35.3)
aHADS167,168
0 8 (30.8)d 8 (32.0)d 16 (31.4)d
14 (maximum) 18 (69.2) 17 (68.0) 35 (68.6)
Stigma Scale of Epilepsy62
0 8 (30.8)d 8 (32.0)d 16 (31.4)d
3 (maximum) 18 (69.2) 17 (68.0) 35 (68.6)
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Number of questions of study assessment tool
completed at each time point
Treatment arm, n (%)
Total, n (%)SAFE plus TAU TAU
bClient Service Receipt Inventory171
0 8 (30.8)d 8 (32.0)d 16 (31.4)d
3 0 (0.0) 1 (4.0) 1 (2.0)
4 1 (3.8) 1 (4.0) 2 (3.9)
5 4 (15.4) 5 (20.0) 9 (17.7)
6 (maximum) 13 (50.0) 10 (40.0) 23 (45.0)
EQ-5D172
0 8 (30.8)d 8 (32.0)d 16 (31.4)d
6 18 (69.2) 17 (68.0) 35 (68.6)
Wagner 6-item Mastery Scale61
0 8 (30.8)d 8 (32.0)d 16 (31.4)d
5 0 (0.0) 1 (4.0) 1 (2.0)
6 18 (69.2) 16 (64.0) 34 (66.6)
Epilepsy Knowledge and Management Questionnaire:163 fear of seizures subscale163
0 10 (38.5)d 8 (32.0)d 18 (35.3)d
1 1 (3.8) 0 (0.0) 1 (2.0)
2 1 (3.8) 0 (0.0) 1 (2.0)
3 1 (3.8) 7 (28.0) 8 (15.7)
4 5 (19.2) 5 (20.0) 10 (19.6)
5 (maximum) 8 (30.9) 5 (20.0) 13 (25.5)
a Completeness of the whole HADS scale (both anxiety and depression subscales).
b Only six mandatory questions counted. Conditional questions (e.g. ‘if yes, then’) were not counted towards
total completion.
c Including two patient participants from the TAU arm who had withdrawn by the 6-month (T2) visit.
d Including four patient participants (three from the TAU arm and one from the SAFE plus TAU arm) who had
withdrawn by the 12-month (T3) visit.
Number of questions of study assessment tool completed by significant
other participants at each time point
Number of questions of study assessment tool
completed at each time point
Treatment arm, n (%)
Total, n (%)SAFE plus TAU TAU
Baseline (T0) (N = 18) (N = 19) (N = 37)
Zarit caregiver burden170
16 0 (0.0) 1 (5.3) 1 (2.7)
21 1 (5.6) 1 (5.3) 2 (5.4)
22 (maximum) 17 (94.4) 17 (89.5) 34 (91.9)
aHADS167,168
13 1 (5.6) 1 (5.3) 2 (5.4)
14 (maximum) 17 (94.4) 18 (94.7) 35 (94.6)
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Number of questions of study assessment tool
completed at each time point
Treatment arm, n (%)
Total, n (%)SAFE plus TAU TAU
Parent Response to Child Illness scale186
6 (maximum) 18 (100.0) 19 (100.0) 37 (100.0)
Epilepsy Knowledge and Management Questionnaire:163 fear of seizures subscale163
0 2 (11.1) 2 (10.5) 4 (10.8)
1 2 (11.1) 2 (10.5) 4 (10.8)
2 1 (5.6) 3 (15.8) 4 (10.8)
3 1 (5.6) 2 (10.5) 3 (8.1)
4 6 (33.3) 6 (31.6) 12 (32.4)
5 (maximum) 6 (33.3) 4 (21.1) 10 (27.0)
6 months (T2) (N = 18) (N = 19) (N = 37)
Zarit caregiver burden170
0 2 (11.1)b 9 (47.4)b 11 (29.7)b
10 0 (0.0) 1 (5.3) 1 (2.7)
21 1 (5.6) 1 (5.3) 2 (5.4)
22 (maximum) 15 (83.4) 8 (42.0) 23 (62.2)
Parent Response to Child Illness scale186
0 2 (11.1)b 10 (52.6)b 12 (32.4)b
6 (maximum) 16 (88.9) 9 (47.4) 25 (67.6)
12 months (T3) (N = 18) (N = 19) (N = 37)
Zarit caregiver burden170
0 7 (38.9)c 9 (47.4)c 16 (43.2)c
22 (maximum) 11 (61.1) 10 (52.6) 21 (56.8)
aHADS167,168
0 7 (38.9)c 9 (47.4)c 16 (43.2)c
14 (maximum) 11 (61.1) 10 (52.6) 21 (56.8)
Parent Response to Child Illness scale186
0 7 (38.9)c 9 (47.4)c 16 (43.2)c
6 (maximum) 11 (61.1) 10 (52.6) 21 (56.8)
Epilepsy Knowledge and Management Questionnaire:163 fear of seizures subscale163
0 7 (38.9)c 10 (52.7)c 17 (46.0)c
1 1 (5.6) 0 (0.0) 1 (2.7)
2 2 (11.1) 2 (10.5) 4 (10.8)
3 2 (11.1) 3 (15.8) 5 (13.5)
4 0 (0.0) 2 (10.5) 2 (5.4)
5 (maximum) 6 (33.3) 2 (10.5) 8 (21.6)
a Completeness of the whole HADS scale (both anxiety and depression subscales).
b Including four SO participants (one in the SAFE plus TAU arm and three in the TAU arm) who had withdrawn by the
6-month (T2) visit.
c Including four SO participants (one in the SAFE plus TAU arm and four in the TAU arm) who had withdrawn by the
12-month (T3) visit.
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Appendix 14 Bland–Altman plot of agreement
between self-reported and Hospital Episode
Statistics data on emergency department visits
at baseline, without any exclusions
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Appendix 15 Demographic characteristics of
significant other participants
Demographic characteristic
Treatment arm
TotalSAFE plus TAU TAU
Relationship with patient participant, n (%) (N = 18) (N = 19) (N = 37)
Parent 4 (22.2) 4 (21.1) 8 (21.6)
Son/daughter 2 (11.1) 4 (21.1) 6 (16.2)
Grandparent 0 (0.0) 0 (0.0) 0 (0.0)
Spouse/partner 9 (50.0) 7 (36.8) 16 (43.2)
Sibling 1 (5.6) 0 (0.0) 1 (2.7)
Cousin, aunt/uncle 0 (0.0) 0 (0.0) 0 (0.0)
Niece/nephew 0 (0.0) 1 (5.3) 1 (2.7)
Friend 2 (11.1) 3 (15.8) 5 (13.5)
Other 0 (0.0) 0 (0.0) 0 (0.0)
Missing 0 (0.0) 0 (0.0) 0 (0.0)
Co-habitation with patient participant, n (%) (N = 18) (N = 19) (N = 37)
Yes 14 (77.8) 14 (73.4) 28 (75.7)
No 4 (22.2) 5 (26.3) 9 (24.3)
Missing 0 (0.0) 0 (0.0) 0 (0.0)
Contact with patient participant (days per week), n (%) (N = 18) (N = 19) (N = 37)
0 0 (0.0) 0 (0.0) 0 (0.0)
1 1 (5.6) 0 (0.0) 1 (2.7)
2 0 (0.0) 1 (5.3) 1 (2.7)
3 0 (0.0) 2 (10.5) 2 (5.4)
4 0 (0.0) 0 (0.0) 0 (0.0)
5 0 (0.0) 0 (0.0) 0 (0.0)
6 0 (0.0) 0 (0.0) 0 (0.0)
7 (every day) 17 (94.4) 16 (84.2) 33 (89.2)
Missing 0 (0.0) 0 (0.0) 0 (0.0)
Sex, n (%) (N = 18) (N = 19) (N = 37)
Male 6 (33.3) 9 (47.4) 15 (40.5)
Female 12 (67.7) 10 (52.6) 22 (59.5)
Missing 0 (0.0) 0 (0.0) 0 (0.0)
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Demographic characteristic
Treatment arm
TotalSAFE plus TAU TAU
Age (years) at consent into the trial
n (%) 17 (94.4) 19 (100.0) 36 (94.6)
Mean, years 41.3 44.9 43.2
SD, years 18.66 15.69 17.01
Minimum, years 17.8 18.1 17.8
Median, years 43.5 49.7 48.0
Maximum, years 79.7 71.5 79.7
Missing, n (%) 1 (5.6) 0 (0.0) 1 (2.7)
Ethnicity, n (%) (N = 18) (N = 19) (N = 37)
White 18 (100.0) 18 (94.5) 36 (97.3)
Asian/Asian British 0 (0.0) 0 (0.0) 0 (0.0)
Black/African/Caribbean/black British 0 (0.0) 0 (0.0) 0 (0.0)
Mixed/multiple 0 (0.0) 0 (0.0) 0 (0.0)
Other 0 (0.0) 1 (5.3) 1 (2.7)
Missing 0 (0.0) 0 (0.0) 0 (0.0)
Significant medical history, n (%) (N = 18) (N = 19) (N = 37)
No, none 13 (72.2) 12 (63.2) 25 (67.6)
Yes, a medical condition 5 (27.8) 6 (31.6) 11 (29.7)
Yes, a psychiatric condition 0 (0.0) 0 (0.0) 0 (0.0)
Yes, both medical and psychiatric conditions 0 (0.0) 1 (5.3) 1 (2.7)
Missing 0 (0.0) 0 (0.0) 0 (0.0)
Education, n (%) (N = 18) (N = 19) (N = 37)
O levels/GCSEs/Level 1 or 2 NVQ 9 (50.0) 14 (73.7) 23 (62.2)
A levels/Level 3 NVQ 4 (22.2) 2 (10.5) 6 (16.2)
University degree/graduate certificate or diploma 5 (27.8) 3 (15.8) 8 (21.6)
Postgraduate university degree (e.g. PGCE, MSc, MA, PhD) 0 (0.0) 0 (0.0) 0 (0.0)
Missing 0 (0.0) 0 (0.0) 0 (0.0)
A level, Advanced level; MA, Master of Arts; MSc, Master of Science; PGCE, Postgraduate Certificate in Education;
PhD, Doctor of Philosophy.
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Appendix 16 Adherence ratings for each
checklist item and module
Module
Mean adherence rating
for module across
courses (SD; range) Item
Mean adherence
rating for item across
courses (range)
Orientation and behaviour
change optimisation
1.98 (0.08; 1.50–2.00) 1. Welcome 1.92 (1.50–2.00)
2. Goals of this course 2.00 (2.00–2.00)
3. What would you like from
today?
2.00 (2.00–2.00)
4. True or false? 2.00 (2.00–2.00)
5. Taking on information
(kindness questionnaire)
2.00 (2.00–2.00)
Basic epilepsy and first aid
knowledge
1.86 (0.37; 0.00–2.00) 6. Epilepsy, seizures and how the
brain works
2.00 (2.00–2.00)
7. First aid for convulsive
seizures exercise
2.00 (2.00–2.00)
8. What can you do to help
someone during a seizure?
2.00 (2.00–2.00)
9. What not to do during
a seizure
2.00 (2.00–2.00)
10. What to do after the seizure
has stopped
2.00 (2.00–2.00)
11. Questions or comments 2.00 (2.00–2.00)
12. Post-seizure states 1.64 (1.00–2.00)
13. Injuries 1.07 (0.00–2.00)
14. When to call an ambulance? 1.92 (1.50–2.00)
15. Questions or comments 2.00 (2.00–2.00)
Recovery position 1.55 (0.78; 0.00–2.00) 16. Recovery position I 0.79 (0.00–2.00)
17. Recovery position II 2.00 (2.00–2.00)
18. Let’s practise the recovery
position
1.71 (0.00–2.00)
19. Questions or comments 1.71 (0.00–2.00)
Informing others about
epilepsy and how to help
if seizures occur
1.95 (0.14; 1.50–2.00) 1. Who needs to know how
to help?
1.93 (1.50–2.00)
2. What they need to know
and why
2.00 (2.00–2.00)
3. How to get this information
to them: family, friends and
work colleagues
2.00 (2.00–2.00)
4. How to get this information to
them: members of the public and
health workers
2.00 (2.00–2.00)
5. Questions or comments 1.86 (1.50–2.00)
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Module
Mean adherence rating
for module across
courses (SD; range) Item
Mean adherence
rating for item across
courses (range)
Medical identification,
seizure triggers and
home safety
2.00 (0.00; 2.00–2.00) 6. Personal stories: introduction 2.00 (2.00–2.00)
7. Ben’s story 2.00 (2.00–2.00)
8. How to change what happened
to Ben
2.00 (2.00–2.00)
9. Triggers 2.00 (2.00–2.00)
10. Knowing your triggers 2.00 (2.00–2.00)
11. Some ways of dealing
with triggers
2.00 (2.00–2.00)
12. Sandra’s story 2.00 (2.00–2.00)
13. How to change what
happened to Sandra (warning
signs; home safety)
2.00 (2.00–2.00)
Summary and
consolidating learning
1.77 (0.50; 0.00–2.00) 14. Main points to remember if
you have epilepsy
1.93 (1.50–2.00)
15. Main points to remember if
you know someone with epilepsy
2.00 (2.00–2.00)
16. Sources of further
information
1.57 (0.00–2.00)
17. What’s on the back table and
accessing the study website
1.50 (0.00–2.00)
18. Questions or comments 1.86 (1.00–2.00)
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Appendix 17 Number of self-reported
epilepsy-related emergency department visits
Number of epilepsy-related ED visits
Treatment arm
TotalSAFE plus TAU TAU
During the 12 months prior to baseline (T0)
n (%) 24 (92.3) 21 (84.0) 45 (88.2)
Mean 4.2 8.4 6.2
SD 2.91 22.75 15.63
Minimuma 0 0 0
Median 3.5 4.0 4.0
Maximum 12 107 107
Missing 2 (7.7) 4 (16.0) 6 (11.8)
During the 12 months following randomisation according to participant self-report
n (%) 17 (65.4) 17 (68.0) 34 (67.7)
Mean 1.2 2.9 2.1
SD 1.60 5.55 4.11
Minimum 0 0 0
Median 0 1 1
Maximum 4 23 23
Missing 9 (34.6) 8 (32.0) 17 (33.3)
Change from baseline over 12 months following randomisation according to participant self-reportb
n (%) 16 (61.5) 14 (56.0) 30 (58.8)
Mean –2.6 –0.3 –1.5
SD 2.83 6.17 4.75
Minimum –10 –10 –10
Median –2 –2 –2
Maximum 1 18 18
Missing 10 (38.5) 11 (44.0) 21 (41.2)
a Four participants reported no ED visits in the 12 months prior to baseline, even though the inclusion criteria for
eligibility into the trial required at least two ED visits in the 12 months prior to baseline. This reflects inaccuracy and
inconsistency in self-reporting.
b Calculated only for patient participants with a baseline and 12-month measure reported.
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Appendix 18 Baseline scores of patient
participants and significant other participants
and change over follow-up period on
secondary outcome measures
Quality of life
Total QOLIE-31-P score (patient participants with complete clinical research form data)
Total QOLIE-31-P scorea
Treatment arm
TotalSAFE plus TAU TAU
Baseline (T0)
n (%) 23 (88.5) 16 (64.0) 39 (76.5)
Mean 51.2 44.1 48.3
SD 18.4 14.92 17.25
Minimum 17.7 17.1 17.1
Median 48.8 42.6 46.3
Maximum 78.7 79.5 79.5
Missing, n (%) 3 (11.5) 9 (36.0) 12 (23.5)
6 months (T2)
n (%) 16 (61.5) 12 (48.0) 28 (54.9)
Mean 49.5 43.0 46.7
SD 21.86 10.46 17.92
Minimum 10.4 20.4 10.4
Median 50.2 45.1 47.7
Maximum 85.7 59.8 85.7
Missing, n (%) 10 (38.5) 13 (52.0) 23 (45.1)
12 months (T3)
n (%) 10 (38.5) 8 (32.0) 18 (35.3)
Mean 47.6 42.9 45.5
SD 20.35 12.23 16.93
Minimum 9.7 23.8 9.7
Median 48.6 48.6 47.0
Maximum 72.9 57.0 72.9
Missing, n (%) 16 (61.5) 17 (68.0) 33 (64.7)
Change from baseline (T0) at 6 months (T2)b
n (%) 14 (53.8) 8 (32.0) 22 (43.1)
Mean –5.9 –0.7 –4.0
SD 13.81 8.57 12.20
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Total QOLIE-31-P scorea
Treatment arm
TotalSAFE plus TAU TAU
Minimum –33.7 –12.0 –33.7
Median –6.5 –1.8 –3.2
Maximum 18.7 12.9 18.7
Missing, n (%) 12 (46.2) 17 (68.0) 29 (56.9)
Change from baseline (T0) at 12 months (T3)b
n (%) 10 (38.5) 6 (24.0) 16 (31.4)
Mean 0.8 –2.18 –0.3
SD 10.72 10.48 10.38
Minimum –14.9 –19.5 –19.5
Median 1.0 –0.9 0.2
Maximum 20.5 12.9 20.5
Missing, n (%) 16 (61.5) 19 (76.0) 35 (68.6)
a Total QOLIE-31-P score ranges from 0 to 100; higher scores correspond to a better quality of life.
b Calculated only for patient participants with a baseline and 12-month measurement reported.
Total QOLIE-31-P score (patient participants with complete data following data imputation)
Total QOLIE-31-P scorea
Treatment arm
TotalSAFE plus TAU TAU
Baseline (T0)
n (%) 25 (96.2) 24 (96.0) 49 (96.1)
Mean 51.6 44.3 48.0
SD 18.63 16.38 17.77
Minimum 17.7 12.3 12.3
Median 48.8 42.6 46.3
Maximum 78.7 79.5 79.5
Missing, n (%) 1 (3.8) 1 (4.0) 2 (3.9)
6 months (T2)
n (%) 21 (80.8) 14 (56.0) 35 (68.6)
Mean 47.8 42.6 45.7
SD 21.67 9.76 17.86
Minimum 10.4 20.4 10.4
Median 49.7 43.6 44.4
Maximum 85.7 59.8 85.7
Missing, n (%) 5 (19.2) 11 (44.0) 16 (31.4)
12 months (T3)
n (%) 18 (69.2) 12 (48.0) 30 (58.8)
Mean 51.0 44.0 48.2
SD 20.43 11.72 17.58
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Total QOLIE-31-P scorea
Treatment arm
TotalSAFE plus TAU TAU
Minimum 9.7 23.8 9.7
Median 48.6 47.3 47.3
Maximum 82.8 57.0 82.8
Missing, n (%) 8 (30.8) 13 (52.0) 21 (41.2)
Change from baseline (T0) at 6 months (T2)b
n (%) 20 (76.9) 13 (52.0) 33 (64.7)
Mean –3.0 –0.8 –2.2
SD 13.16 9.07 11.61
Minimum –33.7 –12.3 –33.7
Median –2.4 –1.6 –1.6
Maximum 18.7 15.7 18.7
Missing, n (%) 6 (23.1) 12 (48.0) 18 (35.3)
Change from baseline (T0) at 12 months (T3)b
n (%) 18 (69.2) 12 (48.0) 30 (58.9)
Mean 2.2 –1.9 0.6
SD 11.27 12.13 11.59
Minimum –20.5 –22.7 –22.7
Median 2.1 –0.9 1.0
Maximum 20.5 18.6 20.5
Missing, n (%) 8 (30.8) 13 (52.0) 21 (41.2)
a Total QOLIE-31-P score ranges from 0 to 100; higher scores correspond to a better quality of life.
b Calculated only for patient participants with a baseline and 12-month measurement reported.
Caregiver burden
Total burden score (significant other participants with complete clinical research form data)
Total burden scorea
Treatment arm
TotalSAFE plus TAU TAU
Baseline (T0)
n (%) 17 (94.4) 17 (89.5) 34 (91.9)
Mean 15.8 20.6 18.2
SD 11.01 13.59 12.42
Minimum 0 0 0
Median 14.0 19.0 15.5
Maximum 45 45 45
Missing, n (%) 1 (5.6) 2 (10.5) 3 (8.1)
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Total burden scorea
Treatment arm
TotalSAFE plus TAU TAU
6 months (T2)
n (%) 15 (83.3) 8 (42.1) 23 (62.2)
Mean 19.7 22.7 20.7
SD 12.13 11.3 11.68
Minimum 0 13 0
Median 19 20 19
Maximum 42 48 48
Missing, n (%) 3 (16.7) 11 (57.9) 14 (37.8)
12 months (T3)
n (%) 11 (61.1) 10 (52.6) 21 (56.8)
Mean 19.5 24.9 22.1
SD 16.24 15.83 15.88
Minimum 0 7 0
Median 15 20 18
Maximum 48 54 54
Missing, n (%) 7 (38.9) 9 (47.4) 16 (43.2)
Change from baseline (T0) at 6 months (T2)b
n (%) 14 (77.8) 7 (36.8) 21 (56.8)
Mean 2.7 1.6 2.3
SD 7.01 6.21 6.62
Minimum –9 –5 –9
Median 1 1 1
Maximum 20 12 20
Missing, n (%) 4 (22.2) 12 (63.2) 16 (43.2)
Change from baseline (T0) at 12 months (T3)b
n (%) 10 (55.6) 9 (47.4) 19 (51.4)
Mean 1.4 0.8 1.1
SD 10.04 8.38 9.04
Minimum –20 –12 –20
Median 0.5 2.0 1.0
Maximum 15 14 15
Missing, n (%) 8 (44.4) 10 (52.6) 18 (48.6)
a Total burden score ranges from 0 to 88; higher scores correspond to a greater level of burden.
b Calculated only for SO participants with a baseline and 12-month measurement reported.
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Burden categories (significant other participants with complete clinical research form data)
Burden category
Treatment arm, n (%)
Total, n (%)SAFE plus TAU TAU
Baseline (T0)
Little or no burden 12 (66.7) 10 (52.7) 22 (59.5)
Mild to moderate burden 4 (22.2) 5 (26.3) 9 (24.3)
Moderate to severe burden 1 (5.6) 2 (10.5) 3 (8.1)
Severe burden 0 (0.0) 0 (0.0) 0 (0.0)
Missing 1 (5.6) 2 (10.5) 3 (8.1)
6 months (T2)
Little or no burden 9 (50.0) 4 (21.1) 13 (35.1)
Mild to moderate burden 5 (27.7) 3 (15.8) 8 (21.6)
Moderate to severe burden 1 (5.6) 1 (5.3) 2 (5.4)
Severe burden 0 (0.0) 0 (0.0) 0 (0.0)
Missing 3 (16.7) 11 (57.8) 14 (37.8)
12 months (T3)
Little or no burden 6 (33.3) 5 (26.3) 11 (29.7)
Mild to moderate burden 4 (22.2) 3 (15.8) 7 (18.9)
Moderate to severe burden 1 (5.6) 2 (10.5) 3 (8.1)
Severe burden 0 (0.0) 0 (0.0) 0 (0.0)
Missing 7 (38.9) 9 (47.4) 16 (43.2)
Total burden score (all significant other participants, including those with missing clinical
research form data)
Total burden scorea
Treatment arm
TotalSAFE plus TAU TAU
Baseline (T0)
n (%) 18 (100.0) 19 (100.0) 37 (100.0)
Mean 17.1 20.7 18.9
SD 12.00 13.03 12.51
Minimum 0 0 0
Median 14.5 19.0 16.0
Maximum 45 45 45
Missing, n (%)b 0 (0.0) 0 (0.0) 0 (0.0)
6 months (T2)
n (%) 16 (88.9) 10 (52.6) 26 (70.3)
Mean 19.4 22.7 20.7
SD 11.78 9.98 11.04
Minimum 0 13 0
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Total burden scorea
Treatment arm
TotalSAFE plus TAU TAU
Median 19.0 22.0 19.5
Maximum 42 48 48
Missing, n (%)b 2 (11.1) 9 (47.4) 11 (29.7)
12 months (T3)
n (%) 11 (61.1) 10 (52.6) 21 (56.8)
Mean 19.5 24.9 22.1
SD 16.24 15.83 15.88
Minimum 0 7 0
Median 15 20 18
Maximum 48 54 54
Missing, n (%)b 7 (38.9) 9 (47.4) 16 (43.2)
Change from baseline (T0) at 6 months (T2)c
n (%) 16 (88.9) 10 (52.6) 26 (70.3)
Mean 1.4 2.0 1.7
SD 7.89 6.96 7.41
Minimum –15 –7 –15
Median 0.0 1.5 0.5
Maximum 20 13 20
Missing, n (%) 2 (11.1) 9 (47.4) 11 (29.7)
Change from baseline (T0) at 12 months (T3)c
n (%) 11 (61.1) 10 (52.6) 21 (56.8)
Mean 2.1 0.9 1.5
SD 9.79 7.91 8.74
Minimum –20 –12 –20
Median 1 2 1
Maximum 15 14 15
Missing, n (%) 7 (38.9) 9 (47.4) 16 (43.2)
a Total burden score ranges from 0 to 88; higher scores correspond to a greater level of burden.
b Participants had no data recorded for the outcome.
c Calculated only for SO participants with a baseline and 12-month measurement reported.
Burden categories (all significant other participants, including those with missing clinical
research form data)
Burden category
Treatment arm, n (%)
Total, n (%)SAFE plus TAU TAU
Baseline (T0)
Little or no burden 12 (67.7) 11 (57.9) 23 (62.2)
Mild to moderate burden 5 (27.8) 6 (31.6) 11 (29.7)
Moderate to severe burden 1 (5.6) 2 (10.5) 3 (8.1)
Severe burden 0 (0.0) 0 (0.0) 0 (0.0)
Missing 0 (0.0) 0 (0.0) 0 (0.0)
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Burden category
Treatment arm, n (%)
Total, n (%)SAFE plus TAU TAU
6 months (T2)
Little or no burden 10 (55.6) 4 (21.1) 14 (37.8)
Mild to moderate burden 5 (27.8) 5 (26.3) 10 (27.0)
Moderate to severe burden 1 (5.6) 1 (5.3) 2 (5.4)
Severe burden 0 (0.0) 0 (0.0) 0 (0.0)
Missing 2 (11.1) 9 (47.4) 11 (29.7)
12 months (T3)
Little or no burden 6 (33.3) 5 (26.3) 11 (29.7)
Mild to moderate burden 4 (22.2) 3 (15.8) 7 (18.9)
Moderate to severe burden 1 (5.6) 2 (10.5) 3 (8.1)
Severe burden 0 (0.0) 0 (0.0) 0 (0.0)
Missing 7 (38.9) 9 (47.4) 16 (43.2)
Distress
Total anxiety score (patient participants with complete clinical research form data)
Total anxiety scorea
Treatment arm
TotalSAFE plus TAU TAU
Baseline (T0)
n (%) 25 (96.2) 25 (100.0) 50 (98.0)
Mean 10.2 10.4 10.3
SD 5.22 4.54 4.84
Minimum 2 0 0
Median 11 11 11
Maximum 20 18 20
Missing, n (%) 1 (3.8) 0 (0.0) 1 (2.0)
12 months (T3)
n (%) 18 (69.2) 17 (68.0) 35 (68.6)
Mean 10.8 10.6 10.7
SD 5.49 3.18 4.46
Minimum 3 5 3
Median 10.5 10.0 10.0
Maximum 19 16 19
Missing, n (%) 8 (30.8) 8 (32.0) 16 (31.4)
Change from baseline (T0) at 12 months (T3)b
n (%) 18 (69.2) 17 (68.0) 35 (68.6)
Mean 0.2 –0.6 –0.2
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Total anxiety scorea
Treatment arm
TotalSAFE plus TAU TAU
SD 3.91 3.26 3.58
Minimum –7 –7 –7
Median –0.5 –1 –1
Maximum 13 6 13.0
Missing, n (%) 8 (30.8) 8 (32.0) 16 (31.4)
a Total anxiety score ranges from 0 to 21; higher scores correspond to higher levels of anxiety.
b Calculated only for patient participants with a baseline and 12-month measurement reported.
Anxiety categories (patient participants with complete clinical research form data)
Anxiety category
Treatment arm, n (%)
Total, n (%)SAFE plus TAU TAU
Baseline (T0)
Normal range 9 (34.6) 5 (20.0) 14 (27.5)
Suggestive of anxiety 3 (11.5) 7 (28.0) 10 (19.6)
Probable anxiety 13 (50.0) 13 (52.0) 26 (50.9)
Missing 1 (3.8) 0 (0.0) 1 (2.0)
12 months (T3)
Normal range 6 (33.3) 2 (8.0) 8 (15.6)
Suggestive of anxiety 3 (16.7) 8 (32.0) 11 (21.6)
Probable anxiety 9 (50.0) 7 (28.0) 16 (31.4)
Missing 8 (30.8) 8 (32.0) 16 (31.4)
Total anxiety score (patient participants with complete data following data imputation)
Total anxiety scorea
Treatment arm
TotalSAFE plus TAU TAU
Baseline (T0)
n (%) 25 (96.2) 25 (100.0) 50 (98.0)
Mean 10.2 10.4 10.3
SD 5.22 4.54 4.84
Minimum 2 0 0
Median 11 11 11
Maximum 20 18 20
Missing, n (%) 1 (3.8) 0 (0.0) 1 (2.0)
12 months (T3)
n (%) 18 (69.2) 17 (68.0) 35 (68.6)
Mean 10.8 10.6 10.7
SD 5.49 3.18 4.46
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Total anxiety scorea
Treatment arm
TotalSAFE plus TAU TAU
Minimum 3 5 3
Median 10.5 10.0 10.0
Maximum 19 16 19
Missing, n (%) 8 (30.8) 8 (40.0) 16 (31.4)
Change from baseline (T0) at 12 months (T3)b
n (%) 18 (69.2) 17 (68.0) 35 (68.6)
Mean 0.2 –0.6 –0.2
SD 3.91 3.26 3.58
Minimum –7 –7 –7
Median –0.5 –1 –1
Maximum 13 6 13.0
Missing, n (%) 8 (30.8) 8 (40.0) 16 (31.4)
a Total anxiety score ranges from 0 to 21; higher scores correspond to higher levels of anxiety.
b Calculated only for patient participants with a baseline and 12-month measurement reported.
Anxiety categories (patient participants with complete data following data imputation)
Anxiety category
Treatment arm, n (%)
Total, n (%)SAFE plus TAU TAU
Baseline (T0)
Normal range 9 (34.6) 5 (20.0) 14 (27.5)
Suggestive of anxiety 3 (11.5) 7 (28.0) 10 (19.6)
Probable anxiety 13 (50.0) 13 (52.0) 26 (50.9)
Missing 1 (3.8) 0 (0.0) 1 (2.0)
12 months (T3)
Normal range 6 (33.3) 2 (8.0) 8 (15.6)
Suggestive of anxiety 3 (16.7) 8 (32.0) 11 (21.6)
Probable anxiety 9 (50.0) 7 (28.0) 16 (31.4)
Missing 8 (30.8) 8 (32.0) 16 (31.4)
Total depression score (patient participants with complete clinical research form data)
Total depression scorea
Treatment arm
TotalSAFE plus TAU TAU
Baseline (T0)
n (%) 23 (88.5) 24 (96.0) 47 (92.2)
Mean 6.6 8.7 7.7
SD 4.51 4.67 4.66
Minimum 0 0 0
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Total depression scorea
Treatment arm
TotalSAFE plus TAU TAU
Median 7.0 8.5 7
Maximum 17 19 19
Missing, n (%) 3 (11.5) 1 (4.0) 4 (7.8)
12 months (T3)
n (%) 18 (69.2) 17 (68.0) 35 (68.6)
Mean 7.2 8.6 7.9
SD 4.07 3.46 3.80
Minimum 1 4 1
Median 7 9 8
Maximum 14 16 16
Missing, n (%) 8 (30.8) 8 (32.0) 16 (31.4)
12 months (T3)b
n (%) 16 (61.5) 16 (64.0) 32 (62.7)
Mean –0.5 0.1 –0.2
SD 1.97 2.90 2.46
Minimum –3 –5 –5
Median –0.5 1.0 0.0
Maximum 3 5 5
Missing, n (%) 10 (38.5) 9 (36.0) 19 (37.3)
a Total depression score ranges from 0 to 21; higher scores correspond to higher levels of depression.
b Calculated only for patient participants with a baseline and 12-month measurement reported.
Depression categories (patient participants with complete clinical research form data)
Depression category
Treatment arm, n (%)
Total, n (%)SAFE plus TAU TAU
Baseline (T0)
Normal range 14 (53.9) 10 (40.0) 24 (47.1)
Suggestive of depression 5 (19.2) 7 (28.0) 12 (23.5)
Probable depression 4 (15.4) 7 (28.0) 11 (21.6)
Missing 3 (11.5) 1 (4.0) 4 (7.8)
12 months (T3)
Normal range 10 (38.4) 7 (28.0) 17 (33.3)
Suggestive of depression 4 (15.4) 4 (16.0) 8 (15.7)
Probable depression 4 (15.4) 6 (24.0) 10 (19.6)
Missing 8 (30.8) 8 (32.0) 16 (31.4)
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Total depression score (patient participants with complete data following data imputation)
Total depression scorea
Treatment arm
TotalSAFE plus TAU TAU
Baseline (T0)
n (%) 25 (96.2) 25 (100.0) 50 (98.0)
Mean 6.7 8.6 7.6
SD 4.36 4.61 4.53
Minimum 0 0 0
Median 7 8 7.5
Maximum 17 19 19
Missing, n (%) 1 (3.8) 0 (0.0) 1 (2.0)
12 months (T3)
n (%) 18 (69.2) 17 (68.0) 35 (68.6)
Mean 7.2 8.6 7.9
SD 4.07 3.46 3.80
Minimum 1 4 1
Median 7 9 8
Maximum 14 16 16
Missing, n (%) 8 (30.8) 8 (32.0) 16 (31.4)
Change from baseline (T0) at 12 months (T3)b
n (%) 18 (69.2) 17 (68.0) 35 (68.6)
Mean –0.2 0.5 0.1
SD 2.39 3.16 2.77
Minimum –3.0 –5.0 –5.0
Median –0.5 1.0 0.0
Maximum 5.8 6.2 6.2
Missing, n (%) 8 (30.8) 8 (32.0) 16 (31.4)
a Total depression score ranges from 0 to 21; higher scores correspond to higher levels of depression.
b Calculated only for patient participants with a baseline and 12-month measurement reported.
Depression categories (patient participants with complete data following data imputation)
Depression category
Treatment arm, n (%)
Total, n (%)SAFE plus TAU TAU
Baseline (T0)
Normal range 14 (53.8) 11 (44.0) 25 (49.0)
Suggestive of depression 7 (26.9) 7 (28.0) 14 (27.5)
Probable depression 4 (15.3) 7 (28.0) 11 (21.6)
Missing 1 (3.8) 0 (0.0) 1 (2.0)
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Depression category
Treatment arm, n (%)
Total, n (%)SAFE plus TAU TAU
12 months (T3)
Normal range 10 (38.4) 7 (28.0) 17 (33.3)
Suggestive of depression 4 (15.3) 4 (16.0) 8 (15.7)
Probable depression 4 (15.3) 6 (24.0) 10 (19.6)
Missing 8 (30.8) 8 (32.0) 16 (31.4)
Total anxiety score (significant other participants with complete clinical research form data)
Total anxiety scorea
Treatment arm
TotalSAFE plus TAU TAU
Baseline (T0)
n (%) 17 (94.4) 18 (94.7) 35 (94.6)
Mean 8.4 7.9 8.1
SD 4.21 4.37 4.24
Minimum 2 0 0
Median 9 10 9
Maximum 15 14 15
Missing, n (%) 1 (5.6) 1 (5.3) 2 (5.4)
12 months (T3)
n (%) 11 (61.1) 10 (52.6) 21 (56.8)
Mean 9.2 8.2 8.7
SD 5.15 2.39 4.01
Minimum 1 4 1
Median 9 9 9
Maximum 16 12 16
Missing, n (%) 7 (38.9) 9 (47.8) 16 (43.2)
Change from baseline (T0) at 12 months (T3)b
n (%) 11 (61.1) 10 (52.6) 21 (56.8)
Mean 0.5 –0.5 0.0
SD 2.70 3.13 2.88
Minimum –3 –5 –5
Median 1 –1.5 –1
Maximum 3 5 5
Missing, n (%) 7 (38.9) 9 (47.8) 16 (43.2)
a Total anxiety score ranges from 0 to 21; higher scores correspond to higher levels of anxiety.
b Calculated only for SO participants with a baseline and 12-month measurement reported.
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Anxiety categories (significant other participants with complete clinical research form data)
Anxiety category
Treatment arm, n (%)
Total, n (%)SAFE plus TAU TAU
Baseline (T0)
Normal range 7 (38.9) 7 (36.8) 14 (37.8)
Suggestive of anxiety 4 (22.2) 3 (15.8) 7 (18.8)
Probable anxiety 6 (33.3) 8 (42.1) 14 (37.8)
Missing 1 (5.6) 1 (5.3) 2 (5.4)
12 months (T3)
Normal range 4 (22.2) 4 (21.1) 8 (21.7)
Suggestive of anxiety 2 (11.1) 5 (26.3) 7 (18.9)
Probable anxiety 5 (27.8) 1 (5.3) 6 (16.2)
Missing 7 (38.9) 9 (47.8) 16 (43.2)
Total anxiety score (significant other participants with complete data following data imputation)
Total anxiety scorea
Treatment arm
TotalSAFE plus TAU TAU
Baseline (T0)
n (%) 18 (100.0) 19 (100.0) 37 (100.0)
Mean 8.4 8.3 8.3
SD 4.09 4.47 4.23
Minimum 2 0.0 0.0
Median 9.0 10.0 9.3
Maximum 15 14 15
Missing, n (%) 0 (0.0) 0 (0.0) 0 (0.0)
12 months (T3)
n (%) 11 (61.1) 10 (52.6) 21 (56.8)
Mean 9.2 8.2 8.7
SD 5.15 2.39 4.01
Minimum 1 4 1
Median 9 9 9
Maximum 16 12 16
Missing, n (%) 7 (38.9) 9 (47.4) 16 (43.2)
Change from baseline (T0) at 12 months (T3)b
n (%) 11 (61.1) 10 (52.6) 21 (56.8)
Mean 0.5 –0.5 0.0
SD 2.70 3.13 2.88
DOI: 10.3310/hsdr08390 Health Services and Delivery Research 2020 Vol. 8 No. 39
© Queen’s Printer and Controller of HMSO 2020. This work was produced by Noble et al. under the terms of a commissioning contract issued by the Secretary of State for
Health and Social Care. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in
professional journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial
reproduction should be addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House,
University of Southampton Science Park, Southampton SO16 7NS, UK.
173
Total anxiety scorea
Treatment arm
TotalSAFE plus TAU TAU
Minimum –3 –5 –5
Median 1.0 –1.5 –1.0
Maximum 3 5 5
Missing, n (%) 7 (38.9) 9 (47.4) 16 (43.2)
a Total anxiety score ranges from 0 to 21; higher scores correspond to higher levels of anxiety.
b Calculated only for SO participants with a baseline and 12-month measurement reported.
Anxiety categories (significant other participants with complete data following data imputation)
Anxiety category
Treatment arm, n (%)
Total, n (%)SAFE plus TAU TAU
Baseline (T0)
Normal range 7 (38.9) 7 (36.8) 14 (37.8)
Suggestive of anxiety 5 (27.8) 3 (15.8) 8 (21.7)
Probable anxiety 6 (33.3) 9 (47.4) 15 (40.5)
Missing 0 (0.0) 0 (0.0) 0 (0.0)
12 months (T3)
Normal range 4 (22.2) 4 (21.1) 8 (21.7)
Suggestive of anxiety 2 (11.1) 5 (26.3) 7 (18.9)
Probable anxiety 5 (27.8) 1 (5.3) 6 (16.2)
Missing 7 (38.9) 9 (47.4) 16 (43.2)
Total depression score (significant other participants with complete clinical research form data)
Total depression scorea
Treatment arm
TotalSAFE plus TAU TAU
Baseline (T0)
n (%) 18 (100.0) 19 (100.0) 37 (100.0)
Mean 4.3 3.4 3.8
SD 4.40 2.65 3.59
Minimum 0 0 0
Median 2.5 3.0 3.0
Maximum 12 8 12
Missing, n (%) 0 (0.0) 0 (0.0) 0 (0.0)
12 months (T3)
n (%) 11 (61.1) 10 (52.6) 21 (56.8)
Mean 5.2 5.1 5.1
SD 3.60 3.60 3.51
Minimum 0 0 0
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Total depression scorea
Treatment arm
TotalSAFE plus TAU TAU
Median 5 5 5
Maximum 12 11 12
Missing, n (%) 7 (38.9) 9 (47.4) 16 (43.2)
Change from baseline at 12 months (T3)b
n (%) 11 (61.1) 10 (52.6) 21 (56.8)
Mean –0.4 1.3 0.4
SD 3.14 1.83 2.68
Minimum –9 –1 –9
Median 0 1 1
Maximum 3 4 4
Missing, n (%) 7 (38.9) 9 (47.4) 16 (43.2)
a Total depression score ranges from 0 to 21; higher scores correspond to higher levels of depression.
b Calculated only for SO participants with a baseline and 12-month measurement reported.
Depression categories (significant other participants with complete clinical research form data)
Depression category
Treatment arm, n (%)
Total, n (%)SAFE plus TAU TAU
Baseline (T0)
Normal range 14 (77.8) 18 (94.7) 32 (86.5)
Suggestive of depression 1 (5.6) 1 (5.3) 2 (5.4)
Probable depression 3 (16.7) 0 (0.0) 3 (8.1)
Missing 0 (0.0) 0 (0.0) 0 (0.0)
12 months (T3)
Normal range 7 (38.9) 8 (42.1) 15 (40.6)
Suggestive of depression 3 (16.7) 1 (5.3) 4 (10.8)
Probable depression 1 (5.6) 1 (5.3) 2 (5.4)
Missing 7 (38.9) 9 (47.4) 16 (43.2)
Total depression score (significant other participants with complete data following
data imputation)
Total depression scorea
Treatment arm
TotalSAFE plus TAU TAU
Baseline (T0)
n (%) 18 (100.0) 19 (100.0) 37 (100.0)
Mean 4.3 3.4 3.8
SD 4.40 2.65 3.59
Minimum 0 0 0
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Total depression scorea
Treatment arm
TotalSAFE plus TAU TAU
Median 2.5 3.0 3
Maximum 12 8 12
Missing, n (%) 0 (0.0) 0 (0.0) 0 (0.0)
12 months (T3)
n (%) 11 (61.1) 10 (52.6) 21 (56.8)
Mean 5.2 5.1 5.1
SD 3.60 3.60 3.51
Minimum 0 0 0
Median 5 5 5
Maximum 12 11 12
Missing, n (%) 7 (38.9) 9 (47.4) 16 (43.2)
Change from baseline (T0) at 12 months (T3)b
n (%) 11 (61.1) 10 (52.6) 21 (56.8)
Mean –0.4 1.3 0.4
SD 3.14 1.83 2.68
Minimum –9 –1 –9
Median 0 1 1
Maximum 3 4 4
Missing, n (%) 7 (38.9) 9 (47.4) 16 (43.2)
a Total depression score ranges from 0 to 21; higher scores correspond to higher levels of depression.
b Calculated only for SO participants with a baseline and 12-month measurement reported.
Depression categories (significant other participants with complete data following
data imputation)
Depression category
Treatment arm, n (%)
Total, n (%)SAFE plus TAU TAU
Baseline (T0)
Normal range 14 (77.8) 18 (94.7) 32 (86.5)
Suggestive of depression 1 (5.6) 1 (5.3) 2 (5.4)
Probable depression 3 (16.7) 0 (0.0) 3 (8.1)
Missing 0 (0.0) 0 (0.0) 0 (0.0)
12 months (T3)
Normal range 7 (38.9) 8 (42.1) 15 (40.6)
Suggestive of depression 3 (16.7) 1 (5.3) 4 (10.8)
Probable depression 1 (5.6) 1 (5.3) 2 (5.4)
Missing 7 (38.9) 9 (47.4) 16 (43.2)
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Stigma
Total stigma score (patient participants with complete clinical research form data)
Total stigma scorea
Treatment arm
TotalSAFE plus TAU TAU
Baseline (T0)
n (%) 24 (92.3) 24 (96.0) 48 (94.1)
Mean 3.2 4.1 3.6
SD 2.45 3.26 2.89
Minimum 0 0 0
Median 3 3 3
Maximum 7 9 9
Missing, n (%) 2 (7.7) 1 (4.0) 3 (5.9)
12 months (T3)
n (%) 18 (69.2) 17 (68.0) 35 (68.6)
Mean 3.2 3.9 3.5
SD 2.57 3.03 2.79
Minimum 0 0 0
Median 3.5 3.0 3.0
Maximum 8 9 9
Missing, n (%) 8 (30.8) 8 (32.0) 16 (31.4)
Change from baseline (T0) at 12 months (T3)b
n (%) 17 (65.4) 17 (68.0) 34 (66.7)
Mean –0.1 0.3 0.1
SD 2.30 1.79 2.04
Minimum –6 –2 –6
Median 0 0 0
Maximum 4 4 4
Missing, n (%) 9 (34.6) 8 (32.0) 17 (33.3)
a Total stigma score ranges from 0 to 9; higher scores correspond to higher levels of stigma.
b Calculated only for patient participants with a baseline and 12-month measurement reported.
Stigma categories (patient participants with complete clinical research form data)
Stigma category
Treatment arm, n (%)
Total, n (%)SAFE plus TAU TAU
Baseline (T0)
No stigma 4 (15.4) 3 (12.0) 7 (13.7)
Mildly to moderately stigmatised 13 (50.0) 13 (52.0) 26 (51.0)
Highly stigmatised 7 (26.9) 8 (32.0) 15 (29.4)
Missing 2 (7.7) 1 (4.0) 3 (5.9)
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Stigma category
Treatment arm, n (%)
Total, n (%)SAFE plus TAU TAU
12 months (T3)
No stigma 4 (15.4) 3 (12.0) 7 (13.7)
Mildly to moderately stigmatised 10 (38.4) 8 (32.0) 18 (35.3)
Highly stigmatised 4 (15.4) 6 (24.0) 10 (19.6)
Missing 8 (30.8) 8 (32.0) 16 (31.4)
Total stigma score (all patient participants, including those with missing clinical research
form data)
Total stigma scorea
Treatment arm
TotalSAFE plus TAU TAU
Baseline (T0)
n (%) 25 (96.2) 24 (96.0) 49 (96.8)
Mean 3.2 4.1 3.6
SD 2.41 3.26 2.87
Minimum 0 0 0
Median 3 3 3
Maximum 7 9 9
Missing, n (%)b 1 (3.8) 1 (4.0) 2 (3.9)
12 months (T3)
n (%) 18 (69.2) 17 (68.0) 35 (68.6)
Mean 3.2 3.9 3.5
SD 2.57 3.03 2.79
Minimum 0 0 0
Median 3.5 3.0 3.0
Maximum 8 9 9
Missing, n (%)b 8 (30.8) 8 (32.0) 16 (31.4)
Change from baseline (T0) at 12 months (T3)c
n (%) 17 (65.4) 17 (68.0) 34 (66.7)
Mean –0.1 0.3 0.1
SD 2.30 1.79 2.04
Minimum –6 –2 –6
Median 0 0 0
Maximum 4 4 4
Missing, n (%) 9 (34.6) 8 (32.0) 17 (33.3)
a Total stigma score ranges from 0 to 9; higher scores correspond to higher levels of stigma.
b Participants had no data recorded for the outcome.
c Calculated only for patient participants with a baseline and 12-month measurement reported.
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Stigma categories (all patient participants, including those with missing clinical research
form data)
Stigma category
Treatment arm, n (%)
Total, n (%)SAFE plus TAU TAU
Baseline (T0)
No stigma 4 (15.4) 3 (12.0) 7 (13.7)
Mildly to moderately stigmatised 14 (53.9) 13 (52.0) 27 (52.9)
Highly stigmatised 7 (26.9) 8 (32.0) 15 (29.4)
Missing 1 (3.8) 1 (4.0) 2 (3.9)
12 months (T3)
No stigma 4 (15.4) 3 (12.0) 7 (13.7)
Mildly to moderately stigmatised 10 (38.4) 8 (32.0) 18 (35.3)
Highly stigmatised 4 (15.4) 6 (24.0) 10 (19.6)
Missing 8 (30.8) 8 (32.0) 16 (31.4)
Fear of seizures
Total fear score (patient participants with complete clinical research form data)
Total fear scorea
Treatment arm
TotalSAFE plus TAU TAU
Baseline (T0)
n (%) 16 (61.5) 9 (36.0) 25 (49.0)
Mean 16.4 17.6 16.8
SD 5.48 4.77 5.16
Minimum 6 8 6
Median 17 18 17
Maximum 24 25 25
Missing, n (%) 10 (38.5) 16 (64.0) 26 (51.0)
12 months (T3)
n (%) 8 (30.8) 5 (20.0) 13 (25.5)
Mean 15.5 20.8 17.5
SD 5.32 2.49 5.07
Minimum 8 17 8
Median 16 21 18
Maximum 23 23 23
Missing, n (%) 18 (69.2) 20 (80.0) 38 (74.5)
Change from baseline (T0) at 12 months (T3)b
n (%) 6 (23.1) 3 (12.0) 9 (17.6)
Mean –1.5 2.0 –0.3
SD 2.66 1.00 2.78
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Total fear scorea
Treatment arm
TotalSAFE plus TAU TAU
Minimum –6 1 –6
Median –1.5 2.0 0.0
Maximum 2 3 3
Missing, n (%) 20 (76.9) 22 (88.0) 42 (82.4)
a Total fear score ranges from 5 to 30; higher scores correspond to greater levels of fear.
b Calculated only for patient participants with a baseline and 12-month measurement reported.
Total fear score (all patient participants, including those with missing clinical research
form data)
Total fear scorea
Treatment arm
TotalSAFE plus TAU TAU
Baseline (T0)
n (%) 23 (88.5) 23 (92.0) 46 (90.2)
Mean 15.2 13.6 14.4
SD 5.32 5.80 5.56
Minimum 5 3b 3b
Median 16 14 14
Maximum 24 25 25
Missing, n (%)c 3 (11.5) 2 (8.0) 5 (9.8)
12 months (T3)
n (%) 16 (61.5) 17 (68.0) 33 (64.7)
Mean 14.4 16.0 15.2
SD 4.88 4.15 4.52
Minimum 5 10 5
Median 15 16 16
Maximum 23 23 23
Missing, n (%)c 10 (38.5) 8 (32.0) 18 (35.3)
Change from baseline (T0) at 12 months (T3)d
n (%) 15 (57.7) 17 (68.0) 32 (62.8)
Mean 0.6 1.5 1.1
SD 4.03 7.25 5.89
Minimum –6 –10 –10
Median 0 1 0
Maximum 9 18 18
Missing, n (%) 11 (42.3) 8 (32.0) 19 (37.2)
a Total fear score ranges from 5 to 30; higher scores correspond to greater levels of fear.
b Minimum reported score less than minimum possible score of 5 owing to missing data treated as zeros.
c Participants had no data recorded for the outcome.
d Calculated only for patient participants with a baseline and 12-month measurement reported.
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Total fear score (significant other participants with complete clinical research form data)
Total fear scorea
Treatment arm
TotalSAFE plus TAU TAU
Baseline (T0)
n (%) 6 (33.3) 4 (21.1) 10 (27.0)
Mean 15.5 16.0 15.7
SD 3.45 3.92 3.43
Minimum 10 11 10
Median 15.5 16.5 15.5
Maximum 20 20 20
Missing, n (%) 12 (66.7) 21 (78.9) 27 (73.0)
12 months (T3)
n (%) 6 (33.3) 2 (10.5) 8 (21.6)
Mean 20.7 22.5 21.1
SD 3.78 0.71 3.31
Minimum 16 22 16
Median 22.0 22.5 22.5
Maximum 24 23 24
Missing, n (%) 12 (67.7) 17 (89.5) 29 (78.4)
Change from baseline (T0) at 12 months (T3)b
n (%) 3 (16.7) 0 3 (8.8)
Mean 6.7 NAc 6.7
SD 7.02 NAc 7.02
Minimum 0 NAc 0
Median 6 NAc 6.0
Maximum 14 NAc 14
Missing, n (%) 15 (83.3) 19 (100.0) 34 (91.2)
NA, not applicable.
a Total fear score ranges from 5 to 30; higher scores correspond to greater levels of fear.
b Calculated only for SO participants with a baseline and 12-month measurement reported.
c No SO participants in the TAU arm had complete CRF data at both baseline (T0) and at 12 months (T3); therefore,
change in total fear score could not be calculated.
Total fear score (all significant other participants, including those with missing clinical
research form data)
Total fear scorea
Treatment arm
TotalSAFE plus TAU TAU
Baseline (T0)
n (%) 16 (88.9) 17 (89.5) 33 (89.2)
Mean 13.8 12.4 13.1
SD 4.83 5.10 4.95
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Total fear scorea
Treatment arm
TotalSAFE plus TAU TAU
Minimum 4b 1b 1b
Median 14.5 13.0 14.0
Maximum 20 20 20
Missing, n (%)c 2 (11.1) 2 (10.5) 4 (10.8)
12 months (T3)
n (%) 11 (61.1) 9 (47.4) 20 (54.0)
Mean 15.6 16.0 15.8
SD 6.59 5.00 5.78
Minimum 5 9 5
Median 16 16 16
Maximum 24 23 24
Missing, n (%)c 7 (38.9) 10 (52.6) 17 (46.0)
Change from baseline (T0) at 12 months (T3)d
n (%) 9 (50.0) 8 (42.1) 17 (45.9)
Mean 2.2 1.9 2.1
SD 5.40 4.76 4.96
Minimum –4 –5 –5
Median 0.0 2.5 0.0
Maximum 14 7 14
Missing, n (%) 9 (50.0) 11 (57.9) 20 (54.1)
a Total fear score ranges from 5 to 30; higher scores correspond to greater levels of fear.
b Minimum reported score less than minimum possible score of 5 owing to missing data treated as zeros.
c Participants had no data recorded for the outcome.
d Calculated only for SO participants with a baseline and 12-month measurement reported.
Confidence in managing seizures/epilepsy
Total mastery score (patient participants with complete clinical research form data)
Total mastery scorea
Treatment arm
TotalSAFE plus TAU TAU
Baseline (T0)
n (%) 26 (100.0) 21 (84.0) 47 (92.3)
Mean 13.9 12.1 13.1
SD 2.86 2.95 3.00
Minimum 8 7 7
Median 14 12 13
Maximum 20 19 20
Missing, n (%) 0 (0.0) 4 (16.0) 4 (7.8)
6 months (T2)
n (%) 21 (84.6) 15 (60.0) 36 (70.6)
Mean 12.7 11.7 12.3
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Total mastery scorea
Treatment arm
TotalSAFE plus TAU TAU
SD 3.89 2.97 3.53
Minimum 7 6 6
Median 11 12 11
Maximum 21 17 21
Missing, n (%) 4 (15.4) 10 (40.0) 15 (29.4)
12 months (T3)
n (%) 18 (69.2) 16 (64.0) 34 (66.7)
Mean 13.8 11.3 12.6
SD 3.47 2.60 3.29
Minimum 9 6 6
Median 13.5 12.0 12.0
Maximum 21 16 21
Missing, n (%) 8 (30.8) 9 (36.0) 17 (33.3)
Change from baseline (T0) at 6 months (T2)b
n (%) 21 (80.8) 12 (48.0) 33 (64.7)
Mean –0.7 –1.4 –0.9
SD 3.71 3.34 3.54
Minimum –8 –8 –8
Median –1 –2 –1
Maximum 8 4 8
Missing, n (%) 5 (19.2) 13 (52.0) 18 (35.3)
Change from baseline (T0) at 12 months (T3)b
n (%) 18 (69.2) 14 (56.0) 32 (62.7)
Mean 0.2 –1.1 –0.4
SD 2.96 3.41 3.17
Minimum –5 –9 –9
Median 0.5 –1.0 0.0
Maximum 6 3 6
Missing, n (%) 8 (30.8) 11 (44.0) 19 (37.3)
a Total mastery score ranges between 6 and 24; higher scores correspond to higher levels of mastery.
b Calculated only for patient participants with a baseline and 12-month measurement reported.
Total mastery score (all patient participants, including those with missing clinical research
form data)
Total mastery scorea
Treatment arm
TotalSAFE plus TAU TAU
Baseline (T0)
n (%) 26 (100.0) 25 (100.0) 51 (100)
Mean 13.9 11.4 12.7
SD 2.86 3.50 3.40
Minimum 8 3b 3b
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Total mastery scorea
Treatment arm
TotalSAFE plus TAU TAU
Median 14 12 13
Maximum 20 19 20
Missing, n (%)c 0 (0.0) 0 (0.0) 0 (0.0)
6 months (T2)
n (%) 22 (84.6) 17 (68.0) 39 (76.5)
Mean 12.3 11.4 11.9
SD 4.32 2.91 3.76
Minimum 3d 6 3d
Median 11 11 11
Maximum 21 17 21
Missing, n (%)c 4 (15.4) 8 (32.0) 12 (23.5)
12 months (T3)
n (%) 18 (69.2) 17 (68.0) 35 (68.6)
Mean 13.8 11.5 12.7
SD 3.47 2.60 3.25
Minimum 9 6 6
Median 13.5 12.0 12.0
Maximum 21 16 21
Missing, n (%)c 8 (30.8) 8 (32.0) 16 (31.4)
Change from baseline (T0) at 6 months (T2)c
n (%) 22 (84.6) 17 (68.0) 39 (76.5)
Mean –1.2 –0.2 –0.8
SD 4.35 4.25 4.28
Minimum –12 –8 –12
Median –1 –1 –1
Maximum 8 11 11
Missing, n (%) 4 (15.4) 8 (32.0) 12 (23.5)
Change from baseline (T0) at 12 months (T3)c
n (%) 18 (69.2) 17 (68.0) 35 (68.6)
Mean 0.2 –0.5 –0.2
SD 2.96 3.36 3.13
Minimum –5 –9 –9
Median 0.5 0.0 0.0
Maximum 6 3 6
Missing, n (%) 8 (30.8) 8 (32.0) 16 (31.4)
a Total mastery score ranges between 6 and 24; higher scores correspond to higher levels of mastery.
b Calculated only for patient participants with a baseline and 12-month measurement reported.
c Participants had no data recorded for the outcome.
d Minimum reported score less than minimum possible score of 6 owing to missing data treated as zeros.
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Total confidence score (significant other participants with complete clinical research form data)
Total confidence scorea
Treatment arm
TotalSAFE plus TAU TAU
Baseline (T0)
n (%) 18 (100.0) 19 (100.0) 37 (100.0)
Mean 3.5 3.8 3.6
SD 0.62 0.72 0.69
Minimum 2.0 2.3 2.0
Median 3.5 3.8 3.7
Maximum 4.5 5.0 5.0
Missing, n (%) 0 (0.0) 0 (0.0) 0 (0.0)
6 months (T2)
n (%) 16 (88.9) 9 (47.4) 25 (67.6)
Mean 4.2 3.9 4.1
SD 0.75 0.71 0.73
Minimum 2.7 2.8 2.7
Median 4.1 4.0 4.0
Maximum 5.0 4.8 5.0
Missing, n (%) 2 (11.1) 10 (52.6) 12 (32.4)
12 months (T3)
n (%) 11 (61.1) 10 (52.6) 21 (56.8)
Mean 4.3 4.1 4.2
SD 0.57 0.99 0.78
Minimum 3.5 2.2 2.2
Median 4.2 4.7 4.3
Maximum 5.0 5.0 5.0
Missing, n (%) 7 (38.9) 9 (47.4) 16 (43.2)
Change from baseline (T0) at 6 months (T2)b
n (%) 16 (88.9) 9 (47.4) 25 (67.6)
Mean 0.6 0.2 0.5
SD 0.70 0.32 0.61
Minimum –0.8 –0.2 –0.8
Median 0.6 0.2 0.2
Maximum 1.7 0.8 1.7
Missing, n (%) 3 (11.1) 10 (52.6) 12 (32.4)
Change from baseline (T0) at 12 months (T3)b
n (%) 11 (61.1) 10 (52.6) 21 (56.8)
Mean 0.7 0.3 0.5
SD 0.49 0.43 0.50
Minimum 0.0 –0.2 –0.2
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Total confidence scorea
Treatment arm
TotalSAFE plus TAU TAU
Median 0.7 0.3 0.5
Maximum 1.7 1.0 1.7
Missing, n (%) 7 (38.9) 9 (47.4) 16 (43.2)
a Total confidence score ranges between 1 and 5; higher scores correspond to higher levels of confidence.
b Calculated only for SO participants with a baseline and 12-month measurement reported.
Total confidence score (all significant other participants, including those with missing
clinical research form data)
Total confidence scorea
Treatment arm
TotalSAFE plus TAU TAU
Baseline (T0)
n (%) 18 (100.0) 19 (100.0) 37 (100.0)
Mean 3.5 3.8 3.6
SD 0.62 0.72 0.69
Minimum 2.0 2.3 2.0
Median 3.5 3.8 3.7
Maximum 4.5 5.0 5.0
Missing, n (%)b 0 (0.0) 0 (0.0) 0 (0.0)
6 months (T2)
n (%) 16 (88.9) 9 (47.4) 25 (67.6)
Mean 4.2 3.9 4.1
SD 0.75 0.71 0.73
Minimum 2.7 2.8 2.7
Median 4.1 4.0 4.0
Maximum 5.0 4.8 5.0
Missing, n (%)b 2 (11.1) 10 (52.6) 12 (32.4)
12 months (T3)
n (%) 11 (61.1) 10 (52.6) 21 (56.6)
Mean 4.3 4.1 4.2
SD 0.57 0.99 0.78
Minimum 3.5 2.2 2.2
Median 4.2 4.7 4.3
Maximum 5.0 5.0 5.0
Missing, n (%)b 7 (38.9) 9 (47.4) 16 (43.24)
Change from baseline (T0) at 6 months (T2)c
n (%) 16 (88.9) 9 (47.4) 25 (67.6)
Mean 0.6 0.2 0.5
SD 0.70 0.32 0.61
Minimum –0.8 –0.2 –0.8
Median 0.6 0.2 0.2
Maximum 1.7 0.8 1.7
Missing, n (%) 3 (11.1) 10 (52.6) 12 (32.4)
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Total confidence scorea
Treatment arm
TotalSAFE plus TAU TAU
Change from baseline (T0) at 12 months (T3)c
n (%) 11 (61.1) 10 (52.6) 21 (56.8)
Mean 0.7 0.3 0.5
SD 0.49 0.43 0.50
Minimum 0.0 –0.2 –0.2
Median 0.7 0.3 1.0
Maximum 1.7 1.0 1.7
Missing, n (%) 7 (38.9) 9 (47.4) 16 (43.2)
a Total confidence score ranges between 1 and 5; higher scores correspond to higher levels of confidence.
b Participants had no data recorded for the outcome.
c Calculated only for SO participants with a baseline and 12-month measurement reported.
Knowledge of what to do when faced with a seizure
Total knowledge score (patient participants)
Total knowledge scorea
Treatment arm
TotalSAFE plus TAU TAU
Baseline (T0)
n (%) 26 (100.0) 25 (100.0) 51 (100)
Mean 9.0 9.0 9.0
SD 4.05 4.19 4.08
Minimum 0 0 0
Median 10 11 11
Maximum 13 13 13
Missing, n (%) 0 (0.0) 0 (0.0) 0 (0.0)
12 months (T3)
n (%) 18 (69.2) 17 (68.0) 35 (68.6)
Mean 9.4 9.4 9.4
SD 3.68 3.69 3.63
Minimum 1 3 1
Median 10.5 11.0 6.0
Maximum 13 13 13
Missing, n (%) 8 (30.8) 8 (32.0) 16 (31.4)
Change from baseline (T0) at 12 months (T3)b
n (%) 18 (69.2) 17 (68.0) 35 (68.6)
Mean –0.4 0.8 0.1
SD 3.62 3.15 3.41
Minimum –8 –8 –8
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Total knowledge scorea
Treatment arm
TotalSAFE plus TAU TAU
Median 0 1 0
Maximum 7 5 7
Missing, n (%) 8 (30.8) 8 (32.0) 16 (31.4)
a Knowledge score is calculated based on the number of questions about epilepsy answered correctly out of a
total of 13.
b Calculated only for patient participants with a baseline and 12-month measurement reported.
Total knowledge score (significant other participants)
Total knowledge scorea
Treatment arm
TotalSAFE plus TAU TAU
Baseline (T0)
n (%) 18 (100.0) 19 (100.0) 37 (100.0)
Mean 9.9 7.7 8.8
SD 3.07 4.19 3.81
Minimum 4 1 1
Median 11 7 9
Maximum 13 13 13
Missing, n (%) 0 (0.0) 0 (0.0) 0 (0.0)
12 months (T3)
n (%) 15 (83.3) 13 (68.4) 28 (75.7)
Mean 7.4 8.15 7.8
SD 5.36 5.40 5.29
Minimum 0 0 0
Median 9 11 9.5
Maximum 13 13 13
Missing, n (%) 3 (16.7) 6 (31.6) 9 (24.3)
Change from baseline (T0) at 12 months (T3)b
n (%) 15 (83.3) 13 (68.4) 28 (75.7)
Mean –2.0 –0.8 –1.5
SD 5.03 5.01 4.96
Minimum –12 –12 –12
Median 0 0 0
Maximum 4 8 8
Missing, n (%) 3 (16.7) 6 (31.6) 9 (24.3)
a Knowledge score is calculated based on the number of questions about epilepsy answered correctly out of a
total of 13.
b Calculated only for SO participants with a baseline and 12-month measurement reported.
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Appendix 19 Adverse events occurring during
pilot trial in descending order, according to
frequency overall
Adverse event
Treatment arm
TotalSAFE plus TAU TAU
Category of
event (e.g.
body system) Event
Events,
n
Patients,
n (%)
Events,
n
Patients,
n (%)
Events,
n
Patients,
n (%)
Eyes, ear, nose
and throat
Problem with eyes and
sinuses
0 0 (0.0) 1 1 (9.1) 1 1 (5.6)
Genitourinary Overnight hospital
admission required owing
to urinary tract infection
(pre-existing)
0 0 (0.0) 1 1 (9.1) 1 1 (5.6)
Haematological Dislocated shoulder 0 0 (0.0) 1 1 (9.1) 1 1 (5.6)
Neoplasiaa Change in seizure pattern 1 1 (14.3) 0 0 (0.0) 1 1 (5.6)
Increase in seizure
frequency
1 1 (14.3) 0 0 (0.0) 1 1 (5.6)
Neurological Increased seizures;
medications changed
1 1 (14.3) 3 3 (27.3) 4 4 (22.2)
Increased seizures (shift
patterns at work)
1 1 (14.3) 0 0 (0.0) 1 1 (5.6)
New seizure type; frequent
absence seizures as well as
usual seizure types
1 1 (14.3) 0 0 (0.0) 1 1 (5.6)
Seizure frequency; sodium
levels requiring in patient
monitoring
0 0 (0.0) 1 1 (9.1) 1 1 (5.6)
Seizures more severe
(tonic–clonic)
0 0 (0.0) 1 1 (9.1) 1 1 (5.6)
Vagus nerve stimulation not
working properly; going to
hospital for observation
0 0 (0.0) 1 1 (9.1) 1 1 (5.6)
Respiratory Increases number of
seizures owing to chest
infection and antibiotics
0 0 (0.0) 1 1 (9.1) 1 1 (5.6)
Other Adverse events occurring
during pilot trial increase in
the number of fits owing
to being pregnant/just
given birth
0 0 (0.0) 2 1 (9.1) 2 1 (5.6)
Diagnosis of status
epilepticus
1 1 (14.3) 0 0 (0.0) 1 1 (5.6)
Vertigo 0 0 (0.0) 1 1 (9.1) 1 1 (5.6)
Total 6 6 (100.0) 13 11 (100.0) 19 18 (100.0)
a Two participants were under investigation to determine whether or not a brain tumour could be the cause of their
seizure changes; hence, the event was classified as neoplasia rather than neurological.
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